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Abstract: The pathogenesis of autoimmune thyroid diseases (AITD) is poorly understood and the association 42 
between different immune features and the germline variants involved in AITD are yet unclear. We previously 43 
observed systemic depletion of IgG core fucosylation and antennary α1,2 fucosylation in peripheral blood 44 
mononuclear cells in AITD, correlated with anti-thyroid peroxidase antibody (TPOAb) levels. Fucose depletion 45 
is known to potentiate strong antibody-mediated NK cell activation and enhanced target antigen-expressing cell 46 
killing. In autoimmunity, this may translate to autoantibody-mediated immune cell recruitment and attack of 47 
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self-antigen expressing normal tissues. Hence, we investigated the crosstalk between immune cell traits, secreted 48 
proteins, genetic variants and the glycosylation patterns of serum IgG, in a multi-omic and cross-sectional study 49 
of 622 individuals from the TwinsUK cohort, 172 of whom were diagnosed with AITD. We observed associations 50 
between two genetic variants (rs505922 and rs687621), AITD status, the secretion of Desmoglein-2 protein, and 51 
the profile of two IgG N-glycan traits in AITD, but further studies need to be performed to better understand 52 
their crosstalk in AITD. On the other side, enhanced afucosylated IgG was positively associated with activatory 53 
CD335-CD314+CD158b+ NK cell subsets. Increased levels of the apoptosis and inflammation markers Caspase-54 
2 and Interleukin-1α positively associated with AITD. Two genetic variants associated with AITD, rs1521 and 55 
rs3094228, were also associated with altered expression of the thyrocyte-expressed ligands known to recognize 56 
the NK cell immunoreceptors CD314 and CD158b. Our analyses reveal a combination of heightened Fc-active 57 
IgG antibodies, effector cells, cytokines and apoptotic signals in AITD, and AITD genetic variants associated 58 
with altered expression of thyrocyte-expressed ligands to NK cell immunoreceptors. Together, TPOAb 59 
responses, dysregulated immune features, germline variants associated with immunoactivity profiles, are 60 
consistent with a positive autoreactive antibody-dependent NK cell-mediated immune response likely drawn to 61 
the thyroid gland in AITD. 62 
Keywords: Multi-omic; autoimmune thyroid diseases (AITD); genetic variants; apoptosis; antibody-63 
dependent cell-mediated cytotoxicity (ADCC); anti-thyroid peroxidase antibody (TPOAb) 64 
 65 
1. Introduction 66 
Autoimmune thyroid diseases (AITD) are a class of chronic, organ-specific disorders of the 67 
thyroid gland with a high genetic heritability (55-75%) [1–4] affecting approximately 5% of the 68 
population and with a gender disparity (i.e., women: 5-15%; men: 1-5%) [5–7]. Pathologically, AITD 69 
are characterized by autoantibodies against three main thyroid proteins (thyroid peroxidase (TPO), 70 
thyroglobulin (Tg), and the thyroid-stimulating hormone (TSH) receptor (TSH-R)), infiltration of the 71 
thyroid gland by immune cells (e.g. lymphocytes, NK cells, monocytes, and macrophages), the 72 
formation of germinal centers in the thyroid gland [8] and dysregulated TSH levels [9,10]. However, 73 
some studies have failed to observe a significant difference in peripheral blood immune cell 74 
composition between AITD patients and healthy individuals [11], while others report significant 75 
differences in particular cell types or in immune marker expression [12]. Immune cells, thyroid 76 
autoantibodies, and secreted proteins including cytokines may play critical roles in AITD 77 
development [13] and in immune responses, including in antibody-dependent cell-mediated 78 
cytotoxicity (ADCC) pathways [14,15]. However, the underlying autoimmune signatures associated 79 
with AITD remain unclear. 80 
ADCC is triggered via antigen/antibody/Fc receptor complex formation, bringing the effector 81 
cell (macrophages, NK cells) and the target cell (expressing the antigen) in close contact. The 82 
formation and function of antigen/antibody complexes are modulated by various factors including 83 
post-translational modifications of glycans decorating antibodies [16,17]. One example is lack of 84 
fucose on the N-linked core glycan of IgG. Afucosylated antibodies have a higher affinity (~100-fold) 85 
for the immunoglobulin Fc receptor FcγRIIIa (CD16a), expressed on NK cells, macrophages and γδ 86 
T cells, and are shown to confer enhanced ADCC potential in vitro and anti-tumor activity in vivo [18–87 
21]. This could result in antibodies with more potent Fc-mediated effector functions able to more 88 
effectively recruit and activate immune effector cells such as NK cells to kill target antigen-expressing 89 
cells [22,23]. IgG core fucose, observed in approximately 95% of IgG in healthy individuals, is 90 
considered a “safe switch” that can attenuate potentially harmful antibody-dependent damage 91 
against self-antigen-expressing normal tissues [18–21,24]. However, it is possible that these processes 92 
may be altered in autoimmune diseases. 93 
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We previously studied the glycosylation profiles of total immunoglobulin G (IgG) and of 94 
peripheral blood mononuclear cells (PBMC) in patients with AITD [4], as well as the glycosylation of 95 
IgG-depleted serum proteins in Hashimoto’s thyroiditis (HT) patients [25]. In peripheral blood, we 96 
identified both depleted core fucosylation of IgG antibodies and decreased antennary α1,2 97 
fucosylation of PBMC to be associated with autoantibodies to thyroid peroxidase (TPOAb) and AITD 98 
status [4]. We also identified a network of genes, including FUT8 and IKZF1 that regulate 99 
fucosylation, to be implicated in the development of AITD [4,26]. Based on these findings, we 100 
speculated that IgG core fucose deficiencies together with elevated levels of autoantibodies may 101 
participate in autoimmune responses in AITD by enhancing effector cell activation and heightened 102 
immune and inflammatory signals. 103 
Therefore, here we investigated immune features that may signify dysregulated, and likely 104 
heightened immune effector cells, antibodies, and immune mediators in AITD. In this in silico study 105 
in the blood of 622 subjects from the TwinsUK cohort, of whom 172 have AITD features, we aimed 106 
to investigate: 1) the association of different components of antigen/antibody/Fc receptor complexes 107 
with AITD; 2) the associations between these different immune components in a cohort of samples 108 
from volunteers regardless of disease status, and 3) potential genetic drivers on these components 109 
(study design summarized in Fig. 1). Specifically, we examined the association of total serum IgG 110 
glycosylation, immune traits, such as immune cell subpopulation frequencies (CSFs; i.e. relative 111 
frequencies of circulating immune cell subsets), immune cell surface protein expression levels (SPELs; 112 
i.e. the measurement of the cell-surface expression of critical proteins) and secreted proteins, in the 113 
peripheral blood of patients with AITD compared with those of healthy volunteers (sample sizes of 114 





Figure 1. Multi-omics computational analyses were used to study the components of 117 
antigen/antibody/effector cell complex structure in AITD. 1) We previously performed glycome-wide 118 
association studies of AITD and TPOAb levels using 3,146 individuals from three European cohorts, 119 
including the TwinsUK cohort. We identified 17 AITD-IgG N-glycan traits in the discovery TwinsUK 120 
cohort, and seven of these 17 have been then replicated in two other cohorts [4]. 2) In the present 121 
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study, we studied the association of total IgG N-glycan traits with 23,485 immune cell traits in 383 122 
individuals from the TwinsUK cohort (regardless of disease status). We showed that 6 out of the 17 123 
AITD-IgG glycan traits were correlated with 51 immune cell traits featuring the CD335, CD134, and 124 
CD158b receptors. 3) None of these 51 immune cell traits appeared to be associated with AITD in 374 125 
individuals (34 with AITD). 4) The heritability of AITD, TPOAb level and several -omic features (IgG 126 
N-glycan traits and immune cell traits) were performed in previous studies of the TwinsUK cohort 127 
[4,27–29]. Here we estimated the heritability of secreted proteins, but we could not determine shared 128 
additive genetic variance between different phenotypes studied (AITD status, TPOAb level, level of 129 
IgG N-glycan traits, of immune cell traits and of circulating proteins in the bloodstream). 5) We 130 
identified genetic variants that alter the expression of genes, proteins and cell-bound immune 131 
receptors (highlighted in this study) using the previous GWASs performed in the TwinsUK cohort or 132 
from GWAS catalog, eQTLs from GTEx project and pQTLs from INTERVAL project [27,28,30–35]. 6) 133 
We previously performed transcriptome-wide association studies of AITD, TPOAb level, and N-134 
glycan structures in the whole blood of approximately 300 individuals and we found no significant 135 
associations [4]. 7) We observed 3 out of 1,113 circulating proteins tested in plasma of almost 300 136 
individuals shown to be associated with AITD status (TSH, Caspase-2, and Interleukin-1α). 8) Several 137 
secreted proteins were correlated with the level of plasma IgG glycan traits in 164 individuals, but 138 
none of them were also associated with AITD. The sample sizes of these different studies are described 139 
in Table S1. GlcNAc = N-acetylglucosamine. The numbers in black depict analyses performed 140 
previously [4,27–29] while the numbers in red depict analyses presented for the first time in the 141 
present study. 142 
2. Materials and Methods 143 
2.1. Study Sample  144 
The study was conducted using immune cell traits, glycosylation, proteomics, genotyping, 145 
and phenotypes in samples from research volunteers from the UK Adult Twin Registry (TwinsUK 146 
cohort). The TwinsUK cohort is comprised of approximately 14,000 monozygotic and dizygotic same-147 
sex adult twins from the UK, unselected for any particular disease or trait (Table S1). The cohort is 148 
of Northern European/UK ancestry and has been shown to be representative of singleton populations 149 
and the UK population in general [36,37]. Ethical approval was granted by the National Research 150 
Ethics Service London-Westminster, the St Thomas’ Hospital Research Ethics Committee (EC04/015 151 
and 07/H0802/84). Informed consent was obtained from all study participants. 152 
2.2. Data Statement 153 
Multi-omic data were derived from samples in the TwinsUK cohort. Individual-level 154 
TwinsUK data, including phenotypes and genotypes, are not permitted to be shared or deposited 155 
due to the original consent given at the time of data collection. Access data can be applied for through 156 
the TwinsUK data access committee (http://twinsuk.ac.uk/resources-for-researchers/access-our-157 
data/). 158 
2.3. Definition of AITD and detection of TSH and TPOAb 159 
The study was performed using a clinical AITD definition and TPOAb as a threshold trait; it 160 
was not possible for AITD (Hashimoto’s disease and Graves’ disease) clinical diagnosis to be 161 
confirmed by a clinician. However, approximately 90% of individuals with Hashimoto’s disease, 162 
about 75% with Graves’ disease, <20% with other thyroid diseases, and <10% of normal individuals 163 
are known to have TPOAb-positivity [38–40]. Therefore, individuals were considered to have AITD 164 
if they either showed significantly higher than normal TPOAb serum titers (set at 3-fold higher than 165 
the threshold set by the manufacturer [18 IU/mL for the Abbott assay and 100 IU/mL for the Roche 166 
assay]) or had TSH serum levels >10 mIU/L. We considered individuals as controls if they had normal 167 
levels of TSH and a negative TPOAb titer, with no previous clinical diagnosis of thyroid disease and 168 
who were not treated with thyroid medications or steroids. Individuals with a history of thyroid 169 
cancer or thyroid surgery were excluded. Among the 622 individuals studied, 172 (27.65%) were 170 
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identified with AITD, 236 (37.94%) considered normal controls, and 214 (34.41%) have TPOAb or 171 
TSH serum levels outside the normal range, but do not reach the 3-fold cutoff for inclusion in the 172 
AITD cohort. Evaluations of sera to measure TPOAb and TSH levels are described in Appendix A. 173 
2.4. Detection of IgG glycosylation profiling for discovery  174 
Plasma specimens for analysis of IgG glycosylation was collected between 1997 and 2013 in 175 
2,279 individuals from the TwinsUK cohort. IgG glycosylation profiling was performed on total 176 
plasma IgGs glycome (combined Fc and Fab glycans and all IgG subclasses) in Genos Glycoscience 177 
Research Laboratory, Croatia using UPLC analysis of 2AB-labelled glycans. Protocol, data pre-178 
processing and normalization in the TwinsUK cohort were previously described [4] (Appendix A).  179 
2.5. Detection of immune cell traits  180 
Plasma samples for assessment of 78,000 immune traits were collected between 2010 and 2012 181 
in 669 female participants from the TwinsUK cohort using high-resolution deep 182 
immunophenotyping flow cytometry analysis as previously described [28]. 78,000 different cell 183 
surface marker combinations captured by 7 distinct 14-color immunophenotyping panels were 184 
detected and described immune cell subset frequencies (CSF) and immune cell-surface protein 185 
expression levels (SPELs). After quality control to remove immune cell traits that appeared as poor 186 
reproducibility or out of range, 23,485 immune cell traits from 497 individuals of the TwinsUK cohort 187 
were analyzed. For this analysis, only 374 twins had immune cell traits data and TPOAb level 188 
detected by Roche immunoassay and 245 individuals in a case-control study by combining Roche 189 
and Abbott assays (204 controls and 41 AITD). Immune traits were quantile normalized residuals of 190 
a linear mixed effect model where age was included as fixed effects, and the batches were considered 191 
as random effects. 192 
2.6. Detection of protein profiling in plasma 193 
With an aptamer-based multiplex protein assay (SOMAscan v2, SomaLogic Inc, Boulder, CO) 194 
[41,42], 1,129 proteins were measured (2013) on plasma samples collected between 2004 and 2011 195 
from 211 female twins of the TwinsUK cohort (Appendix A).  196 
2.7. Statistical analyses 197 
All statistical analyses were run using R version 3.2.3. Linear mixed effect models were 198 
conducted using the R lme of package lme4 [43], and linear models were done in using R function lm 199 
of package stat. Custom R scripts developed for this study are available at this URL: 200 
https://github.com/TiphaineCMartin/multiomic_AITD.git. 201 
For determination of effective number of independent tests for different -omic data, association 202 
studies between -omics features and thyroid phenotypes and heritability analysis for proteins 203 
(Appendix A). 204 
2.8. Genome-wide Association Analysis on IgG N-glycan traits 205 
To define genetic variants (i.e., single nucleotide polymorphisms (SNP), short insertions and 206 
deletions (indels)) associated with glycosylation profiles regardless of specific phenotypes in the 207 
TwinsUK cohort, we ran analyses with the GenABEL software package [44] designed for genome-208 
wide association study (GWAS) analysis of family-based data by incorporating pairwise kinship 209 
matrix calculated using genotyping data in the polygenic model to correct relatedness and hidden 210 
population stratification. Data were recently published with other datasets [26,45]. We selected 211 
genetic variants for each IgG N-glycan traits with a P-value under the GWAS threshold (P-value < 212 
5x10-8) and added the list of previously-defined genetic variants [29,45] (Appendix A).  213 
2.9. Determination of shared genetic variants and genes between IgG N-glycan traits, immune cell traits, 214 
protein abundance, and thyroid functions and diseases 215 
Cells 2020, 9, x FOR PEER REVIEW 6 of 28 
 
To examine whether IgG N-glycan, immune cell traits, proteins, thyroid functions and 216 
diseases shared genetic variants or genes, we compared the genetic variants from GWASs on 217 
TwinsUK data (NHGRI GWAS catalog and other projects). As genetic variants detected by GWASs 218 
could be lead genetic variants but not necessarily causal genetic variants [46], we extended the list of 219 
genetic variants to other variants in linkage disequilibrium (LD) with an r² threshold of 0.8 from 220 
1000G Phase 1 European population. Using HaploReg V4.1 [47] and GTeX data [32,33], we extracted 221 
tissue-specific expression quantitative traits (eQTLs) associated with these genetic variants. 222 
2.10. Visualization 223 
Heatmaps were created in using R package ComplexHeatmap. Correlation plots were 224 
created with R package corrplot. Boxplots and scatter plot were created in using R package ggplot2. 225 
3. Results 226 
3.1. Depletion of IgG core fucose is positively associated with increased CD158b+CD314+CD335- NK cell 227 
subset counts  228 
IgG N-glycosylation is considered indispensable for the effector functions of IgG and 229 
inflammation control [48–52] and plays an essential role in the recognition and binding to Fc receptors 230 
of immune cells [51]. Using high-resolution deep immunophenotyping flow cytometry analysis in 231 
669 twins from the TwinsUK cohort and IgG N-Glycan traits in 2,297 twins from the same cohort 232 
[4,27,28], we identified 383 samples with measurements of 23,485 immune cell and 17 AITD-IgG N-233 
glycan traits (IGP2, IGP7, IGP8, IGP15, IGP21, IGP33, IGP36, IGP42, IGP45, IGP46, IGP48, IGP56, 234 
IGP58, IGP59, IGP60, IGP62 and IGP63) and searched for any associations between them (Table S1).  235 
In our cohort, we identified 1,357 independent immune cell traits among 23,485 potential 236 
tested immune cell traits, where the partial correlation between immune cell traits is highlighted in 237 
Fig. S1a, 20 independent IgG N-glycan traits among 75 potential tested IgG N-glycan traits, and 6 238 
independent AITD-IgG N-glycan traits among 17 potential tested AITD-IgG N-glycan traits [53]. 239 
Association studies of total IgG N-glycan traits with immune cell traits showed that 6 of the 17 240 
identified significant IgG N-glycan traits (IGP2, IGP42, IGP46, IGP58, IGP59, IGP60) previously 241 
associated with TPOAb level and AITD status in the TwinsUK cohort, were also associated with 51 242 
immune cell traits, which are all NK cells (CD16+CD56) featuring different combinations of 6 243 
immunoreceptors (CD2, CD158a, CD158b, CD314, CD335, R7) (Table S2, Fig. 2). Three IgG N-glycan 244 
traits without core fucose (IGP2, IGP42, IGP46) were negatively associated with the level of the 245 
activating subpopulation of CD16+CD56+CD158b-CD335+ NK cells and positively associated with the 246 
level of the CD16+CD56+CD335- effector NK cell subpopulation and with the activating subpopulation 247 
CD16+CD56+CD158b+CD314+CD335- NK cells [54–59]. In contrast, three other significant IgG N-248 
glycan traits with core fucose (IGP58, IGP59, and IGP60) had the opposite effect associations with the 249 
same subpopulations of NK cells (Fig. 2a). In agreement with our previous report, there are therefore 250 
negative correlations between the set of IgG N-glycan traits without core fucose (IGP2, IGP42, IGP46) 251 
and the set of IgG N-glycan traits describing IgG core fucose (IGP58, IGP59, and IGP60) [4] 252 
(highlighted in Fig. 2b). Moreover, we observed strong correlations between these 51 immune cell 253 
traits (Fig. 2c). The presence of correlation patterns between the 17 AITD-IgG N-glycan traits (Fig. 254 
2b) as well as between the 51 immune cell traits (Fig. 2c) is consistent with our observation of 255 
correlations between the 6 AITD-IgG N-glycan traits and the 51 immune cell traits (Fig. 2a). When 256 
we extended our analysis to the 58 remaining IgG N-glycan traits also identified in our samples, but 257 
not associated with AITD, we observed no significant association between them and the 23,485 258 
immune cell traits. Moreover, for 23,485 peripheral blood immune cell traits (Table S1), no significant 259 
association with AITD or TPOAb level could be identified (Fig. S1b). 260 
We conclude that a subpopulation of NK cells (CD16+CD56) and specifically the activating 261 
subpopulation CD16+CD56+CD158b+CD314+CD335- NK cells is associated with fucose-depleted IgG 262 
in individuals with AITD. 263 





Figure 2. AITD-IgG N-glycan traits associated with a subpopulation of NK cells. (a) Heatmap of 264 
immune cell traits associated with AITD-IgG N-glycan traits. The 51 NK cell types were significantly 265 
associated with 6 out of 17 AITD-IgG N-glycan traits previously identified [4]. Below the heatmap, 266 
there are one representative of IgG core afucose (IGP2) and one representative of IgG core fucose 267 
(IGP7), that were both associated with AITD and TPOAb levels [4]. (b) Co-expressions between only 268 
17 IgG N-glycan traits previously associated significantly with AITD status and TPOAb level [4]. (c) 269 
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Correlations between the profile of 51 immune cell traits that were associated significantly with at 270 
least one of 17 AITD-IgG N-glycan traits. The order of immune cell traits is the same as that in Fig 2a. 271 
3.2. The AITD-associated genetic variants, rs1521 and rs3094228, alter thyroid cell expression of ligands for 272 
CD314 and CD158b immunoreceptors 273 
The NK cell receptors, CD335 (NKp46), CD314 (NKG2D) and the killer cell immunoglobulin-274 
like receptors (KIRs) including CD158b, are normally associated with activated NK cell states, T cell 275 
co-stimulation, and mediating tumor cell lysis [55,57]. To determine whether genetic factors could 276 
contribute to AITD, related immune features, or their pathways, we inspected genetic variants 277 
associated with AITD, TPOAb levels, and immune cell traits from previous GWAS [27,28,30]. We 278 
then compared these with recent large-scale studies on tissue-specific expression quantitative traits 279 
(eQTLs) [35], mainly from the GTEx project [32–34] in blood and thyroid tissue.  280 
No genetic variants previously associated with AITD or other thyroid phenotypes appeared 281 
to be associated with the expression of CD335 or its known ligands in blood and thyroid cells. 282 
However, we observed that two genetic variants, rs1521 and rs3094228, associated with Graves’ 283 
disease and TPOAb-positivity, respectively, fall in the gene regulatory regions of MIC-A and MIC-B 284 
genes, two ligands of CD314 (NKG2D), and alter their gene expressions in thyroid cells [32–34,60–62] 285 
(Fig. 3, Table S4, Fig. S2). These two AITD-genetic variants, rs1521 and rs3094228, also alter the 286 
expression of the HLA-C gene, ligand of CD158b, in thyroid cells. The Graves’ disease (GD) risk allele 287 
of rs1521 variant is primary associated with a reduced expression of HLA-C gene, ligand of CD158b, 288 
in thyroid cells. Furthermore, the TPOAb-positivity risk allele of rs3094228 variant is primary 289 
associated with an increased expression of MIC-B gene, ligand of CD314 (NKG2D), in thyroid cells. 290 
As about 75% of patients with Graves’ disease have TPOAb-positivity and rs3094228 that has been 291 
associated with TPOAb-positivity and Graves’ disease [61,63], it is possible that the association of 292 
rs1521 with Graves’ disease could be also driven by TPOAb-positivity and, so, associated with its 293 
phenotypes. Downregulation of HLA-C gene expression and upregulation of MIC-A and MIC-B gene 294 
expression in thyrocytes could activate NK cell functions and the cytokine production against 295 
thyrocytes when NK cells and thyrocytes are in contact.  296 
Furthermore, three genetic variants, rs2596460, rs2596457 and rs2523691, previously 297 
associated with higher levels of the subpopulation of NK cells featuring CD16+CD56/CD2-298 
CD314+CD335-CD337-CD158a+CD158b+ [28], are in the same haplotype as the rs3094228 genetic 299 
variant, but with a low linkage disequilibrium (LD, r2< 0.8) (Table S5). Potentially, one of the genetic 300 
variants in this locus are the causal genetic variant of higher abundance of CD158b+CD314+CD335- 301 
NK cells. All of the three genetic variants could also alter the expression of the HLA-C gene, ligand 302 
of CD158b, and MIC-A, ligand of CD314 (NKG2D), in immune cells [32–34,64] (Fig. 3, Table S4).  303 
Overall, two genetic variants, rs1521 and rs3094228, associated with, respectively, Graves’ 304 
disease and TPOAb-positivity, appear to alter thyrocyte expression of ligands of two 305 
immunoreceptors of NK cells, CD314 and CD158b; both of which have the capacity to enhance 306 
cytotoxicity of NK cells after binding with target cells. Additionally, three genetic variants in the same 307 
haplotype than rs3094228 could increase the abundance of the immune active CD158b+CD314+CD335- 308 
NK cell subpopulation. 309 
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 310 
Figure 3. Association of immune cell traits with AITD status. Annotation tracks around MIC-A, MIC-311 
B and HLA-C genes visualize significant GWAS hits for immune cell traits, the ligands of certain 312 
immunoreceptors (such as NK), and thyroid phenotypes previously identified in the TwinsUK cohort 313 
as well as chromatin states identified using chromHMM from whole blood from ENCODE [65] and 314 
thyroid cells from CEMT [66] and eQTLs from GTEx project [32,33]. The plot was produced using 315 
functions from R packages Gviz and coMET [67]. 316 
3.3. AITD is associated with increased serum Caspase-2 and IL-1α 317 
We next evaluated whether the abundance of 1,113 free soluble proteins, which are partially 318 
correlated between each other (Fig. 4a), in peripheral blood may be associated with AITD status (27 319 
AITD patients versus 130 healthy controls) and TPOAb levels (155 individuals of whom 25 have 320 
AITD) in the TwinsUK cohort (Table S1) using aptamer-based multiplex protein assay (SOMAscan) 321 
[68]. Firstly, we observed significant moderate correlations of the TSH levels measured by two 322 
clinical-certificated assays (Abbott and Roche) with the TSH levels measured by the SOMAscan assay 323 
(Fig. 4b). This indicated that the SOMAscan assay could reproduce with good accuracy the estimation 324 
of TSH levels and probably also for other proteins. Levels of three proteins were positively associated 325 
with AITD status (Bonferroni multiple testing correction, P-value<1.9x10-4): TSH (P-value=8.67x10-5; 326 
Beta=0.67; SE=0.16), Caspase-2 (CASP-2; P-value=2.72x10-7; Beta=1.10; SE=0.20) and Interleukin-1α 327 
(IL-1α; P-value=7.46x10-5; Beta=0.41; SE=0.09). We also observed higher mean levels of TSH in patients 328 
with AITD (meanSOMAscan=1443.9, sdSOMAscan=1238.5; meanclinical=7.1 IU/mL, sdclinical=10.47) or TPOAb-329 
positivity (meanSOMAscan=1389.9, sdSOMAscan=1018.3; meanclinical=5.7 IU/mL, sdclinical=7.55) compared with 330 
controls (euthyroidism with TPOAb-negative) (meanSOMAscan=851.1, sdSOMAscan=368.6; meanclinical=1.64 331 
IU/mL, sdclinical=0.79). Although Caspase-2 and IL-1α levels were associated with AITD status, 332 
Caspase-2 and IL-1α levels were not associated with TPOAb or TSH levels as continuous variables 333 
(P-value>1.9x10-4). However, when participants were divided into 4 categories according to TSH and 334 
TPOAb levels (Fig. 4c), reflecting different clinical categories (hyperthyroidism, 335 
euthyroidism/TPOAb-negative, hypothyroidism and euthyroidism/TPOAb-positive), Caspase-2 336 
showed significantly higher mean and variance in two groups: hypothyroidism and 337 
euthyroidism/TPOAb-positive (Fig. 4d). The hypothyroidism and euthyroidism/TPOAb-positivity in 338 
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this cohort potentially indicate underlying Hashimoto’s thyroiditis (HT). This is because HT is the 339 
most common cause of hypothyroidism, spontaneous hypothyroidism (i.e. no previous history of 340 
thyroid ablation) is almost always caused by HT, and euthyroid individuals with TPOAb-positivity 341 
almost always have HT when studied by cytology and histopathology [69–71]. On the other hand, 342 
the variance of IL-1α was significantly larger in groups with euthyroidism/TPOAb-positive and 343 
hyperthyroidism (Fig. 4e), but there was no significant difference for their mean values. Hence, 344 
individuals from 4 categories have the same levels of IL-1α, but there are more inter-individual 345 
variabilities in euthyroidism/TPOAb-positive and hyperthyroidism than euthyroidism/TPOAb-346 
negative and hypothyroidism.  347 
In summary, we confirmed the association of the plasma TSH levels with AITD status, and 348 
we found two novel associations of plasma Caspase-2 and IL-1α with AITD status, but their secretion 349 
(mean and variance) seems to also depend on other factors associated with thyroid diseases such as 350 
the levels of TSH and TPOAb. 351 
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Figure 4. Association of circulating protein abundances with thyroid diseases and with AITD-IgG N-353 
glycan structures. (a) 1,113 circulating proteins were arranged in two dimensions based on the 354 
similarity of their secretion profiles in the serum by the dimensionality reduction technique UMAP 355 
[72] using R package umapr [73]. (b) Correlation of log10-transformed TSH measurements between 356 
two clinical FDA approved clinical immunoassays (Roche and Abbott) and SOMAscan assay in 217 357 
individuals (122 using Roche immunoassay and 95 using Abbott immunoassay). (c) Box plot of the 358 
level of circulating TSH measured by SOMAscan assay in the serum according to the group of thyroid 359 
status. (d) Box plot of the level of circulating Caspase-2 measured by SOMAscan assay in the serum 360 
according to the group of TSH. (e) Box plot of the level of circulating IL-1α measured by SOMAscan 361 
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assay. An extreme outlier sample in the group 4 with an IL-1 α of 250,000mg/ml was discarded for 362 
the analysis. (f) Heatmap of circulating protein abundances associated with AITD-IgG N-glycan 363 
structures. In fig.2c-e, participants were assigned to 4 categories according to TSH level and TPOAb 364 
status: 1=hyperthyroidism (TSH<=0.1 mIU/L; 13 individuals), 2=euthyroidism/TPOAb-negative 365 
(0.4<TSH>4 mIU/L & TPOAb < 6 IU/mL (Abbott) or TPOAb < 34 IU/mL (Roche); 196 healthy 366 
individuals), 3=hypothyroidism (TSH>=4 mIU/L; 21 individuals), and 4=euthyroidism/TPOAb-367 
positive (0.4<TSH>4 mIU/L & TPOAb >= 6 IU/mL (Abbott) or TPOAb >= 34 IU/mL (Roche); 28 368 
individuals). Wilcoxon-Mann-Whitney’s test has been performed between groups to estimate 369 
whether there are mean differences whereas Levene’s test has been performed between groups to 370 
estimate whether there are variance differences. 371 
3.4. Afucosylated IgG is associated with serum levels of several circulating proteins 372 
When we studied the correlation between the level of secreted TSH, Caspase-2 and IL-1α 373 
proteins and IgG N-glycan trait levels in 164 individuals of whom 27 have AITD, we found no 374 
significant associations (P-value>8.3x10-4, Bonferroni test considering 3 independent proteins and 20 375 
independent IgG N-glycan traits) (Table S6, Fig. 4f). However, several AITD-IgG N-glycan traits 376 
appeared to be associated with 7 other circulating proteins (AMHR2, BCMA, β2-microglobulin, 377 
ERBB1, Desmoglein-2, TRAILR4, and FCGR3B) (P-value<3.67x10-5, Bonferroni test in considering 378 
only 227 independent proteins and 6 independent IgG N-glycan traits) (Table S6, Fig. 4f). For 379 
example, three AITD-IgG N-glycan traits (IGP2, IGP42, and IGP46) were positively associated with 380 
circulating FCGR3B (FcγRIIIb or CD16b), an Fc receptor expressed by polymorphonuclear 381 
neutrophils (PMN), whereas three AITD-IgG N-glycan traits (IGP58, IGP59, and IGP60) were 382 
negatively associated with the antibody Fc receptor FCGR3B. Also, IGP56 and IGP48 were negatively 383 
associated with β2-microglobulin, involved in the presentation of intracellular antigens through the 384 
MHC class I complex; and IGP48 was positively associated with ERBB1, the epidermal growth factor 385 
receptor (EGFR), a checkpoint molecule associated with cellular proliferation and differentiation.  386 
Overall, 12 AITD-IgG N-glycan traits (IGP2, IGP8, IGP42, IGP46, IGP48, IGP56, IGP57, IGP58, 387 
IGP59, IGP60, IGP62, and IGP63) were associated with serum levels of 7 circulating proteins 388 
(AMHR2, BCMA, β2-microglobulin, ERBB1, Desmoglein-2, TRAILR4, and FCGR3B) in the TwinsUK 389 
cohort. 390 
3.5. Free-soluble plasma Desmoglein-2 protein is associated with AITD genetic variants and two AITD-IgG 391 
N-glycan traits 392 
We evaluated several GWAS on secreted proteins (protein quantification locus traits, pQTL) 393 
[31], to determine whether the secretion of proteins associated with AITD or with AITD-IgG N-glycan 394 
traits are driven by AITD genetic variants. We found no genetic variants associated with any of 17 395 
AITD-IgG N-glycan structures that are also pQTL. However, four genetic variants associated with 396 
thyroid phenotypes published in the GWAS catalog (rs3761959, rs7528684, rs505922, and rs3184504) 397 
were also associated in cis and trans with nine circulating protein abundances (BGAT, CHSTB, DC-398 
SIGN, Desmoglein-2, DYR, FCRL3, GP1BA, MBL, and VCAM-1) (Table S7). None of these proteins 399 
were associated directly with AITD or TPOAb levels in our study. However, we found that 400 
Desmoglein-2 was associated with two AITD-IgG N-glycan traits, IGP8, and IGP63 [4] (Fig. S3). 401 
Desmoglein-2 is highly expressed in epithelial cells including thyrocytes and cardiomyocytes and 402 
plays a role in the cell-cell junctions between epithelial, myocardial, and certain other cell types and 403 
is thought to be a regulator of apoptosis [74].  404 
Therefore, four genetic variants associated with thyroid phenotypes are also associated with nine 405 
secreted protein abundances, including the apoptosis regulator Desmoglein-2 in blood. Desmoglein-406 
2 was also associated with two AITD-IgG N-glycan traits. 407 
4. Discussion 408 
The dysregulation of the immune system may affect several biological structures and 409 
processes in AITD, such as antigen/antibody/Fc receptor complex formation, possibly driven by 410 
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genetic and environmental factors [75]. Little is known about the key players and the genetic variants 411 
identified in previous GWASs of patients with AITD. Targeting of self-antigen expressing tissues by 412 
immune cells may depend on the formation of antigen/antibody/Fc receptor complexes featuring 413 
substantial affinity or avidity properties. In the peripheral blood of individuals with AITD, we 414 
previously detected depletion in IgG core fucose that is known to enhance such interactions and may 415 
influence immune effector cell engagement of target cells by antibodies. We proposed that this 416 
signature is associated with TPOAb levels and with immune effector cell activation in patients with 417 
AITD [4]. Here, we reveal immune and genetic features pointing to activated NK cell subsets, thyroid 418 
cell-derived ligands for immunoreceptors on NK cells, alongside secreted mediators of apoptosis and 419 
immune activation, all signals of heightened antibody and innate effector cell responses in AITD.  420 
We applied an in silico multi-omic approach on peripheral blood specimens from individuals 421 
from the TwinsUK cohort to investigate any association between immune features and genetic 422 
variants in AITD. In AITD patient samples, we observed increased levels of three circulating proteins 423 
(TSH, Caspase-2, and Interleukin-1α) and a decreased level of IgG core fucosylation associated with 424 
an activated subpopulation of NK cells defined primarily by the expression of CD335, CD134, and 425 
CD158b receptors. Our data confirms the previously reported association of plasma TSH level with 426 
AITD status and also reveals previously unknown potential biomarkers for AITD, which are highly 427 
associated with immunological activation functions, such as ADCC, apoptosis and pro-inflammatory 428 
pathways. Furthermore, several genetic variants previously associated with AITD appear to alter 429 
thyrocyte gene expression of several ligands of NK immunoreceptors and abundance of plasma 430 
circulating proteins. This suggest that the genetic background may also play potential roles in NK 431 
cell activation likely focused on thyroid cells in individuals with AITD.  432 
To our knowledge, no other cohorts have large datasets that are available to interrogate and 433 
feature the same diversity of -omics data with AITD phenotype or TPOAb levels. In our studies, we 434 
note an imbalance in the sample sizes between control individual groups and AITD groups. This is 435 
because the dataset comes from unselected twins and reflects the general European population [37], 436 
where approximately 5% of the population, but 5-15% for women, present individuals with AITD [5–437 
7]. To overcome such imbalances in our sample sizes and low samples sizes with large -omics data, 438 
we applied machine learning and non-parametric methods with correction for multiple testing. 439 
Another limitation in our present study is the absence of AITD clinical diagnosis confirmed by 440 
clinicians for all individuals. We consequently applied more stringent criteria to define patients with 441 
AITD versus control individuals, by using TSH and TPOAb levels (see Section 2.3 of our Materials & 442 
Methods). We also performed analysis on TPOAb levels, as this is considered the main clinical 443 
quantitative biomarker of AITD status [38–40]. Replication and meta-analysis studies on larger -omic 444 
datasets incorporating clinical features will help to confirm our present findings. 445 
Two secreted proteins (Caspase-2 and IL-1α), which play roles in apoptosis and the 446 
inflammatory response, were positively associated with AITD. TPOAb have been proposed to target 447 
thyroid cells by engaging effector cells via their Fc receptors [4,14,15,76,77], and the apoptosis protein 448 
Caspase-2 may represent a marker potentially signifying antibody-mediated destruction of thyroid 449 
cells [78]. In concordance, IL-1α, produced by activated immune, epithelial and endothelial cells in 450 
response to cell injury and apoptosis, is considered an apoptosis index of the target cell [79] and 451 
proportional to the degree of lymphoid infiltration in thyroid disorders [80]. IL-1α seems to reduce 452 
the thyroid epithelial barrier, even in the absence of any other signs of cytotoxicity [81]. In 453 
concordance, in our study we found higher levels of secreted IL-1α in AITD blood compared with 454 
levels in healthy individuals, and its variance was greater in euthyroidism/TPOAb-positive blood 455 
and in hyperthyroidism. This may signify dysregulation in cellular structures in the thyroid gland. 456 
Overall, Caspase-2 and IL-1α may reflect the degree of thyroid cell death or apoptosis and of 457 
lymphoid infiltration towards the thyroid gland.  458 
A subpopulation of NK cells expressing combinations of immunoreceptors (CD2, CD158a, 459 
CD158b, CD314, CD335, R7) was associated with the depletion of IgG core fucose in individuals with 460 
AITD. These included an activating NK receptor (CD314) and a differentiation receptor (CD335); 461 
whilst, fucose-depleted IgG was also positively associated with a subpopulation of NK cells with an 462 
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inhibitory NK receptor (CD158b) [54–59,82]. The combination of potentially autoreactive antibodies 463 
with enhanced Fc domains and activated effector cells such as NK cells may signal increased 464 
inflammation and susceptibility to autoimmune disease [83]. Previous studies showed that 465 
afucosylated antibodies have a much higher affinity (100-fold) for FcγRIIIa (CD16a) and may thus 466 
have enhanced ADCC [84]. Moreover, ADCC via FcγRIIIa may require NK cells, but not monocytes 467 
or polymorphonuclear cells, and activity levels of the antigen/antibody/effector cell complexes have 468 
been correlated only with the NK cell numbers present in the PBMC [20]. Our associations between 469 
the levels of IgG core fucose and of a subpopulation of NK cells reinforce the notion that there is a 470 
complementarity between IgG core fucose levels and NK cells, that could influence effector cell 471 
potency, potentially against a range of antigens including self-antigens. 472 
It has been previously estimated that AITD are highly heritable (55-75%) and that most of 473 
IgG N-glycan traits and the immune cell traits associated with AITD are moderately heritable (Table 474 
S8) [4,27]. By estimating the proportion of genetic and environmental variance of 1,129 proteins in 475 
our study using the Structural Equation Modeling and twin structures present in the TwinsUK cohort 476 
(Table S9), we found a small proportion of proteins having additive genetic variances in their 477 
heritability, in concordance with previous findings on a smaller dataset [85]. As the best model of 478 
heritability in AITD is only with dominant genetic variance, the shared genetic variance between 479 
AITD and proteins as well as with IgG N-glycan traits and immune cell traits could not be estimated 480 
with accuracy. However, in our study, we identified several genetic variants previously associated 481 
with thyroid phenotypes to be also associated with the secretion of proteins and gene expression of 482 
ligands of two NK cell immunoreceptors. Specifically, genetic variants, rs1521 and rs3094228, 483 
associated with Graves’ disease and TPOAb-positivity, alter the expression of thyroid cell-expressed 484 
ligands, MIC-A, MIC-B, and HLA-C, known to recognize CD314 and CD158b immunoreceptors 485 
expressed on NK cells. Moreover, rs3094228 falls in the same European haplotype as three genetic 486 
variants associated with higher abundance of the activated CD158b+CD314+CD335- NK cell subset. 487 
Thus, individuals having the AITD-risk allele of rs1521 variant have reduced expression of HLA-C 488 
gene and, at a lesser extent, expression of MIC-A in thyrocytes, whereas the carriers of AITD-risk 489 
allele of rs3094228 genetic variant associated with TPOAb-positivity showed increased expression of 490 
MIC-B gene in thyrocytes and potentially higher abundance of the highly active 491 
CD158b+CD314+CD335- NK cells. Consequently, if the thyrocytes in carriers of AITD-risk alleles for 492 
CD158b and CD314 ligands crosstalk with the subpopulation of NK cells with CD158b and CD314 493 
immunoreceptors with the help of the antibodies, they could trigger the production of cytokines and 494 
cytotoxicity against thyrocytes by these NK cells.  495 
Our findings thus highlight different immune features (glycan structures on antibodies, a 496 
subpopulation of immunoactive NK cells, the secretion of Caspase-2 and IL-1α) as potential signals 497 
of AITD status detectable in the bloodstream in addition to TSH and TPOAb levels. Moreover, if one 498 
speculates that active antibodies with low core-fucose might be thyroid autoantibodies (e.g., TPOAb) 499 
[86] and target cells are thyroid cells, it is conceivable (Fig. 5) that that immune cell-antibody-target 500 
cell interactions may lead to cytotoxicity functions targeting thyroid tissues [76,86,87]. Together, these 501 
may form part of a dysregulated autoimmune response in AITD. Further replication studies and 502 
validation studies of real-time functional evaluations associated with these immune features and 503 
genetic analyses are needed to confirm this model. These features could also be tested in the context 504 
of thyroid cancer immunotherapy [77] in future studies. 505 
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 506 
Figure 5. Model of different potential contributing players and their pathways activated in proposed 507 
antibody-dependent NK cell-mediated cytotoxicity in the thyroid gland of AITD patients. 1) The 508 
depletion of IgG core fucose was associated with TPOAb level and AITD status [4]. 2) The IgG N-509 
glycan traits associated with AITD were also associated with a subpopulation of NK cells in our 510 
current study; for example, the depletion of IgG core fucose is associated positively with NK cells 511 
with the patterns of co-receptors CD335- or CD335-CD158b+CD314+. 3) Previous studies showed that 512 
afucosylated antibodies had increased affinity for binding to CD16 (FcγRIIIa), cell receptors of NK 513 
cells, and to enhance ADCC [18–21] via 4) protein tyrosine kinase-dependent pathways, through 514 
crosstalk with 5) NKG2D receptor (CD314) [88,89]. 6) Two SNPs, rs3094228 and rs1521, were 515 
associated with GD and TPOAb-positivity [60–62] and fall in gene regulatory regions of the MIC-A 516 
and MIC-B genes and increase their expression in thyroid cells [32]. These two genes encode heavily 517 
glycosylated proteins that are ligands for the NKG2D type II receptor (CD314). 7) The KIR2DL 518 
(CD158b) receptor is known to regulate the cytotoxicity of NK cells by unknown pathways, whereas 519 
8) the NCR1 (CD335) receptor can contribute to the increased potency of activated NK cells to mediate 520 
cell lysis by unknown pathway [54,55]. 9) The SNP, rs1521 associated with GD[60], is also shown to 521 
reduce the expression of HLA-C gene, producing the ligand of CD158b, in thyroid cells [32,33,58,59]. 522 
10) All together (the binding of NK cells with target cells through antibodies and their ligands), these 523 
lead to the activation of NK cells, which release cytotoxic granules containing perforin and 524 
granzymes. This release mediates ADCC of target cells (3), which are thyrocytes in AITD. Also, 11) a 525 
positive association between the circulation abundance of Caspase-2 protein and AITD were found 526 
in this study that could be associated with the destruction of thyrocytes. 12) A positive correlation of 527 
circulating abundance of IL-1α with AITD was also found in the bloodstream that could be a marker 528 
of lymphocyte infiltration in the thyroid gland of individuals with AITD, and thus of inflammation 529 
[80,81].  530 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1,  531 
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 532 
Figure S1: Immune cell traits and AITD status. (a) Immune cell traits were arranged in two dimensions based on 533 
the similarity of their quantification profiles by the dimensionality reduction technique UMAP [72] using R 534 
package umapr [73]. Some clusters that emerge spontaneously can be associated with specific immune cell types 535 
(colors). (b) Overview of associations observed between IgG core-fucose, a subpopulation of NK cells and AITD 536 
status in the TwinsUK cohort. *Glycome-wide association studies of AITD and TPOAb levels were previously 537 
performed [4]. 538 
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Figure S2. Overview of associations between AITD-SNP and eQTL in thyroid and blood cells. *Genome-wide 540 
association studies of AITD and TPOAb-positivity were previously performed, and the findings are available 541 
via GWAS catalog [30] whereas **eQTLs come from GTEx project [34] and Westra and al. [35]. (a) Associations 542 
between AITD-SNP and eQTL in thyroid and blood cells for the genetic variant rs3094228. (b) Associations 543 
between AITD-SNP and eQTL in thyroid and blood cells for the genetic variant rs1521. 544 
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Figure S3. Overview of multi-omic findings associated with Desmoglein-2 in individuals with AITD status and 546 
general population. We highlighted a locus with high LD having SNPs and two IgG glycan traits that are both 547 
associated with GD and the abundance of secreted plasma Desmoglein-2 in plasma. However, no direct 548 
association of AITD status with the abundance of secreted plasma Desmoglein-2. We previously performed 549 
glycome-wide association studies of AITD and TPOAb levels [4]. Genome-wide association studies of AITD and 550 
TPOAb-positivity were previously performed, and the findings are available via GWAS catalog [30] whereas 551 
pQTLs come from INTERVAL project[31]. IGP8 = the percentage of FA2[3]G1 glycan in total IgG glycans. IGP63 552 
= The percentage of fucosylation (without bisecting GlcNAc) of agalactosylated structures. 553 
Table S1: Description of TwinsUK cohort used for different analysis performed here 554 
Table S2: Significant glycome associations with immune cell traits in the TwinsUK cohort 555 
Table S3: Associations of 51 immune cell traits with AITD and TPOAb level in the TwinsUK cohort 556 
Table S4: Hits from selected eQTL studies for two SNPs, rs1521 and rs3094228 in the thyroid cells and whole 557 
blood 558 
Table S5: Genes reported for genetic variants associated with thyroid phenotypes and immune cell traits 559 
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Table S6: Glycome-wide associations studies of 17 AITD-IgG N-glycan traits with 1,113 circulating proteins. 560 
Only significant ones were put here. 561 
Table S7: Genetic variants associated with thyroid phenotypes and AITD-IgG N-glycan traits overlapping pQTL 562 
identified in INTERVAL project (LD r2>0.8) 563 
Table S8: Heritability of AITD, 17 IgG N-glycan traits and 51 immune cell traits in the TwinsUK cohort 564 
Table S9: Heritability of 1,113 proteins in the TwinsUK cohort 565 
Abbreviations. ADCC (Antibody-Dependent Cell-mediated Cytotoxicity), AITD (AutoImmune Thyroid 566 
Diseases), CDC (Complement-Dependent Cytotoxicity), CD158b (KIR2DL2/L3 - Killer Cell Immunoglobulin 567 
Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 2 or 3 - or NKAT6 - Natural Killer-Associated 568 
Transcript 6), CD314 (NKG2D or KLRK1 - Killer Cell Lectin Like Receptor K1), eQTL (gene Expression 569 
Quantitative Trait Loci), FcγR (Fc gamma Receptor), GD (Graves’ Diseases), GlcNAc (N-acetylglucosamine), 570 
GWAS (Genome-wide Association Study), HT (Hashimoto’s thyroiditis), IgG (Immunoglobulin G), MIC-A 571 
(MHC Class I Polypeptide-Related Sequence A), MIC-B (MHC Class I Polypeptide-Related Sequence B), NK 572 
(Natural Killer cell), PBMC (Peripheral Blood Mononuclear Cells), pQTL (Protein expression Quantitative Trait 573 
Loci), Tg (Thyroglobulin), TSH (Thyroid-Stimulating Hormone), TSH-R (Thyroid-Stimulating Hormone 574 
Receptor), TPO (Thyroid PerOxidase), TPOAb (TPO Antibody). 575 
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Appendix A 606 
A.1. Detection of TSH and TPOAb in human sera 607 
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Sera to assess TPOAb and TSH levels were collected by a trained nurse or phlebotomist using 608 
venepuncture and a SafetyLokTM Blood Collection Kit (21G3/4 Needles) and plain 10 ml serum-609 
separating tube vacutainer (no additives) between February 1994 and May 2007. After collection from 610 
the study subject, whole blood was held at 22°C for 50 min at room temperature for a clot to form 611 
and serum separated within 60 minutes of collection. Processing of blood was performed using a 612 
refrigerated (4°C) clinical centrifuge at 3000xg for 10 minutes with the serum supernatant 613 
subsequently collected, transferred to a 2ml screw capped Nunc Cryotubes and immediately frozen 614 
at -80°C and kept frozen in 2ml screw capped Nunc Cryotube at -80°C until use. Quantitative 615 
determination of TSH and TPOAb (only IgG class) levels was performed on the sera either by a 616 
chemiluminescent microparticle immunoassay (CMIA) [ARCHITECT® Anti-TPO or TSH (ABBOTT 617 
Diagnostics Division, Wiesbaden, Germany, 2005)] (TPOAb titer>6 mIU/L considered positive; 618 
reference range for TSH level 0.4-4.0 mIU/L) or by an electrochemiluminescence immunoassay 619 
"ECLIA” [Elecsys and Cobas e analyzers, (Roche Diagnostics, Indianapolis, lN, USA, 2010)] (TPOAb 620 
titer>34 IU/mL considered positive; reference range for TSH 0.4-4.0 mIU/L).  621 
A.2. Detection of IgG glycosylation profiling 622 
For IgG glycosylation analysis, using UPLC analysis of 2AB-labelled glycans, 623 
chromatograms were separated in the same manner into 24 peaks, and the amount of glycans in each 624 
peak was expressed as a percentage of the total integrated area. One glycan was excluded before any 625 
transformation and standardization of data because of its co-elution with a contaminant that 626 
significantly affected its values in some samples whereas two glycan peaks (GP) GP20 and GP21 627 
(Zagreb code) were combined into a single trait called GP2021 (Zagreb code) because of difficulty in 628 
distinguishing between these peaks in some samples. A global normalization and natural logarithm 629 
transformation were applied to 22 directly measured glycan structures. As many of these structures 630 
share the same structural features (galactose, sialic acid, core-fucose, bisecting N-acetylglucosamine 631 
(GlcNAc)), 55 additional derived traits were calculated that average these features across multiple 632 
glycans from the 22 normalized and non-transformed directly measured glycans. Technical 633 
confounders (batch and run-day effects) were addressed using R package ComBat. The 22 directly 634 
measured glycans and 55 derived glycan traits were centered and scaled to have a mean of 0 and 635 
standard deviation (SD) of 1. Samples being more than 6 SD from the mean were considered as 636 
outliers and excluded from the analysis. 637 
A.3. Detection of protein profiling in plasma 638 
Plasma protein profiling was conducted using SOMAscan v2 (SomaLogic Inc, Boulder, CO) 639 
as previously described [29,30]. Briefly, hemolyzed samples were first excluded. Proteins were then 640 
measured using a SOMAmer-based capture array called “SOMAscan.” Quality control was 641 
performed at the sample and SOMAmer level and involves the use of control SOMAmers on the 642 
microarray and calibration samples. At the sample level, hybridization controls on the microarray 643 
are used to monitor sample-by-sample variability in hybridization, while the median signal over all 644 
SOMAmers is used to monitor overall technical variability. The resulting hybridization scale factor 645 
and median scale factor are used to normalize data across samples. The acceptance criteria for these 646 
values are 0.4–2.5, based on historical trends in these values. Somamer-by-somamer calibration 647 
occurs through the repeated measurement of calibration samples; these samples are of the same 648 
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matrix as the study samples and are used to monitor repeatability and batch to batch variability. 649 
Historical values for these calibrator samples for each SOMAmer are used to generate a calibration 650 
scale factor. The acceptance criteria for calibrator scale factors is that 95% of SOMAmers must have a 651 
calibration scale factor within ±0.4 of the median. For the current analysis, only 1,113 proteins were 652 
then studied.  653 
A.4. Selection of SNPs associated with immune cell traits 654 
To define the list of SNPs associated with immune cell traits regardless to any specific phenotypes in 655 
the TwinsUK cohort, we extracted SNPs for each immune cell traits that have a P-value under GWAS 656 
P-value threshold (P-value < 5x10-8) from previous published GWASs on these immune cell traits 657 
[27,28]. To define the list of SNPs associated with protein abundance found in this study, we extracted 658 
the significant SNPs reported in INTERVAL project [31]. To define the list of SNPs associated with 659 
gene expression (eQTL), we extracted the eQTLs reported significant by GTEx and previous papers 660 
present in HaploReg V4.1 [47]. To define the list of SNPs associated with AITD and thyroid functions, 661 
we selected to SNPs listed in the NHGRI GWAS catalog [52] with words “thyroid” or “Graves” or 662 
“Hashimoto.” 663 
A.5. Determination of effective number of independent tests for different -omic data 664 
Due to high and partial correlations within glycans, proteins and immune cell traits, we 665 
decided to use the equation 5 proposed by Li & Ji ((2005) [45] to define an effective number (Meff) of 666 
independent tests. We then used this number to define the effective Bonferroni P-value threshold 667 
such as 0.05/Meff instead of 0.05/M, with M the actual number of tests. 20 independent tests were 668 
estimated for 76 glycans. Consequently, to account for multiple testing in the discovery cohort, we 669 
present results surpassing a conservative Bonferroni correction assuming 20 independent tests, thus 670 
giving a significant threshold of (P-value <2.5x10-3=0.05/20). 1,357 independent tests were estimated 671 
for 23,485 immune cell traits, thus giving a significant threshold of 3.68x10-5 (0.05/1,357). 227 672 
independent tests were estimated among 1,113 proteins (P<0.05/227=1.9x10-4). 673 
A.6. Association studies between -omics features and thyroid phenotypes 674 
To examine whether one of the 17 AITD-IgG N-glycan traits was significantly associated with 675 
one of the 23,485 immune cell traits, we compared the fitted model in equation (2) with a model that 676 
did not include the residual of glycan in equation (1): 677 
Model null:  Yi ~ a + h (fixe intercepts) + g (random intercepts) + εij           (1) 678 
Model 1:    Yi ~ a + bGij + h (fixe intercepts) + g (random intercepts) + εij     (2) 679 
Where Yi represents the quantification of immune cell traits for individual i and Gij is glycan structure 680 
of type j among 75 N-glycans for the same individual i. If biological covariates (age, sex) have not 681 
been adjusted before association analysis, they have been added in the model. A random intercept 682 
was added only in the discovery cohort in order to model the family-relatedness. 683 
To examine whether an immune cell trait was significantly associated with TPOAb level and 684 
AITD status, we compared the fitted model in equation (2) with a model that did not include the 685 
immune cell traits in equation (1) where Gij become the immune cell trait of type j among 23,485 in 686 
discovery cohort for the same individual i. For the discovery and replication cohorts in TwinsUK, we 687 
added a random intercept in order to model the family-relatedness.  688 
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To examine whether one of the 1,113 protein was significantly associated with TPOAb level 689 
and AITD status, we compared the fitted model in equation (2) with a model that did not include the 690 
protein in equation (1): where Gij become the protein of type j among 1,129 in discovery cohort for 691 
the same individual i. We added a random intercept in order to model the family-relatedness. To 692 
examine whether one of 1,113 proteins was significantly associated with one of 17 significant glycans, 693 
we compared the fitted model in equation (2) with a model that did not include the protein in 694 
equation (1): where Gij become the protein of type j among 1,129 in discovery cohort for the same 695 
individual i. We added a random intercept in order to model the family-relatedness.  696 
11.7. Heritability analysis for proteins 697 
Using twin data and ADCE models (additive genetics (A), dominante genetics (D), shared 698 
environment (C) and non-shared environment (E)), heritability of glycosylation structures, immune 699 
cell traits and AITD were estimated using the R package called mets that allows us to run the analysis 700 
with monozygotic and dizygotic twins as well as unrelated individuals. The significance of variance 701 
components A, D, and C was assessed by dropping each component sequentially from the full model 702 
(ADCE) and comparing the sub-model fit to the full model. Sub-models were compared to full 703 
models by hierarchical χ2 tests. The difference between log-likelihood values between sub-model and 704 
full model is asymptotically distributed as χ2 with degrees of freedom (df) equal to the difference in 705 
df of sub-model and the full model. A statistical indicator of goodness-of-fit is the Akaike information 706 
criterion (AIC), computed as χ2 - 2df; sub-models are accepted as the best-fitting model if there is no 707 
significant loss of fit when a latent variable (A, C, D, or E) is fixed to equal zero. When two sub-708 
models have the same AIC compared to the full model, we decide to keep the model the most likely 709 
(with additive genetic variance) or with the lowest P-value for different components. 710 
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Table S1: Description of TwinsUK cohort used for different analysis performed here
* Roederer, M et al., Cell, 2015, doi: 10.1016/j.cell.2015.02.046 and Mangino et al, Nature Communications, 2017, https://doi.org/10.1038/ncomms13850
Analysis GWAS on immune cell traits*
immune cell traits-wide 






TPOAb immunoassay NA Roche Abbott Roche Abbott Roche NA Roche Abbott Roche Abbott Roche NA
threshold of TPOAb-
positivity (UI/mL) NA 34 6 34 6 34 NA 34 6 34 6 34 NA
Number of individuals 497 374 77 127 19 22 383 155 25 105 9 18 164
Age (mean/sd) 60 (8.2) 55.8 (8.4) 52.59 (7.20) 55.41 (8.4) 51.58 (7.49) 53.40 (8.02) 60 (8.2) 61.19 (6.96) 56.59 (8.10) 61.64 (7.8) 55.20 (4.65) 60.66 (6.73) 64.20 (7.27)
Sex (F/M) 497/0 374/0 77/0 127/0 19/0 22/0 383/0 155/0 25/0 105/0 9/0 18/0 164/0
TPOAb (mean/sd) NA 50.5 (108.4) 1.42 (8.49) 10.50 (5.37) 463.86 (568.45) 312.68 (146.01) NA 66.65 (36.19) 0.14 (0.37) 9.33 (5.05) 585.66 (1156.48) 324.81 (147.69) NA





Table S2: Significant glycome associations with immune cell traits in the TwinsUK cohort
SE=standart error
Glycan 
ID Description immuneTrait ID Trait ID
Canonical 
name Lineage Subset name Pvalue Beta SE Zscore
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 9.22E-08 0.285 0.052 5.445
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 5.10E-08 0.277 0.050 5.555
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 9.29E-08 0.237 0.044 5.443
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 7.88E-08 -0.228 0.042 -5.477
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 8.11E-08 -0.234 0.043 -5.468
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 2.14E-08 -0.242 0.042 -5.718
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 8.47E-08 0.286 0.052 5.461
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 4.69E-08 0.278 0.050 5.571
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 8.94E-08 0.237 0.044 5.451
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 7.49E-08 -0.228 0.042 -5.487
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 7.62E-08 -0.234 0.043 -5.480
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 2.03E-08 -0.243 0.042 -5.728
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 9.58E-08 0.285 0.052 5.437
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 5.24E-08 0.277 0.050 5.550
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 9.70E-08 0.237 0.044 5.435
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 8.37E-08 -0.227 0.042 -5.466
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 8.77E-08 -0.233 0.043 -5.454
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 2.28E-08 -0.242 0.042 -5.706
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 8.51E-08 0.286 0.052 5.460
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 4.64E-08 0.278 0.050 5.573
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 8.68E-08 0.238 0.044 5.456
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 7.57E-08 -0.228 0.042 -5.485
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 7.85E-08 -0.234 0.043 -5.475
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 2.06E-08 -0.243 0.042 -5.726
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_62860 P4:18 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b-R7- 8.79E-07 -0.250 0.050 -4.999
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_62860 P4:18 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b-R7- 8.06E-07 -0.240 0.048 -5.025
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_62860 P4:18 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b-R7- 5.26E-07 0.208 0.040 5.154
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 1.77E-08 -0.284 0.049 -5.752
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 9.79E-09 -0.275 0.047 -5.863
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 4.86E-07 -0.211 0.041 -5.131
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 3.67E-07 0.202 0.039 5.183
IGP59 The percentage of fucosylation of agalactosylated structures immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 7.23E-07 0.204 0.040 5.044
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 6.14E-08 0.221 0.040 5.540
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63596 P4:2461 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b-R7- 4.61E-07 -0.256 0.050 -5.134
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63596 P4:2461 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b-R7- 3.39E-07 -0.248 0.048 -5.206
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63596 P4:2461 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b-R7- 4.44E-07 0.210 0.040 5.189
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63597 P4:2462 NK Activating 2 16+56 16+56/314+335+337-158a-158b-R7- 5.91E-08 -0.276 0.050 -5.527
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63597 P4:2462 NK Activating 2 16+56 16+56/314+335+337-158a-158b-R7- 4.89E-08 -0.264 0.047 -5.565
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63597 P4:2462 NK Activating 2 16+56 16+56/314+335+337-158a-158b-R7- 1.61E-06 -0.203 0.042 -4.891
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63597 P4:2462 NK Activating 2 16+56 16+56/314+335+337-158a-158b-R7- 2.99E-07 0.212 0.040 5.239
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 4.19E-08 -0.278 0.050 -5.594
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 2.47E-08 -0.269 0.047 -5.697
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 1.23E-06 -0.205 0.041 -4.945
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 1.19E-06 0.195 0.039 4.948
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 2.07E-07 0.214 0.040 5.312
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63623 P4:2486 NK Activating 2 16+56 16+56/CD2+335+158a-158b-R7- 8.58E-07 -0.250 0.050 -5.010
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63623 P4:2486 NK Activating 2 16+56 16+56/CD2+335+158a-158b-R7- 6.33E-07 -0.242 0.048 -5.082
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63623 P4:2486 NK Activating 2 16+56 16+56/CD2+335+158a-158b-R7- 7.60E-07 0.206 0.040 5.082
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63625 P4:2488 NK Activating 2 16+56 16+56/314+335+158a-158b-R7- 9.03E-08 -0.272 0.050 -5.447
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63625 P4:2488 NK Activating 2 16+56 16+56/314+335+158a-158b-R7- 7.32E-08 -0.261 0.048 -5.490
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63625 P4:2488 NK Activating 2 16+56 16+56/314+335+158a-158b-R7- 4.19E-07 0.210 0.041 5.173
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63626 P4:2489 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b-R7- 1.54E-06 -0.245 0.050 -4.885
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63626 P4:2489 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b-R7- 1.34E-06 -0.236 0.048 -4.921
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63626 P4:2489 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b-R7- 8.03E-07 0.206 0.041 5.070
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 4.62E-09 -0.282 0.047 -5.994
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 2.85E-09 -0.272 0.045 -6.079
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 2.26E-07 -0.207 0.039 -5.276
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 1.79E-07 0.198 0.037 5.319
IGP59 The percentage of fucosylation of agalactosylated structures immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 4.57E-07 0.198 0.039 5.131
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 3.49E-08 0.215 0.038 5.638
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63675 P4:2532 NK Activating 2 16+56 16+56/CD2+335+337-158b-R7- 2.26E-07 -0.251 0.048 -5.270
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63675 P4:2532 NK Activating 2 16+56 16+56/CD2+335+337-158b-R7- 1.72E-07 -0.241 0.045 -5.333
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63675 P4:2532 NK Activating 2 16+56 16+56/CD2+335+337-158b-R7- 1.62E-06 0.184 0.038 4.902
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63675 P4:2532 NK Activating 2 16+56 16+56/CD2+335+337-158b-R7- 4.20E-07 0.200 0.038 5.190
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 1.42E-08 -0.275 0.048 -5.793
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 1.37E-08 -0.262 0.045 -5.798
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 7.02E-07 -0.200 0.040 -5.052
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 8.60E-07 0.189 0.038 5.008
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 1.39E-07 0.207 0.039 5.377
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63678 P4:2535 NK Activating 2 16+56 16+56/CD2+314+335+337-158b-R7- 3.64E-07 -0.248 0.048 -5.174
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63678 P4:2535 NK Activating 2 16+56 16+56/CD2+314+335+337-158b-R7- 3.79E-07 -0.236 0.046 -5.172
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63678 P4:2535 NK Activating 2 16+56 16+56/CD2+314+335+337-158b-R7- 5.68E-07 0.199 0.039 5.129
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 6.83E-09 -0.280 0.047 -5.924
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 4.04E-09 -0.270 0.045 -6.017
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 2.97E-07 -0.205 0.039 -5.224
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 2.41E-07 0.197 0.037 5.262
IGP59 The percentage of fucosylation of agalactosylated structures immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 6.17E-07 0.196 0.039 5.071
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 4.67E-08 0.214 0.038 5.585
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63704 P4:2559 NK Activating 2 16+56 16+56/CD2+335+158b-R7- 3.13E-07 -0.248 0.048 -5.206
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63704 P4:2559 NK Activating 2 16+56 16+56/CD2+335+158b-R7- 2.36E-07 -0.239 0.045 -5.271
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63704 P4:2559 NK Activating 2 16+56 16+56/CD2+335+158b-R7- 5.59E-07 0.198 0.039 5.133
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 1.98E-08 -0.272 0.048 -5.731
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 1.94E-08 -0.259 0.045 -5.734
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 1.06E-06 -0.197 0.040 -4.969
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 1.29E-06 0.185 0.038 4.925
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 2.06E-07 0.204 0.039 5.303
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63708 P4:2562 NK Activating 2 16+56 16+56/CD2+314+335+158b-R7- 4.66E-07 -0.246 0.048 -5.125
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63708 P4:2562 NK Activating 2 16+56 16+56/CD2+314+335+158b-R7- 4.49E-07 -0.235 0.046 -5.138
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_63708 P4:2562 NK Activating 2 16+56 16+56/CD2+314+335+158b-R7- 6.39E-07 0.198 0.039 5.105
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63835 P4:2677 NK Activating 2 16+56 16+56/335+337-158a-R7- 1.61E-06 -0.222 0.045 -4.881
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63925 P4:2758 NK Activating 2 16+56 16+56/335+337-R7- 1.32E-06 -0.210 0.043 -4.916
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 1.57E-08 -0.286 0.050 -5.775
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 8.68E-09 -0.277 0.047 -5.885
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 5.85E-07 -0.210 0.041 -5.094
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 4.26E-07 0.202 0.039 5.154
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 7.39E-07 0.205 0.041 5.040
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 7.26E-08 0.221 0.040 5.509
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64342 P4:3132 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b- 4.75E-07 -0.256 0.050 -5.128
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64342 P4:3132 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b- 3.55E-07 -0.247 0.048 -5.196
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64342 P4:3132 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b- 4.46E-07 0.210 0.040 5.186
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 4.41E-08 -0.278 0.050 -5.582
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 3.59E-08 -0.267 0.047 -5.623
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 1.38E-06 -0.205 0.042 -4.921
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 1.59E-06 0.194 0.040 4.887
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 2.30E-07 0.214 0.040 5.290
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64345 P4:3135 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b- 7.22E-07 -0.252 0.050 -5.040
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64345 P4:3135 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b- 6.52E-07 -0.242 0.048 -5.068
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64345 P4:3135 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b- 3.94E-07 0.211 0.040 5.211
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 2.28E-08 -0.283 0.050 -5.706
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 1.27E-08 -0.274 0.047 -5.817
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 8.59E-07 -0.208 0.041 -5.018
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 6.07E-07 0.200 0.039 5.084
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 1.07E-06 0.202 0.041 4.965
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 1.03E-07 0.219 0.040 5.444
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64371 P4:3159 NK Activating 2 16+56 16+56/CD2+335+158a-158b- 7.27E-07 -0.252 0.050 -5.043
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64371 P4:3159 NK Activating 2 16+56 16+56/CD2+335+158a-158b- 5.35E-07 -0.244 0.048 -5.115
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64371 P4:3159 NK Activating 2 16+56 16+56/CD2+335+158a-158b- 5.96E-07 0.208 0.040 5.130
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64374 P4:3161 NK Activating 2 16+56 16+56/314+335+158a-158b- 6.54E-08 -0.275 0.050 -5.508
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64374 P4:3161 NK Activating 2 16+56 16+56/314+335+158a-158b- 5.23E-08 -0.264 0.048 -5.553
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64374 P4:3161 NK Activating 2 16+56 16+56/314+335+158a-158b- 2.93E-07 0.213 0.041 5.243
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64375 P4:3162 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b- 1.52E-06 -0.245 0.050 -4.887
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64375 P4:3162 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b- 1.36E-06 -0.235 0.048 -4.918
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64375 P4:3162 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b- 8.44E-07 0.205 0.041 5.060
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 4.09E-09 -0.284 0.047 -6.015
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 2.54E-09 -0.274 0.045 -6.099
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 2.24E-07 -0.207 0.039 -5.277
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 1.80E-07 0.199 0.037 5.319
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 4.14E-07 0.199 0.039 5.151
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 3.60E-08 0.215 0.038 5.632
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64432 P4:3213 NK Activating 2 16+56 16+56/CD2+335+337-158b- 1.89E-07 -0.253 0.048 -5.305
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64432 P4:3213 NK Activating 2 16+56 16+56/CD2+335+337-158b- 1.46E-07 -0.243 0.045 -5.363
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64432 P4:3213 NK Activating 2 16+56 16+56/CD2+335+337-158b- 1.46E-06 0.185 0.038 4.922
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64432 P4:3213 NK Activating 2 16+56 16+56/CD2+335+337-158b- 3.89E-07 0.201 0.039 5.204
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 1.37E-08 -0.275 0.047 -5.799
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 1.40E-08 -0.262 0.045 -5.794
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 7.93E-07 -0.199 0.040 -5.027
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 9.69E-07 0.188 0.038 4.984
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 1.61E-07 0.206 0.039 5.348
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64435 P4:3216 NK Activating 2 16+56 16+56/CD2+314+335+337-158b- 3.63E-07 -0.248 0.048 -5.175
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64435 P4:3216 NK Activating 2 16+56 16+56/CD2+314+335+337-158b- 3.74E-07 -0.236 0.046 -5.174
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64435 P4:3216 NK Activating 2 16+56 16+56/CD2+314+335+337-158b- 5.36E-07 0.199 0.039 5.140
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 4.94E-09 -0.283 0.047 -5.982
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 2.97E-09 -0.273 0.045 -6.072
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 2.69E-07 -0.206 0.039 -5.243
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 2.31E-07 0.197 0.037 5.271
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 4.83E-07 0.198 0.039 5.120
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 4.55E-08 0.214 0.038 5.589
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64462 P4:3240 NK Activating 2 16+56 16+56/CD2+335+158b- 2.95E-07 -0.249 0.048 -5.218
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64462 P4:3240 NK Activating 2 16+56 16+56/CD2+335+158b- 2.28E-07 -0.240 0.045 -5.277
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64462 P4:3240 NK Activating 2 16+56 16+56/CD2+335+158b- 5.76E-07 0.198 0.039 5.126
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 2.02E-08 -0.272 0.048 -5.727
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 2.01E-08 -0.259 0.045 -5.728
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 1.16E-06 -0.196 0.040 -4.951
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 1.41E-06 0.185 0.038 4.908
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 2.28E-07 0.204 0.039 5.282
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64465 P4:3243 NK Activating 2 16+56 16+56/CD2+314+335+158b- 4.83E-07 -0.246 0.048 -5.118
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64465 P4:3243 NK Activating 2 16+56 16+56/CD2+314+335+158b- 4.53E-07 -0.235 0.046 -5.136
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64465 P4:3243 NK Activating 2 16+56 16+56/CD2+314+335+158b- 6.49E-07 0.199 0.039 5.102
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64610 P4:3374 NK Activating 2 16+56 16+56/335+337-158a- 1.18E-06 -0.225 0.045 -4.944
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64641 P4:3401 NK Activating 2 16+56 16+56/335+158a- 1.61E-06 -0.222 0.046 -4.880
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64700 P4:3455 NK Activating 2 16+56 16+56/335+337- 1.14E-06 -0.211 0.043 -4.945
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64730 P4:3482 NK Activating 2 16+56 16+56/335+ 1.56E-06 -0.208 0.043 -4.881
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63906 P4:2740 NK Effector 16+56 16+56/335-337-R7- 1.83E-06 0.224 0.046 4.852
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63906 P4:2740 NK Effector 16+56 16+56/335-337-R7- 1.19E-06 0.217 0.044 4.943
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_63935 P4:2767 NK Effector 16+56 16+56/335-R7- 1.60E-06 0.225 0.046 4.880
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_63935 P4:2767 NK Effector 16+56 16+56/335-R7- 1.05E-06 0.218 0.044 4.969
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64084 P4:2900 NK Effector 16+56 16+56/335-337-158a-158b+R7- 1.67E-06 0.246 0.051 4.862
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64084 P4:2900 NK Effector 16+56 16+56/335-337-158a-158b+R7- 9.62E-07 0.219 0.044 4.982
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64084 P4:2900 NK Effector 16+56 16+56/335-337-158a-158b+R7- 8.06E-07 -0.219 0.044 -5.017
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 1.61E-07 0.286 0.054 5.340
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 1.68E-07 0.274 0.051 5.328
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 1.60E-07 0.240 0.045 5.339
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 5.30E-07 -0.225 0.044 -5.104
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 5.31E-07 -0.227 0.045 -5.100
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 8.38E-08 -0.244 0.045 -5.463
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 1.52E-07 0.287 0.054 5.351
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 1.58E-07 0.274 0.051 5.339
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 1.52E-07 0.240 0.045 5.349
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 5.15E-07 -0.225 0.044 -5.110
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 5.10E-07 -0.227 0.045 -5.108
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 8.11E-08 -0.244 0.045 -5.470
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64680 P4:3437 NK Effector 16+56 16+56/335-337- 1.80E-06 0.207 0.043 4.851
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64710 P4:3464 NK Effector 16+56 16+56/335- 1.68E-06 0.207 0.043 4.866
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 1.54E-07 0.286 0.054 5.349
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 1.58E-07 0.274 0.051 5.340
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 1.47E-07 0.240 0.045 5.356
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 4.96E-07 -0.226 0.044 -5.118
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 4.98E-07 -0.228 0.045 -5.112
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 7.72E-08 -0.244 0.045 -5.479
IGP2 The percentage of A2 glycan in total  IgG glycans immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 1.51E-07 0.287 0.054 5.353
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 1.54E-07 0.275 0.051 5.345
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 1.42E-07 0.240 0.045 5.362
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 4.85E-07 -0.226 0.044 -5.122
IGP59 The percentage of fucosylation of agalactosylated structures immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 4.90E-07 -0.228 0.045 -5.116
IGP60 The percentage of fucosylation of monogalactosylated structures immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 7.54E-08 -0.244 0.045 -5.483
Table S3: Associations of 51 immune cell traits with AITD and TPOAb level in the TwinsUK cohort
immuneTrait ID Trait ID Canonical name Lineage Subset name Pvalue Beta SE Zscore Pvalue Beta SE Zscore
immuno_64464 P4:3242 NK Activating 2 16+56 16+56/314+335+158b- 0.043 -0.049 0.024 -2.060 0.768 0.000 0.001 -0.297
immuno_63707 P4:2561 NK Activating 2 16+56 16+56/314+335+158b-R7- 0.045 -0.049 0.024 -2.041 0.769 0.000 0.001 -0.296
immuno_64374 P4:3161 NK Activating 2 16+56 16+56/314+335+158a-158b- 0.049 -0.046 0.023 -1.998 0.709 0.000 0.001 -0.377
immuno_63625 P4:2488 NK Activating 2 16+56 16+56/314+335+158a-158b-R7- 0.050 -0.046 0.023 -1.990 0.723 0.000 0.001 -0.357
immuno_64434 P4:3215 NK Activating 2 16+56 16+56/314+335+337-158b- 0.051 -0.047 0.024 -1.986 0.850 0.000 0.001 -0.191
immuno_63677 P4:2534 NK Activating 2 16+56 16+56/314+335+337-158b-R7- 0.051 -0.047 0.024 -1.985 0.817 0.000 0.001 -0.233
immuno_63703 P4:2558 NK Activating 2 16+56 16+56/335+158b-R7- 0.051 -0.048 0.024 -1.980 0.949 0.000 0.001 -0.065
immuno_64460 P4:3239 NK Activating 2 16+56 16+56/335+158b- 0.052 -0.047 0.024 -1.969 0.951 0.000 0.001 -0.062
immuno_64344 P4:3134 NK Activating 2 16+56 16+56/314+335+337-158a-158b- 0.055 -0.045 0.023 -1.951 0.756 0.000 0.001 -0.314
immuno_63597 P4:2462 NK Activating 2 16+56 16+56/314+335+337-158a-158b-R7- 0.056 -0.045 0.023 -1.945 0.753 0.000 0.001 -0.317
immuno_63674 P4:2531 NK Activating 2 16+56 16+56/335+337-158b-R7- 0.057 -0.047 0.024 -1.930 0.994 0.000 0.001 -0.008
immuno_64431 P4:3212 NK Activating 2 16+56 16+56/335+337-158b- 0.059 -0.046 0.024 -1.914 0.984 0.000 0.001 0.021
immuno_64370 P4:3158 NK Activating 2 16+56 16+56/335+158a-158b- 0.065 -0.044 0.023 -1.870 0.851 0.000 0.001 -0.190
immuno_63595 P4:2460 NK Activating 2 16+56 16+56/335+337-158a-158b-R7- 0.066 -0.044 0.023 -1.867 0.925 0.000 0.001 -0.095
immuno_63622 P4:2485 NK Activating 2 16+56 16+56/335+158a-158b-R7- 0.066 -0.044 0.023 -1.865 0.844 0.000 0.001 -0.198
immuno_64341 P4:3131 NK Activating 2 16+56 16+56/335+337-158a-158b- 0.072 -0.043 0.023 -1.826 0.945 0.000 0.001 -0.070
immuno_64641 P4:3401 NK Activating 2 16+56 16+56/335+158a- 0.086 -0.041 0.024 -1.729 0.750 0.000 0.001 0.324
immuno_63906 P4:2740 NK Effector 16+56 16+56/335-337-R7- 0.086 0.043 0.025 1.726 0.351 0.000 0.001 -0.954
immuno_64680 P4:3437 NK Effector 16+56 16+56/335-337- 0.087 0.043 0.025 1.727 0.365 0.000 0.001 -0.926
immuno_63935 P4:2767 NK Effector 16+56 16+56/335-R7- 0.087 0.043 0.025 1.720 0.335 -0.001 0.001 -0.987
immuno_64730 P4:3482 NK Activating 2 16+56 16+56/335+ 0.088 -0.043 0.025 -1.719 0.358 0.000 0.001 0.941
immuno_64710 P4:3464 NK Effector 16+56 16+56/335- 0.088 0.043 0.025 1.718 0.355 0.000 0.001 -0.947
immuno_64610 P4:3374 NK Activating 2 16+56 16+56/335+337-158a- 0.094 -0.040 0.024 -1.688 0.701 0.000 0.001 0.389
immuno_63835 P4:2677 NK Activating 2 16+56 16+56/335+337-158a-R7- 0.096 -0.040 0.024 -1.675 0.710 0.000 0.001 0.378
immuno_64700 P4:3455 NK Activating 2 16+56 16+56/335+337- 0.104 -0.041 0.025 -1.637 0.313 0.001 0.001 1.035
immuno_63925 P4:2758 NK Activating 2 16+56 16+56/335+337-R7- 0.104 -0.041 0.025 -1.636 0.322 0.001 0.001 1.016
immuno_64465 P4:3243 NK Activating 2 16+56 16+56/CD2+314+335+158b- 0.153 -0.033 0.023 -1.443 0.988 0.000 0.001 -0.016
immuno_63708 P4:2562 NK Activating 2 16+56 16+56/CD2+314+335+158b-R7- 0.155 -0.033 0.023 -1.434 0.995 0.000 0.001 0.006
immuno_64375 P4:3162 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b- 0.161 -0.032 0.023 -1.414 0.838 0.000 0.001 -0.211
immuno_63626 P4:2489 NK Activating 2 16+56 16+56/CD2+314+335+158a-158b-R7- 0.162 -0.032 0.023 -1.410 0.855 0.000 0.001 -0.188
immuno_64435 P4:3216 NK Activating 2 16+56 16+56/CD2+314+335+337-158b- 0.164 -0.033 0.023 -1.404 0.916 0.000 0.001 0.109
immuno_63678 P4:2535 NK Activating 2 16+56 16+56/CD2+314+335+337-158b-R7- 0.165 -0.033 0.023 -1.400 0.896 0.000 0.001 0.135
immuno_62860 P4:18 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b-R7- 0.175 -0.031 0.023 -1.368 0.963 0.000 0.001 -0.048
immuno_63623 P4:2486 NK Activating 2 16+56 16+56/CD2+335+158a-158b-R7- 0.178 -0.031 0.023 -1.358 0.875 0.000 0.001 -0.162
immuno_63704 P4:2559 NK Activating 2 16+56 16+56/CD2+335+158b-R7- 0.179 -0.032 0.024 -1.354 0.939 0.000 0.001 0.079
immuno_64371 P4:3159 NK Activating 2 16+56 16+56/CD2+335+158a-158b- 0.179 -0.031 0.023 -1.356 0.856 0.000 0.001 -0.187
immuno_64462 P4:3240 NK Activating 2 16+56 16+56/CD2+335+158b- 0.180 -0.032 0.024 -1.354 0.940 0.000 0.001 0.078
immuno_64345 P4:3135 NK Activating 2 16+56 16+56/CD2+314+335+337-158a-158b- 0.180 -0.031 0.023 -1.351 0.923 0.000 0.001 -0.100
immuno_63675 P4:2532 NK Activating 2 16+56 16+56/CD2+335+337-158b-R7- 0.189 -0.031 0.024 -1.323 0.864 0.000 0.001 0.177
immuno_64432 P4:3213 NK Activating 2 16+56 16+56/CD2+335+337-158b- 0.189 -0.031 0.024 -1.326 0.896 0.000 0.001 0.135
immuno_64342 P4:3132 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b- 0.197 -0.030 0.023 -1.300 0.981 0.000 0.001 -0.024
immuno_63596 P4:2461 NK Activating 2 16+56 16+56/CD2+335+337-158a-158b-R7- 0.202 -0.030 0.023 -1.286 0.978 0.000 0.001 -0.028
immuno_64157 P4:2967 NK Effector 16+56 16+56/335-337-158b+R7- 0.805 0.006 0.023 0.248 0.464 -0.001 0.001 -0.758
immuno_64187 P4:2994 NK Effector 16+56 16+56/335-158b+R7- 0.808 0.006 0.023 0.244 0.466 -0.001 0.001 -0.754
immuno_64980 P4:3707 NK Effector 16+56 16+56/335-158b+ 0.816 0.005 0.023 0.233 0.459 -0.001 0.001 -0.765
immuno_64950 P4:3680 NK Effector 16+56 16+56/335-337-158b+ 0.816 0.005 0.023 0.233 0.457 -0.001 0.001 -0.769
immuno_64161 P4:2970 NK Activating 1 16+56 16+56/314+335-337-158b+R7- 0.893 0.003 0.023 0.135 0.454 -0.001 0.001 -0.778
immuno_64953 P4:3683 NK Activating 1 16+56 16+56/314+335-337-158b+ 0.896 0.003 0.023 0.130 0.453 -0.001 0.001 -0.778
immuno_64190 P4:2997 NK Activating 1 16+56 16+56/314+335-158b+R7- 0.904 0.003 0.023 0.121 0.453 -0.001 0.001 -0.780
immuno_64984 P4:3710 NK Activating 1 16+56 16+56/314+335-158b+ 0.905 0.003 0.023 0.120 0.453 -0.001 0.001 -0.778
immuno_64084 P4:2900 NK Effector 16+56 16+56/335-337-158a-158b+R7- 0.970 0.001 0.024 0.038 0.528 -0.001 0.001 -0.648
AITD TPOAb level
Table S4: Hits from selected eQTL studies for two SNPs, rs1521 and rs3094228 in the thyroid cells and whole blood
* GWAS catalog for the genetic variants associated with thyroid phenotypes(Data downloaded from GWAS Catalog on 17/06/2015) 
** eQTLs from Haploreg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php)  and GTEx  v6,v7, v8 (https://www.gtexportal.org/home/)
Chromosomestart (hg38)end     (hg38) Phenotype Study ID Paper Title PMID ref allele Tissue Correlated gene NES p-value
Thyroid VARS2 ENSG00000137411.16 0.29 5.00E-12
Thyroid MIR6891 ENSG00000277402.1 0.35 6.20E-11
Thyroid HCG27 ENSG00000206344.7 0.21 1.40E-09
Thyroid HLA-C ENSG00000204525.16 -0.24 8.20E-08
Thyroid PSORS1C3 ENSG00000204528.3 0.33 7.50E-08
Thyroid XXbac-BPG181B23.7 ENSG00000272221.1 -0.25 1.40E-06
Thyroid MICA ENSG00000204520.12 -0.18 2.50E-05
Thyroid PRRT1 ENSG00000204314.10 0.12 4.20E-05
Thyroid FLOT1 ENSG00000137312.14 0.11 6.50E-05
Whole_Blood XXbac-BPG181B23.7 ENSG00000272221.1 -0.34 2.20E-17
Whole_Blood MIR6891 ENSG00000277402.1 0.28 1.40E-09
Whole_Blood PSORS1C3 ENSG00000204528.3 0.21 2.30E-08
Whole_Blood XXbac-BPG299F13.17 ENSG00000272501.1 -0.12 2.20E-07
Whole_Blood HCG27 ENSG00000206344.7 0.088 1.20E-05
Whole_Blood VARS2 ENSG00000137411.16 0.1 2.20E-05
Whole_Blood DDR1 ENSG00000204580.13 0.17 2.80E-05
Whole_Blood ZBTB12 ENSG00000204366.3 0.2 3.20E-05
Whole_Blood HLA-C ENSG00000204525.16 -0.12 5.70E-05
Whole_Blood C4A ENSG00000244731.7 -0.2 1.30E-04
Whole_Blood FLOT1 ENSG00000137312.14 0.045 1.70E-04
Thyroid VARS2 ENSG00000137411.12 0.31 3.40E-09
Thyroid HCG27 ENSG00000206344.6 0.23 6.90E-08
Thyroid HLA-C ENSG00000204525.10 -0.25 8.30E-06
Thyroid PSORS1C3 ENSG00000204528.3 0.31 2.00E-05
Whole_Blood XXbac-BPG181B23.7 ENSG00000272221.1 -0.33 7.90E-08
Thyroid HLA-C ENSG00000204525.10 NA 1.28E-08
Thyroid XXbac-BPG248L24.12 NA 1.03E-08
Whole_Blood HLA-C ENSG00000204525.10 NA 2.98E-08
Whole_Blood XXbac-BPG181B23.7 ENSG00000272221.1 NA 2.86E-07
Whole_Blood XXbac-BPG248L24.12 NA 8.29E-09
Whole_Blood - NA 1.11E-35
Whole_Blood - NA 6.64E-38
Whole_Blood AIF1 ENSG00000204472 NA 2.51E-06
Whole_Blood ATP6V1G2|BAT1 ENSG00000213760 NA 9.31E-16
Whole_Blood HCP5 ENSG00000206337.6 NA 4.62E-06
Whole_Blood LTA ENSG00000226979 NA 8.46E-10
Whole_Blood MICB ENSG00000204516.5 NA 5.24E-04
Thyroid C4A ENSG00000244731.7 -0.39 2.00E-16
Thyroid CYP21A1P ENSG00000204338.8 -0.37 2.80E-14
Thyroid MICB ENSG00000204516.9 0.26 3.70E-09
Thyroid HCP5 ENSG00000206337.10 -0.24 3.00E-08
Thyroid FLOT1 ENSG00000137312.14 0.17 5.00E-08
Thyroid PSORS1C1 ENSG00000204540.10 -0.37 7.00E-08
Thyroid CCHCR1 ENSG00000204536.13 0.2 2.00E-07
Thyroid HLA-C ENSG00000204525.16 0.25 9.30E-07
Thyroid HLA-S ENSG00000225851.1 -0.31 3.80E-06
Thyroid RNF5 ENSG00000204308.7 -0.14 2.70E-05
Whole_Blood C4A ENSG00000244731.7 -0.48 1.50E-16
Whole_Blood C4B ENSG00000224389.8 0.47 2.60E-13
Whole_Blood CYP21A1P ENSG00000204338.8 -0.4 1.10E-12
Whole_Blood CYP21A2 ENSG00000231852.6 0.4 3.20E-10
Whole_Blood FLOT1 ENSG00000137312.14 0.058 2.20E-05
Whole_Blood HLA-S ENSG00000225851.1 -0.27 3.70E-05
Whole_Blood CCHCR1 ENSG00000204536.13 0.13 8.10E-05
Whole_Blood XXbac-BPG248L24.12 ENSG00000271581.1 -0.24 1.50E-04
Thyroid C4A ENSG00000244731.3 -0.4 3.40E-13
Thyroid CYP21A1P ENSG00000204338.4 -0.37 1.10E-09
Thyroid HCP5 ENSG00000206337.6 -0.32 1.30E-09
Thyroid PSORS1C1 ENSG00000204540.6 -0.4 4.00E-06
Thyroid HCG22 ENSG00000228789.2 -0.35 5.10E-06
Thyroid MICB ENSG00000204516.5 0.26 5.10E-06
Thyroid CCHCR1 ENSG00000204536.9 0.21 1.70E-05
Whole_Blood C4A ENSG00000244731.3 -0.48 4.00E-09
Whole_Blood CYP21A1P ENSG00000204338.4 -0.41 3.80E-07
Whole_Blood C4B ENSG00000224389.4 0.41 9.90E-06
Whole_Blood CYP21A2 ENSG00000231852.2 0.38 2.90E-05
Thyroid ATP6V1G2 ENSG00000213760.10 0.28 1.10E-05
Thyroid SKIV2L ENSG00000204351.11 0.23 2.20E-05
Thyroid CCHCR1 ENSG00000204536.13 -0.22 1.30E-04
Thyroid VARS2 ENSG00000137411.16 -0.27 2.00E-04
Whole_Blood MICA ENSG00000204520.12 0.22 3.40E-04
Whole_Blood HLA-C ENSG00000204525.10 -0.3 5.60E-05
Thyroid CCHCR1 ENSG00000204536.9 -0.29 2.40E-05
Thyroid ATP6V1G2 ENSG00000213760.10 0.3 2.10E-06
Thyroid SKIV2L ENSG00000204351.11 0.24 8.70E-06
Thyroid VARS2 ENSG00000137411.16 -0.28 1.70E-04
Thyroid CCHCR1 ENSG00000204536.13 -0.21 2.70E-04
Thyroid DDR1 ENSG00000204580.13 -0.18 4.60E-04
Whole blood MICA ENSG00000204520.12 0.22 2.40E-04
Thyroid CCHCR1 ENSG00000204536.9 -0.28 4.80E-05
Thyroid ATP6V1G2 ENSG00000213760.10 0.28 1.10E-05
Thyroid SKIV2L ENSG00000204351.11 0.23 2.20E-05
Thyroid CCHCR1 ENSG00000204536.13 -0.22 1.30E-04
Thyroid VARS2 ENSG00000137411.16 -0.27 2.00E-04
Whole_Blood MICA ENSG00000204520.12 0.22 3.40E-04
Whole_Blood HLA-C ENSG00000204525.10 -0.3 5.50E-05
Thyroid CCHCR1 ENSG00000204536.9 -0.29 1.90E-05
eQTL**
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risk allele
rs3094228-C 6 31462150 31462150
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Table S5 : Genes reported for genetic variants associated with thyroid phenotypes and immune cell traits
* the closest genes reported in GWAS catalog for the genetic variants associated with thyroid phenotypes and immune cell traits (Data downloaded from GWAS Catalog on 17/06/2015) 
** Roederer, M et al., Cell, 2015, doi: 10.1016/j.cell.2015.02.046 and Mangino et al, Nature Communications, 2017, https://doi.org/10.1038/ncomms13850
Lead SNP Chromosome start (hg38)
end     
(hg38) Phenotype










Lead SNP Chromosome start (hg38) end     (hg38) start (hg19)
end     
(hg19)
Immune Name in 
TwinsUK Phenotypes
<0.2 12667 rs2596460 6 31449483 31449483 31449733 31449733 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 12155 rs2596457 6 31449995 31449995 31450245 31450245 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 9490 rs2523691 6 31452660 31452660 31452910 31452910 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
MICA rs1521 6 31382927 31382927 Graves' disease Yes <0.2 -66556 rs2596460 6 31449483 31449483 31449733 31449733 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 365816 rs12603968 17 33771319 33771319 33771319 33771319 P4:3551 NK Effector 16+56/314-158a+
<0.2 366131 rs12602135 17 33771004 33771004 33771004 33771004 P4:3551 NK Effector 16+56/314-158a+
rs6759952 2 217406996 217406996 <0.2 -317240
 rs966423 2 217445617 217445617 <0.2 -278619
GLIS3 rs1571583 9 4267209 4267209 Thyroid hormone levels No <0.2 492850 rs10973456 9 3774359 3774359 3774359 3774359 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
HACE1 rs9322817 6 104784358 104784358 Thyroid stimulating hormone level No <0.2 378569 rs156205 6 104405789 104405789 104405789 104405789 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
L3MBTL4 rs948426 18 6567183 6567183 Hypothyroidism No <0.2 438743 rs17486103 18 6128440 6128440 6128440 6128440 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 -240528 rs11581697 1 61395352 61395352 61395352 61395352 P4:3551 NK Effector 16+56/314-158a+
<0.2 -240632 rs12072379 1 61395456 61395456 61395456 61395456 P4:3551 NK Effector 16+56/314-158a+
NFIB rs10961534 9 14470835 14470835 Hypothyroidism No <0.2 31760 rs11787815 9 14439075 14439075 14439075 14439075 P4:3551 NK Effector 16+56/314-158a+
NR3C2 rs10028213 4 148731458 148731458 Thyroid stimulating hormone level No <0.2 441933 rs3910047 4 148289525 148289525 148289525 148289525 P4:3551 NK Effector 16+56/314-158a+
<0.2 5271541 rs4279551 8 27287215 27287215 27287215 27287215 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 510838  rs2881470 8 32047918 32047918 32047918 32047918 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 488634 rs1462900 8 32070122 32070122 32070122 32070122 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 480970 rs1381871 8 32077786 32077786 32077786 32077786 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 496755 rs1471387 8 32078096 32078096 32078096 32078096 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 494464 rs1947734 8 32080387 32080387 32080387 32080387 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 488995 rs7818326 8 32085856 32085856 32085856 32085856 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 488541 rs16878780 8 32086310 32086310 32086310 32086310 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 488339 rs9297185 8 32086512 32086512 32086512 32086512 P7:110 DC mDC imDC 11c+ (nodim)/1c-/16+/32+
<0.2 152041 rs551901 6 165480954 165480954 165480954 165480954 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 151764 rs684847 6 165481231 165481231 165481231 165481231 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 691727 rs9302936 17 71439668 71439668 71439668 71439668 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 686259 rs1990222 17 71445136 71445136 71445136 71445136 P4:3763 NK Activating 1 16+56/CD2-314+335-337-158a+158b+
<0.2 -121433 rs10494086 1 107935631 107935631 107935631 107935631 P4:3551 NK Effector 16+56/314-158a+
<0.2 -127812 rs1020812 1 107942010 107942010 107942010 107942010 P4:3551 NK Effector 16+56/314-158a+
 rs4915077 1 107823394 107823394 Hypothyroidism No <0.2 -123692  rs6696531 1 107947086 107947086 107947086 107947086 P4:3551 NK Effector 16+56/314-158a+
VAV3
No
SOX9 rs9915657 17 72131395 72131395 Thyroid hormone levels No
PDE10A rs753760 6 165632995 165632995 Thyroid hormone levels
rs12126655
No
rs2439302 8 32574851 32574851 Thyroid cancer No
Thyroid hormone levels
NRG1
rs7825175 8 32558756 32558756
217724236 217724236 16+56/314-158a+
NFIA rs334699 1 61154824 61154824 Thyroid hormone levels No
2 217724236 217724236 P4:3551 NK Effector
No
DIRC3 Thyroid cancer No rs744564
ACCN1 rs9901756 17 34137135 34137135 Hypothyroidism
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Table S6: Glycome-wide associations studies of 17 AITD-IgG N-glycan traits with 1,113 circulating proteins. Only significant ones were put here.
Glycan ID Description Soma ID Target Uniprot P-value Beta SE 
IGP2 The percentage of A2 glycan in total  IgG glycans SL008609 FCG3B O75015 1.46E-06 0.051 0.010
IGP8 The percentage of FA2[3]G1 glycan in total  IgG glycans SL007464 AMHR2 Q16671 1.50E-07 0.029 0.005
IGP8 The percentage of FA2[3]G1 glycan in total  IgG glycans SL004857 Desmoglein-2 Q14126 2.15E-06 0.032 0.007
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) SL008609 FCG3B O75015 2.63E-06 0.050 0.010
IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GPn) SL008609 FCG3B O75015 3.88E-06 0.045 0.009
IGP48 The percentage of FA2[3]G1 glycan in total  neutral IgG glycans (GPn) SL002644 ERBB1 P00533 3.04E-06 0.023 0.005
IGP48 The percentage of FA2[3]G1 glycan in total  neutral IgG glycans (GPn) SL000283 b2-Microglobulin P61769 4.16E-06 -0.034 0.007
IGP56 The percentage of monogalactosylated structures in total neutral  IgG glycans SL000283 b2-Microglobulin P61769 5.10E-07 -0.037 0.007
IGP57 The percentage of digalactosylated structures in total neutral IgG glycans SL004159 TRAIL R4 Q9UBN6 2.95E-06 -0.041 0.008
IGP58 The percentage of all fucosylated (+/- bisecting GlcNAc) structures in total neutral IgG glycans SL008609 FCG3B O75015 5.21E-06 -0.044 0.009
IGP59 The percentage of fucosylation of agalactosylated structures SL008609 FCG3B O75015 9.33E-06 -0.044 0.010
IGP60 The percentage of fucosylation of monogalactosylated structures SL008609 FCG3B O75015 4.06E-07 -0.048 0.009
IGP62 The percentage of fucosylated (without bisecting GlcNAc) structures in total neutral IgG glycans SL004672 BCMA Q02223 5.44E-08 0.041 0.007
IGP63 The percentage of fucosylation (without bisecting GlcNAc) of agalactosylated structures SL004672 BCMA Q02223 1.47E-07 0.041 0.007
IGP63 The percentage of fucosylation (without bisecting GlcNAc) of agalactosylated structures SL004857 Desmoglein-2 Q14126 8.02E-06 0.032 0.007
Table S7: Genetic variants associated with thyroid phenotypes and AITD-IgG N-glycan traits overlapping pQTL identified in INTERVAL project (LD r2>0.8)
*Sun et al, Nature, 2018, doi: 10.1038/s41586-018-0175-2






















1 157699488 157699488 rs3761959-A, rs3761959-G rs3761959
Graves  disease, Multiple 
sclerosis 1q23.1 FCRL3 FCRL3 intron
1 157701026 157701026 rs7528684-T rs7528684
Type 1 diabetes 
autoantibodies, Rheumatoid 
arthritis, Graves disease
1q23.1 FCRL3 FCRL3 nearGene-5 I-A2A
No detected DHFR.9823.2.3 DYR Dihydrofolate reductase P00374 trans ABO rs676457 0.99
SL004516 MBL2.3000.66.1 MBL Mannose-binding protein C P11226 trans ABO rs139840563 0.98




P16442 cis ABO rs505922 1
SL004857 DSG2.9484.75.3 Desmoglein-2 Desmoglein-2 Q14126 trans ABO rs687621 0.97
SL005157 CD209.3029.52.2 DC-SIGN CD209 antigen Q9NNX6 trans ABO rs505922 1





P07359 trans BRAP rs11065979 0.81
VCAM1.2967.8.1 VCAM-1 Vascular cell adhesion protein 1 P19320 trans SH2B3 rs3184504 1
Protein quantitative trait loci, 
Venous thromboembolism, 
End-stage coagulation, 























Type 1 diabetes, Platelet 
counts, Blood metabolite 
levels, Beta-2 microglubulin 
plasma levels, Diastolic blood 
pressure, Coronary artery 
disease, Eosinophil counts, 
Systolic blood pressure, 
Autoimmune hepatitis type-1, 
Red blood cell traits, 





GWAS Catalog (Data downloaded from GWAS Catalog on 17/06/2015) pQTL*
9 133273813 133273813





Table S8: Heritability of AITD, 17 IgG N-glycan traits and 51 immune cell traits in the TwinsUK cohort
* Martin et al, 2018
** Mangino et al, Nature Communications, 2017, https://doi.org/10.1038/ncomms13850
type features  general info best model H2 [95%CI] A [95%CI] D [95%CI] C [95%CI]  E [95%CI]  
AITD DE 0.63 [0.59-0.67] NS 0.63 [0.59-0.67] NS 0.36 [0.32-0.40]
TPOAb-positivity DE 0.57 [0.50-0.65] NS 0.57 [0.50-0.65] NS 0.42 [0.34-0.49]
IGP2 The percentage of A2 glycan in total  IgG glycans AE 0.731 [0.747;0.716] 0.731 [0.697;0.764] NS NS 0.269 [0.236;0.303]
IGP7 The percentage of FA2[6]G1 glycan in total  IgG glycans AE 0.557 [0.563;0.552] 0.557 [0.509;0.605] NS NS 0.443 [0.395;0.491]
IGP8 The percentage of FA2[3]G1 glycan in total  IgG glycans AE 0.662 [0.676;0.65] 0.662 [0.621;0.702] NS NS 0.338 [0.298;0.379]
IGP15 The percentage of FA2G1S1 glycan in total  IgG glycans AE 0.704 [0.72;0.691] 0.704 [0.669;0.739] NS NS 0.296 [0.261;0.331]
IGP21 The percentage of A2BG2S2 glycan in total  IgG glycans AE 0.347 [0.327;0.363] 0.347 [0.288;0.406] NS NS 0.653 [0.594;0.712]





IGP36 Ratio of all fucosylated sialylated structures with and without bisecting GlcNAc AE 0.704 [0.72;0.691] 0.704 [0.669;0.739] NS NS 0.296 [0.261;0.331]
IGP42 The percentage of A2 glycan in total  neutral IgG glycans (GPn) AE 0.739 [0.755;0.724] 0.739 [0.706;0.771] NS NS 0.261 [0.229;0.294]





IGP46 The percentage of A2G1 glycan in total  Ineutral IgG glycans (GP n ) AE 0.725 [0.742;0.711] 0.725 [0.691;0.76] NS NS 0.275 [0.24;0.309]
IGP48 The percentage of FA2[3]G1 glycan in total  neutral IgG glycans (GPn) AE 0.776 [0.793;0.761] 0.776 [0.747;0.805] NS NS 0.224 [0.195;0.253]
IGP56 The percentage of monogalactosylated structures in total neutral  IgG glycans ADE 0.678 [0.492;0.749] 0.475 [0.277;0.674] 0.203 [0;0.411] NS 0.322 [0.281;0.363]





IGP59 The percentage of fucosylation of agalactosylated structures ADE 0.735 [0.591;0.791] 0.333 [0.136;0.531] 0.401 [0.197;0.605] NS 0.265 [0.231;0.3]
IGP60 The percentage of fucosylation of monogalactosylated structures AE 0.714 [0.731;0.7] 0.714 [0.677;0.751] NS NS 0.286 [0.249;0.323]
IGP62 The percentage of fucosylated (without bisecting GlcNAc) structures 
in total neutral IgG glycans 
AE 0.76 [0.777;0.745] 0.76 [0.729;0.79] NS NS 0.24 [0.21;0.271]
IGP63 The percentage of fucosylation (without bisecting GlcNAc) of 
agalactosylated structures 
AE 0.737 [0.754;0.722] 0.737 [0.703;0.771] NS NS 0.263 [0.229;0.297]
P4:3242 16+56/314+335+158b- ACE 0.427 [0.20;0.66] 0.427 [0.20;0.66] NS 0.356[0.14;0.54] 0.217 [0.16;0.31]
P4:2561 16+56/314+335+158b-R7- ACE 0.424 [ 0.19;0.66] 0.424 [ 0.19;0.66] NS 0.358 [0.14;0.54] 0.218 [0.16;0.31]
P4:3161 16+56/314+335+158a-158b- AE 0.792 [0.71;0.81] 0.792 [0.71;0.81] NS NS 0.208 [015;0.29]
P4:2488 16+56/314+335+158a-158b-R7- AE 0.792 [0.71;0.81] 0.792 [0.71;0.81] NS NS 0.208 [015;0.29]
P4:3215 16+56/314+335+337-158b- ACE 0.422 [ 0.19;0.66] 0.422 [ 0.19;0.66] NS 0.358 [0.14;0.54] 0.22[0.16;0.31]
P4:2534 16+56/314+335+337-158b-R7- ACE 0.423 [ 0.19;0.66] 0.423 [ 0.19;0.66] NS 0.356 [0.14;0.54] 0.221[0.16;0.31]
P4:2558 16+56/335+158b-R7- ACE 0.439 [ 0.21;0.68] 0.439 [ 0.21;0.68] NS 0.344 [0.12;0.53] 0.217[0.16;0.31]
P4:3239 16+56/335+158b- ACE 0.437 [ 0.20;0.68] 0.437 [ 0.20;0.68] NS 0.344 [0.12;0.53] 0.22[0.16;0.31]
P4:3134 16+56/314+335+337-158a-158b- AE 0.791 [0.71;0.85] 0.792 [0.71;0.85] NS NS 0.209 [015;0.29]
P4:2462 16+56/314+335+337-158a-158b-R7- AE 0.783 [0.70;0.84] 0.783 [0.70;0.84] NS NS 0.217 [016;0.30]
P4:2531 16+56/335+337-158b-R7- ACE 0.433 [ 0.20;0.67] 0.433 [ 0.20;0.67] NS 0.347 [0.13;0.53] 0.217[0.16;0.31]
P4:3212 16+56/335+337-158b- ACE 0.428 [0.19;0.67] 0.428 [0.19;0.67] NS 0.347[0.12;0.53] 0.225 [0.16;0.32]
P4:3158 16+56/335+158a-158b- AE 0.792 [0.71;0.81] 0.792 [0.71;0.81] NS NS 0.208 [015;0.29]
P4:2460 16+56/335+337-158a-158b-R7- AE 0.782 [0.70;0.84] 0.782 [0.70;0.84] NS NS 0.218 [016;0.30]
P4:2485 16+56/335+158a-158b-R7- AE 0.783 [0.70;0.84] 0.783 [0.70;0.84] NS NS 0.217 [016;0.30]
P4:3131 16+56/335+337-158a-158b- AE 0.781 [0.70;0.84] 0.781 [0.70;0.84] NS NS 0.219 [016;0.30]
P4:3401 16+56/335+158a- ACE 0.475 [ 0.26;0.70] 0.475 [ 0.26;0.70] NS 0.337 [0.12;0.51] 0.188[0.13;0.27]
P4:2740 16+56/335-337-R7- ACE 0.349 [ 0.15;0.55] 0.349 [ 0.15;0.55] NS 0.461 [0.27;0.62] 0.19 [0.14;0.27]
P4:3437 16+56/335-337- ACE 0.303 [ 0.11;0.50] 0.303 [ 0.11;0.50] NS 0.509 [0.33;0.66] 0.188 [0.13;0.27]
P4:2767 16+56/335-R7- ACE 0.352 [ 0.15;0.56] 0.352 [ 0.15;0.56] NS 0.46 [0.27;0.62] 0.188 [0.13;0.27]
P4:3482 16+56/335+ ACE 0.303 [ 0.11;0.50] 0.303 [ 0.11;0.50] NS 0.51 [0.33;0.66] 0.187[0.13;0.27]
P4:3464 16+56/335- ACE 0.305 [ 0.11;0.50] 0.305 [ 0.11;0.50] NS 0.508 [0.33;0.66] 0.187[0.13;0.27]
P4:3374 16+56/335+337-158a- ACE 0.475 [ 0.26;0.70] 0.475 [ 0.26;0.70] NS 0.336 [0.12;0.51] 0.188[0.14;0.27]
P4:2677 16+56/335+337-158a-R7- ACE 0.472 [ 0.26;0.70] 0.472 [ 0.26;0.70] NS 0.339 [0.13;0.51] 0.189 [0.14;0.27]
P4:3455 16+56/335+337- ACE 0.309 [ 0.12;0.50] 0.309 [ 0.12;0.50] NS 0.505 [0.33;0.65] 0.186 [0.13;0.27]
P4:2758 16+56/335+337-R7- ACE 0.306 [ 0.11;0.50] 0.309 [ 0.12;0.50] NS 0.506 [0.33;0.66] 0.187 [0.13;0.27]
P4:3243 16+56/CD2+314+335+158b- ACE 0.461 [ 0.23;0.71] 0.461 [ 0.23;0.71] NS 0.322 [0.10;0.51] 0.217 [0.16;0.31]
P4:2562 16+56/CD2+314+335+158b-R7- ACE 0.465 [ 0.23;0.71] 0.465 [ 0.23;0.71] NS 0.32 [0.09;0.51] 0.215 [0.15;0.30]
P4:3162 16+56/CD2+314+335+158a-158b- AE 0.788 [0.71;0.84] 0.788 [0.71;0.84] NS NS 0.212 [016;0.29]
P4:2489 16+56/CD2+314+335+158a-158b-R7- AE 0.79 [0.71;0.85] 0.79 [0.71;0.85] NS NS 0.21 [015;0.29]
P4:3216 16+56/CD2+314+335+337-158b- ACE 0.459 [ 0.22;0.70] 0.459 [ 0.22;0.70] NS 0.323 [0.10;0.51] 0.218 [0.16;0.31]
P4:2535 16+56/CD2+314+335+337-158b-R7- ACE 0.46 [ 0.23;0.70] 0.46 [ 0.23;0.70] NS 0.324 [0.10;0.51] 0.216 [0.16;0.31]
P4:18 16+56/CD2+314+335+337-158a-158b-R7- AE 0.788 [0.71;0.84] 0.788 [0.71;0.84] NS NS 0.212 [016;0.29]
P4:2486 16+56/CD2+335+158a-158b-R7- AE 0.782 [0.70;0.84] 0.782 [0.70;0.84] NS NS 0.218 [016;0.30]
P4:2559 16+56/CD2+335+158b-R7- ACE 0.471 [ 0.24;0.72] 0.471 [ 0.24;0.72] NS 0.312 [0.08;0.50] 0.217 [0.16;0.31]
P4:3159 16+56/CD2+335+158a-158b- AE 0.78 [0.70;0.84] 0.78 [0.70;0.84] NS NS 0.22 [016;0.30]
P4:3240 16+56/CD2+335+158b- ACE 0.466 [ 0.23;0.71] 0.466 [ 0.23;0.71] NS 0.314 [0.09;0.51] 0.219 [0.15;0.30]
P4:3135 16+56/CD2+314+335+337-158a-158b- AE 0.786 [0.71;0.84] 0.786 [0.71;0.84] NS NS 0.214 [016;0.29]
P4:2532 16+56/CD2+335+337-158b-R7- ACE 0.47 [ 0.24;0.72] 0.47 [ 0.24;0.72] NS 0.313 [0.08;0.50] 0.217 [0.16;0.31]
P4:3213 16+56/CD2+335+337-158b- ACE 0.467 [ 0.23;0.71] 0.467 [ 0.23;0.71] NS 0.314 [0.08;0.51] 0.22 [0.16;0.31]
P4:3132 16+56/CD2+335+337-158a-158b- AE 0.78 [0.70;0.84] 0.78 [0.70;0.84] NS NS 0.22 [0.16;0.30]
P4:2461 16+56/CD2+335+337-158a-158b-R7- AE 0.781 [0.70;0.84] 0.781 [0.70;0.84] NS NS 0.219 [0.16;0.30]
P4:2967 16+56/335-337-158b+R7- AE 0.772 [0.68;0.84] 0.772 [0.68;0.84] NS NS 0.228 [0.16;0.32]
P4:2994 16+56/335-158b+R7- AE 0.772 [0.68;0.84] 0.772 [0.68;0.84] NS NS 0.228 [0.16;0.32]
P4:3707 16+56/335-158b+ AE 0.775 [0.68;0.84] 0.775 [0.68;0.84] NS NS 0.225 [0.16;0.32]
P4:3680 16+56/335-337-158b+ AE 0.775 [0.68;0.84] 0.775 [0.68;0.84] NS NS 0.225 [0.16;0.32]
P4:2970 16+56/314+335-337-158b+R7- AE 0.775 [0.68;0.84] 0.775 [0.68;0.84] NS NS 0.225 [0.16;0.32]
P4:3683 16+56/314+335-337-158b+ AE 0.776 [0.68;0.84] 0.776 [0.68;0.84] NS NS 0.224 [0.16;0.31]
P4:2997 16+56/314+335-158b+R7- AE 0.775 [0.68;0.84] 0.775 [0.68;0.84] NS NS 0.225 [0.16;0.32]
P4:3710 16+56/314+335-158b+ AE 0.777 [0.69;0.84] 0.777 [0.69;0.84] NS NS 0.223 [0.16;0.31]








Table S9: Heritability of 1,113 proteins in the TwinsUK cohort
h2= heritability; CI_2.5=confidence interval at 2.5; CI_97.5=confidence interval at 97.5; A=additive genetic variance; D= dominance genetic variance; C= common environmental variance; E= unique environmental variance
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estimation A CI_2.50 A CI_97.50
D 
estimation D CI_2.50 D CI_97.50
C 
estimation C CI_2.50 C CI_97.50
E 
estimation E CI_2.50 E CI_97.50
SL000125 IL-1a P01583 3552 IL1A RFU Yes No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000589 TSH P01215 P012221081 12372CGA TSHB RFU Yes No DE 0.356 0.229 0.402 0 0 0 0.356 0.122 0.591 0 0 0 0.644 0.409 0.878
SL003710 Caspase-2 P42575 835 CASP2 RFU Yes No DE 0.470 0.443 0.479 0 0 0 0.470 0.238 0.701 0 0 0 0.530 0.299 0.762
SL000283 b2-Microglobulin P61769 567 B2M RFU No Yes CE 0 0 0 0 0 0 0 0 0 0.509 0.356 0.662 0.491 0.338 0.644
SL002644 ERBB1 P00533 1956 EGFR RFU No Yes CE 0 0 0 0 0 0 0 0 0 0.389 0.208 0.569 0.611 0.431 0.792
SL008609 FCG3B O75015 2215 FCGR3B RFU No Yes AE 0.479 0.468 0.485 0.479 0.303 0.655 0 0 0 0 0 0 0.521 0.345 0.697
SL000002 VEGF P15692 7422 VEGFA RFU No No DE 0.500 0.499 0.500 0 0 0 0.500 0.302 0.697 0 0 0 0.500 0.303 0.698
SL000003 Angiogenin P03950 283 ANG RFU No No AE 0.718 0.782 0.677 0.718 0.603 0.832 0 0 0 0 0 0 0.282 0.168 0.397
SL000004 bFGF P09038 2247 FGF2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000006 PAI-1 P05121 5054 SERPINE1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.497 0.343 0.650 0.503 0.350 0.657
SL000007 ER P03372 2099 ESR1 RFU No No DE 0.742 0.827 0.692 0 0 0 0.742 0.613 0.872 0 0 0 0.258 0.128 0.387
SL000009 ERBB2 P04626 2064 ERBB2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000017 vWF P04275 7450 VWF RFU No No AE 0.700 0.776 0.657 0.700 0.563 0.838 0 0 0 0 0 0 0.300 0.162 0.437
SL000019 Apo A-I P02647 335 APOA1 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL000020 Apo B P04114 338 APOB RFU No No CE 0 0 0 0 0 0 0 0 0 0.617 0.491 0.744 0.383 0.256 0.509
SL000021 Insulin P01308 3630 INS RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000022 D-dimer P02671 P02675 P026792243 2 44 2266FGA FGB FGG RFU No No CE 0 0 0 0 0 0 0 0 0 0.279 0.086 0.471 0.721 0.529 0.914
SL000024 TF P13726 2152 F3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.383 0.208 0.558 0.617 0.442 0.792
SL000027 COX-2 P35354 5743 PTGS2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000038 MCP-1 P13500 6347 CCL2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.220 0.026 0.414 0.780 0.586 0.974
SL000039 IL-8 P10145 3576 IL8 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000045 IGFBP-3 P17936 3486 IGFBP3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.423 0.253 0.594 0.577 0.406 0.747
SL000047 IGF-I P05019 3479 IGF1 RFU No No DE 0.296 0.114 0.361 0 0 0 0.296 0.060 0.532 0 0 0 0.704 0.468 0.940
SL000048 Protein C P04070 5624 PROC RFU No No AE 0.444 0.405 0.460 0.444 0.238 0.650 0 0 0 0 0 0 0.556 0.350 0.762
SL000049 Protein S P07225 5627 PROS1 RFU No No AE 0.296 0.145 0.357 0.296 0.083 0.509 0 0 0 0 0 0 0.704 0.491 0.917
SL000051 CRP P02741 1401 CRP RFU No No AE 0.413 0.358 0.437 0.413 0.219 0.606 0 0 0 0 0 0 0.587 0.394 0.781
SL000053 tPA P00750 5327 PLAT RFU No No AE 0.531 0.550 0.522 0.531 0.342 0.720 0 0 0 0 0 0 0.469 0.280 0.658
SL000055 Cadherin E P12830 999 CDH1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.452 0.284 0.621 0.548 0.379 0.716
SL000057 Thymidine kise P04183 7083 TK1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.275 0.079 0.471 0.725 0.529 0.921
SL000062 PSA P07288 354 KLK3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000064 Kallikrein 7 P49862 5650 KLK7 RFU No No CE 0 0 0 0 0 0 0 0 0 0.573 0.435 0.711 0.427 0.289 0.565
SL000070 Glypican 3 P51654 2719 GPC3 RFU No No DE 0 0 0 0 0 0 0.581 0.411 0.752 0 0 0 0.419 0.248 0.589
SL000076 p27Kip1 P46527 1027 CDKN1B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000087 IL-6 P05231 3569 IL6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.270 0.081 0.460 0.730 0.540 0.919
SL000088 TGF-b2 P61812 7042 TGFB2 RFU No No DE 0.437 0.364 0.459 0 0 0 0.437 0.168 0.706 0 0 0 0.563 0.294 0.832
SL000089 TGF-b3 P10600 7043 TGFB3 RFU No No DE 0.250 -0.083 0.341 0 0 0 0.250 -0.036 0.536 0 0 0 0.750 0.464 1.036
SL000091 PSA-ACT P07288  P01011354 12 KLK3 SERPI3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.323 0.135 0.510 0.677 0.490 0.865
SL000104 Bcl-2 P10415 596 BCL2 RFU No No AE 0.190 -0.116 0.293 0.190 -0.058 0.439 0 0 0 0 0 0 0.810 0.561 1.058
SL000124 MMP-2 P08253 4313 MMP2 RFU No No AE 0.593 0.640 0.570 0.593 0.425 0.762 0 0 0 0 0 0 0.407 0.238 0.575
SL000130 Cyclin B1 P14635 891 CCNB1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000131 PC P12004 5111 PC RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000133 MIP-3a P78556 6364 CCL20 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000134 Met P08581 4233 MET RFU No No AE 0.563 0.596 0.547 0.563 0.395 0.732 0 0 0 0 0 0 0.437 0.268 0.605
SL000136 AREG P15514 374 AREG RFU No No CE 0 0 0 0 0 0 0 0 0 0.713 0.612 0.813 0.287 0.187 0.388
SL000138 HB-EGF Q99075 1839 HBEGF RFU No No AE 0.587 0.632 0.565 0.587 0.416 0.758 0 0 0 0 0 0 0.413 0.242 0.584
SL000139 EPI O14944 2069 EREG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000142 TS P04818 7298 TYMS RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000158 PSMA Q04609 2346 FOLH1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000164 Myoglobin P02144 4151 MB RFU No No AE 0.542 0.564 0.531 0.542 0.370 0.714 0 0 0 0 0 0 0.458 0.286 0.630
SL000247 6-Phosphoglucote dehydrogeseP52209 5226 PGD RFU No No AE 0.817 0.878 0.773 0.817 0.737 0.898 0 0 0 0 0 0 0.183 0.102 0.263
SL000248 a1-Antichymotrypsin P01011 12 SERPI3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.278 0.083 0.473 0.722 0.527 0.917
SL000249 a1-Antitrypsin P01009 5265 SERPI1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.346 0.165 0.527 0.654 0.473 0.835
SL000250 a2-Antiplasmin P08697 5345 SERPINF2 RFU No No DE 0.679 0.795 0.628 0 0 0 0.679 0.482 0.876 0 0 0 0.321 0.124 0.518
SL000251 a2-HS-Glycoprotein P02765 197 AHSG RFU No No AE 0.442 0.401 0.459 0.442 0.235 0.649 0 0 0 0 0 0 0.558 0.351 0.765
SL000252 a2-Macroglobulin P01023 2 A2M RFU No No CE 0 0 0 0 0 0 0 0 0 0.602 0.471 0.733 0.398 0.267 0.529
SL000254 Albumin P02768 213 ALB RFU No No CE 0 0 0 0 0 0 0 0 0 0.562 0.419 0.704 0.438 0.296 0.581
SL000268 Angiostatin P00747 5340 PLG RFU No No AE 0.733 0.795 0.693 0.733 0.628 0.838 0 0 0 0 0 0 0.267 0.162 0.372
SL000271 Angiotensinogen P01019 183 AGT RFU No No CE 0 0 0 0 0 0 0 0 0 0.395 0.220 0.571 0.605 0.429 0.780
SL000272 Antithrombin III P01008 462 SERPINC1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.350 0.149 0.552 0.650 0.448 0.851
SL000276 Apo E P02649 348 APOE RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL000277 Apo E2 P02649 348 APOE RFU No No CE 0 0 0 0 0 0 0 0 0 0.675 0.564 0.787 0.325 0.213 0.436
SL000280 GOT1 P17174 2805 GOT1 RFU No No DE 0 0 0 0 0 0 0.588 0.412 0.763 0 0 0 0.412 0.237 0.588
SL000299 b-ECGF P05230 2246 FGF1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000300 b-Endorphin P01189 5443 POMC RFU No No AE 0.524 0.537 0.518 0.524 0.354 0.694 0 0 0 0 0 0 0.476 0.306 0.646
SL000305 b-NGF P01138 4803 NGF RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000306 BNP-32 P16860 4879 NPPB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000308 C1-Esterase Inhibitor P05155 710 SERPING1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.621 0.494 0.747 0.379 0.253 0.506
SL000309 C1q P02745  P02746  P0274712 713 714C1QA C1QB  C1QCRFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000310 C1r P00736 715 C1R RFU No No AE 0.440 0.400 0.457 0.440 0.240 0.640 0 0 0 0 0 0 0.560 0.360 0.760
SL000311 C1s P09871 716 C1S RFU No No AE 0.423 0.368 0.446 0.423 0.214 0.633 0 0 0 0 0 0 0.577 0.367 0.786
SL000312 C3 P01024 718 C3 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL000313 C3a P01024 718 C3 RFU No No DE 0.631 0.697 0.598 0 0 0 0.631 0.463 0.798 0 0 0 0.369 0.202 0.537
SL000314 C3b P01024 718 C3 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL000316 C4 P0C0L4  P0C0L5720 721 C4A C4B RFU No No DE 0.748 0.816 0.704 0 0 0 0.748 0.641 0.855 0 0 0 0.252 0.145 0.359
SL000318 C4b P0C0L4  P0C0L5720 721 C4A C4B RFU No No DCE 0.256 0.005 0.320 0 0 0 0.256 0.002 0.509 0.522 0.284 0.761 0.222 0.123 0.321
SL000319 C5 P01031 727 C5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.390 0.209 0.570 0.610 0.430 0.791
SL000320 C5a P01031 727 C5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.529 0.383 0.676 0.471 0.324 0.617
SL000321 C5b  6 Complex P01031 P13671727 729 C5 C6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.434 0.263 0.605 0.566 0.395 0.737
SL000322 C6 P13671 729 C6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.308 0.122 0.495 0.692 0.505 0.878
SL000323 C7 P10643 730 C7 RFU No No AE 0.448 0.410 0.463 0.448 0.240 0.655 0 0 0 0 0 0 0.552 0.345 0.760
SL000324 C8 P07357 P07358 P07360731 732 733C8A C8B C8G RFU No No DE 0.535 0.560 0.525 0 0 0 0.535 0.330 0.741 0 0 0 0.465 0.259 0.670
SL000325 C9 P02748 735 C9 RFU No No AE 0.502 0.503 0.501 0.502 0.306 0.698 0 0 0 0 0 0 0.498 0.302 0.694
SL000337 Calpain I P07384 P04632823 826 CAPN1 CAPNS1RFU No No AE 0.727 0.792 0.686 0.727 0.616 0.838 0 0 0 0 0 0 0.273 0.162 0.384
SL000338 Calpastatin P20810 831 CAST RFU No No AE 0.581 0.617 0.562 0.581 0.427 0.736 0 0 0 0 0 0 0.419 0.264 0.573
SL000339 carbonic anhydrase II P00918 760 CA2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000342 Catalase P04040 847 CAT RFU No No AE 0.487 0.477 0.490 0.487 0.285 0.688 0 0 0 0 0 0 0.513 0.312 0.715
SL000343 Cathepsin B P07858 1508 CTSB RFU No No AE 0.494 0.491 0.496 0.494 0.321 0.668 0 0 0 0 0 0 0.506 0.332 0.679
SL000344 Cathepsin D P07339 1509 CTSD RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000345 Cathepsin G P08311 1511 CTSG RFU No No DE 0.415 0.139 0.452 0 0 0 0.415 0.033 0.797 0 0 0 0.585 0.203 0.967
SL000346 Cathepsin H P09668 1512 CTSH RFU No No CE 0 0 0 0 0 0 0 0 0 0.557 0.414 0.701 0.443 0.299 0.586
SL000347 CBG P08185 866 SERPI6 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000357 Coagulation Factor IX P00740 2158 F9 RFU No No AE 0.515 0.524 0.511 0.515 0.327 0.704 0 0 0 0 0 0 0.485 0.296 0.673
SL000358 Coagulation Factor VII P08709 2155 F7 RFU No No DE 0.730 0.803 0.686 0 0 0 0.730 0.610 0.850 0 0 0 0.270 0.150 0.390
SL000360 Coagulation Factor X P00742 2159 F10 RFU No No CE 0 0 0 0 0 0 0 0 0 0.396 0.218 0.573 0.604 0.427 0.782
SL000377 CK-BB P12277 1152 CKB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000382 CK-MB P12277 P067321152 1158 CKB CKM RFU No No AE 0.550 0.577 0.537 0.550 0.376 0.725 0 0 0 0 0 0 0.450 0.275 0.624
SL000383 CK-MM P06732 1158 CKM RFU No No AE 0.546 0.573 0.534 0.546 0.364 0.728 0 0 0 0 0 0 0.454 0.272 0.636
SL000384 CTLA-4 P16410 1493 CTLA4 RFU No No DE 0.463 0.377 0.478 0 0 0 0.463 0.114 0.812 0 0 0 0.537 0.188 0.886
SL000396 Cytochrome c P99999 54205 CYCS RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000398 Cytochrome P450 3A4P08684 1576 CYP3A4 RFU No No AE 0.721 0.789 0.679 0.721 0.604 0.839 0 0 0 0 0 0 0.279 0.161 0.396
SL000401 Elastase P08246 1991 ELANE RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000403 Endostatin P39060 80781 COL18A1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.687 0.578 0.797 0.313 0.203 0.422
SL000406 Eotaxin P51671 6356 CCL11 RFU No No CE 0 0 0 0 0 0 0 0 0 0.275 0.085 0.465 0.725 0.535 0.915
SL000408 Epo P01588 2056 EPO RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000409 ERK-1 P27361 5595 MAPK3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.513 0.363 0.663 0.487 0.337 0.637
SL000414 Factor B P00751 629 CFB RFU No No DE 0.405 0.325 0.435 0 0 0 0.405 0.177 0.633 0 0 0 0.595 0.367 0.823
SL000415 Factor H P08603 3075 CFH RFU No No DE 0.371 0.252 0.413 0 0 0 0.371 0.131 0.612 0 0 0 0.629 0.388 0.869
SL000420 Ferritin P02794 P027922495 2512 FTH1 FTL RFU No No AE 0.623 0.673 0.595 0.623 0.479 0.768 0 0 0 0 0 0 0.377 0.232 0.521
SL000424 Fibrinogen P02671 P02675 P026792243 2 44 2266FGA FGB FGG RFU No No CE 0 0 0 0 0 0 0 0 0 0.226 0.024 0.428 0.774 0.572 0.976
SL000426 Fibronectin P02751 2335 FN1 RFU No No AE 0.627 0.683 0.598 0.627 0.476 0.779 0 0 0 0 0 0 0.373 0.221 0.524
SL000427 Fractalkine/CX3CL-1 P78423 6376 CX3CL1 RFU No No AE 0.405 0.349 0.430 0.405 0.220 0.589 0 0 0 0 0 0 0.595 0.411 0.780
SL000428 FSH P01215   P01225081 2488 CGA FSHB RFU No No DE 0.298 0.157 0.357 0 0 0 0.298 0.157 0.357 0 0 0 0.702 0.497 0.908
SL000433 Glucagon P01275 2641 GCG RFU No No CE 0 0 0 0 0 0 0 0 0 0.539 0.394 0.683 0.461 0.317 0.606
SL000437 Haptoglobin  Mixed TypeP00738 3240 HP RFU No No CE 0 0 0 0 0 0 0 0 0 0.370 0.195 0.546 0.630 0.454 0.805
SL000440 Hemopexin P02790 3263 HPX RFU No No AE 0.905 0.944 0.872 0.905 0.860 0.949 0 0 0 0 0 0 0.095 0.051 0.140
SL000441 HGF P14210 3082 HGF RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000445 HIV-2 Rev P18093 1724716 Human-virus RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000449 HSP 40 P25685 3337 DJB1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.211 0.013 0.408 0.789 0.592 0.987
SL000450 HSP 60 P10809 3329 HSPD1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.546 0.403 0.689 0.454 0.311 0.597
SL000451 HSP 70 P08107 3303 HSPA1A RFU No No CE 0 0 0 0 0 0 0 0 0 0.345 0.163 0.527 0.655 0.473 0.837
SL000456 iC3b P01024 718 C3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.496 0.339 0.653 0.504 0.347 0.661
SL000458 IFN-g R1 P15260 3459 IFNGR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000460 IgD P01880 3495 50802 3535IGHD  IGK@ IGL@RFU No No DE 0.454 0.423 0.467 0 0 0 0.454 0.256 0.652 0 0 0 0.546 0.348 0.744
SL000461 IgE P01854 3497  50802 3535IGHE IGK@ IGL@RFU No No AE 0.557 0.586 0.542 0.557 0.384 0.729 0 0 0 0 0 0 0.443 0.271 0.616
SL000462 IGFBP-1 P08833 3484 IGFBP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.567 0.429 0.705 0.433 0.295 0.571
SL000466 IGFBP-2 P18065 3485 IGFBP2 RFU No No AE 0.527 0.541 0.520 0.527 0.352 0.701 0 0 0 0 0 0 0.473 0.299 0.648
SL000467 IgG P01857 3500 3501  3502 3503  50802 3535IGHG1 IGHG2 IGHG3 IGHG4 IGK@ IGL@RFU No No DE 0.502 0.503 0.501 0 0 0 0.502 0.316 0.688 0 0 0 0.498 0.312 0.684
SL000468 IgM P01871 3507 3512 50802 3535IGHM IGJ IGK@ IGL@RFU No No AE 0.432 0.392 0.451 0.432 0.247 0.617 0 0 0 0 0 0 0.568 0.383 0.753
SL000470 IL-11 P20809 3589 IL11 RFU No No DE 0.344 0.196 0.395 0 0 0 0.344 0.101 0.587 0 0 0 0.656 0.413 0.899
SL000474 IL-16 Q14005 3603 IL16 RFU No No AE 0.658 0.723 0.622 0.658 0.512 0.804 0 0 0 0 0 0 0.342 0.196 0.488
SL000478 IL-2 P60568 3558 IL2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.584 0.449 0.719 0.416 0.281 0.551
SL000479 IL-3 P08700 3562 IL3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000480 IL-4 P05112 3565 IL4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000481 IL-5 P05113 3567 IL5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.416 0.245 0.587 0.584 0.413 0.755
SL000483 IL-7 P13232 3574 IL7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000493 LDH-H 1 P07195 3945 LDHB RFU No No AE 0.709 0.772 0.669 0.709 0.593 0.824 0 0 0 0 0 0 0.291 0.176 0.407
SL000496 Lactoferrin P02788 4057 LTF RFU No No DE 0.605 0.650 0.581 0 0 0 0.605 0.455 0.755 0 0 0 0.395 0.245 0.545
SL000497 Laminin P25391  P07942  P11047284217 3912 3915LAMA1 LAMB1  LAMC1RFU No No AE 0.616 0.668 0.589 0.616 0.461 0.771 0 0 0 0 0 0 0.384 0.229 0.539
SL000498 Leptin P41159 3952 LEP RFU No No AE 0.622 0.680 0.593 0.622 0.462 0.783 0 0 0 0 0 0 0.378 0.217 0.538
SL000506 Luteinizing hormone P01215  P012291081 3972 CGA LHB RFU No No CE 0 0 0 0 0 0 0 0 0 0.305 0.119 0.490 0.695 0.510 0.881
SL000507 Lymphotoxin a1/b2 P01374  Q066434049 4050 LTA LTB RFU No No DE 0.538 0.568 0.526 0 0 0 0.538 0.317 0.759 0 0 0 0.462 0.241 0.683
SL000508 Lymphotoxin a2/b1 P01374  Q066434049 4050 LTA LTB RFU No No CE 0 0 0 0 0 0 0 0 0 0.296 0.103 0.489 0.704 0.511 0.897
SL000509 Lymphotoxin b R P36941 4055 LTBR RFU No No CE 0 0 0 0 0 0 0 0 0 0.274 0.080 0.468 0.726 0.532 0.920
SL000510 Lysozyme P61626 4069 LYZ RFU No No CE 0 0 0 0 0 0 0 0 0 0.682 0.570 0.795 0.318 0.205 0.430
SL000515 MCP-2 P80075 6355 CCL8 RFU No No DE 0.388 0.300 0.422 0 0 0 0.388 0.168 0.608 0 0 0 0.612 0.392 0.832
SL000516 MCP-3 P80098 6354 CCL7 RFU No No DE 0.760 0.833 0.713 0 0 0 0.760 0.650 0.870 0 0 0 0.240 0.130 0.350
SL000517 MCP-4 Q99616 6357 CCL13 RFU No No CE 0 0 0 0 0 0 0 0 0 0.172 -0.027 0.372 0.828 0.628 1.027
SL000519 MIP-1a P10147 6348 CCL3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.154 -0.045 0.354 0.846 0.646 1.045
SL000521 MMP-1 P03956 4312 MMP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.367 0.191 0.543 0.633 0.457 0.809
SL000522 MMP-12 P39900 4321 MMP12 RFU No No AE 0.595 0.639 0.572 0.595 0.435 0.755 0 0 0 0 0 0 0.405 0.245 0.565
SL000523 MMP-13 P45452 4322 MMP13 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000524 MMP-3 P08254 4314 MMP3 RFU No No AE 0.203 -0.032 0.294 0.203 -0.018 0.424 0 0 0 0 0 0 0.797 0.576 1.018
SL000525 MMP-7 P09237 4316 MMP7 RFU No No CE 0 0 0 0 0 0 0 0 0 0.570 0.431 0.708 0.430 0.292 0.569
SL000526 MMP-8 P22894 4317 MMP8 RFU No No CE 0 0 0 0 0 0 0 0 0 0.477 0.319 0.636 0.523 0.364 0.681
SL000527 MMP-9 P14780 4318 MMP9 RFU No No DE 0.780 0.845 0.736 0 0 0 0.780 0.686 0.874 0 0 0 0.220 0.126 0.314
SL000528 DPH-P450 OxidoreductaseP16435 5447 POR RFU No No AE 0.332 0.207 0.382 0.332 0.118 0.545 0 0 0 0 0 0 0.668 0.455 0.882
SL000530 OSM P13725 5008 OSM RFU No No CE 0 0 0 0 0 0 0 0 0 0.278 0.085 0.472 0.722 0.528 0.915
SL000532 ON P09486 6678 SPARC RFU No No CE 0 0 0 0 0 0 0 0 0 0.409 0.240 0.579 0.591 0.421 0.760
SL000535 PDGF-AA P04085 5154 PDGFA RFU No No CE 0 0 0 0 0 0 0 0 0 0.397 0.226 0.569 0.603 0.431 0.774
SL000537 PDGF-BB P01127 5155 PDGFB RFU No No CE 0 0 0 0 0 0 0 0 0 0.460 0.300 0.621 0.540 0.379 0.700
SL000539 PHI P06744 2821 GPI RFU No No CE 0 0 0 0 0 0 0 0 0 0.502 0.349 0.655 0.498 0.345 0.651
SL000540 Plasmin P00747 5340 PLG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000541 Plasminogen P00747 5340 PLG RFU No No DE 0.591 0.640 0.568 0 0 0 0.591 0.417 0.766 0 0 0 0.409 0.234 0.583
SL000542 gpIIbIIIa P08514 P051063674  3690 ITGA2B ITGB3 RFU No No AE 0.695 0.762 0.655 0.695 0.566 0.824 0 0 0 0 0 0 0.305 0.176 0.434
SL000545 Prekallikrein P03952 3818 KLKB1 RFU No No AE 0.544 0.569 0.532 0.544 0.362 0.726 0 0 0 0 0 0 0.456 0.274 0.638
SL000546 PRL P01236 5617 PRL RFU No No DE 0.541 0.578 0.528 0 0 0 0.541 0.304 0.778 0 0 0 0.459 0.222 0.696
SL000550 PCI P05154 5104 SERPI5 RFU No No AE 0.689 0.750 0.651 0.689 0.566 0.811 0 0 0 0 0 0 0.311 0.189 0.434
SL000551 PKC-A P17252 5578 PRKCA RFU No No CE 0 0 0 0 0 0 0 0 0 0.562 0.423 0.702 0.438 0.298 0.577
SL000553 PKC-B-II P05771 5579 PRKCB RFU No No AE 0.745 0.810 0.703 0.745 0.641 0.849 0 0 0 0 0 0 0.255 0.151 0.359
SL000554 PKC-D Q05655 5580 PRKCD RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000556 PKC-G P05129 5582 PRKCG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000557 PKC-Z Q05513 5590 PRKCZ RFU No No DE 0.271 0.059 0.345 0 0 0 0.271 0.031 0.511 0 0 0 0.729 0.489 0.969
SL000558 Prothrombin P00734 2147 F2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.181 -0.025 0.388 0.819 0.612 1.025
SL000560 P-Selectin P16109 6403 SELP RFU No No AE 0.732 0.798 0.690 0.732 0.622 0.843 0 0 0 0 0 0 0.268 0.157 0.378
SL000563 RANTES P13501 6352 CCL5 RFU No No AE 0.487 0.478 0.490 0.487 0.292 0.682 0 0 0 0 0 0 0.513 0.318 0.708
SL000565 Renin P00797 5972 REN RFU No No DE 0.467 0.445 0.477 0 0 0 0.467 0.265 0.670 0 0 0 0.533 0.330 0.735
SL000566 RBP P02753 5950 RBP4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000570 Secretin P09683 6343 SCT RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000572 SAA P0DJI8 6288 SAA1 RFU No No AE 0.903 0.943 0.871 0.903 0.859 0.948 0 0 0 0 0 0 0.097 0.052 0.141
SL000573 SAP P02743 325 APCS RFU No No AE 0.475 0.459 0.482 0.475 0.284 0.666 0 0 0 0 0 0 0.525 0.334 0.716
SL000581 SOD P00441 6647 SOD1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.249 0.056 0.441 0.751 0.559 0.944
SL000582 Survivin O15392 332 BIRC5 RFU No No DE 0.759 0.852 0.705 0 0 0 0.759 0.627 0.891 0 0 0 0.241 0.109 0.373
SL000584 TGF-b1 P01137 7040 TGFB1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.227 0.032 0.423 0.773 0.577 0.968
SL000586 Thrombin P00734 2147 F2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.596 0.465 0.728 0.404 0.272 0.535
SL000587 Thyroglobulin P01266 7038 TG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000588 TMA P07202 7173 TPO RFU No No DE 0.513 0.537 0.508 0 0 0 0.513 0.180 0.845 0 0 0 0.487 0.155 0.820
SL000590 Thyroxine-Binding GlobulinP05543 6906 SERPI7 RFU No No DE 0.556 0.585 0.542 0 0 0 0.556 0.388 0.725 0 0 0 0.444 0.275 0.612
SL000591 TIMP-1 P01033 7076 TIMP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.261 0.065 0.457 0.739 0.543 0.935
SL000592 TIMP-2 P16035 7077 TIMP2 RFU No No AE 0.472 0.453 0.480 0.472 0.273 0.671 0 0 0 0 0 0 0.528 0.329 0.727
SL000597 TNF-b P01374 4049 LTA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000601 Transferrin P02787 7018 TF RFU No No CE 0 0 0 0 0 0 0 0 0 0.260 0.062 0.457 0.740 0.543 0.938
SL000603 Trypsin P07477 5644 PRSS1 RFU No No AE 0.600 0.649 0.575 0.600 0.434 0.765 0 0 0 0 0 0 0.400 0.235 0.566
SL000605 Ubiquitin+1 P62979 6233 RPS27A RFU No No CE 0 0 0 0 0 0 0 0 0 0.449 0.284 0.614 0.551 0.386 0.716
SL000613 uPA P00749 5328 PLAU RFU No No CE 0 0 0 0 0 0 0 0 0 0.478 0.319 0.637 0.522 0.363 0.681
SL000615 Vasoactive Intestil PeptideP01282 7432 VIP RFU No No DE 0.546 0.575 0.533 0 0 0 0.546 0.349 0.743 0 0 0 0.454 0.257 0.651
SL000617 ALT P24298 2875 GPT RFU No No CE 0 0 0 0 0 0 0 0 0 0.340 0.158 0.522 0.660 0.478 0.842
SL000622 Coagulation Factor V P12259 2153 F5 RFU No No AE 0.701 0.764 0.662 0.701 0.581 0.821 0 0 0 0 0 0 0.299 0.179 0.419
SL000633 Fas ligand  soluble P48023 356 FASLG RFU No No DE 0.394 0.320 0.425 0 0 0 0.394 0.189 0.599 0 0 0 0.606 0.401 0.811
SL000638 Cadherin-2 P19022 1000 CDH2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000640 Nidogen P14543 4811 NID1 RFU No No AE 0.678 0.755 0.637 0.678 0.528 0.828 0 0 0 0 0 0 0.322 0.172 0.472
SL000645 MMP-10 P09238 4319 MMP10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000655 Keratin 18 P05783 3875 KRT18 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000658 GAS1 P54826 2619 GAS1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000668 CD36 ANTIGEN P16671 948 CD36 RFU No No DE 0.584 0.629 0.562 0 0 0 0.584 0.408 0.759 0 0 0 0.416 0.241 0.592
SL000670 GSTA3 Q16772 2940 GSTA3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL000674 FST P19883 10468 FST RFU No No AE 0.213 -0.141 0.315 0.213 -0.063 0.488 0 0 0 0 0 0 0.787 0.512 1.063
SL000678 Granulysin P22749 10578 GNLY RFU No No AE 0.679 0.740 0.643 0.679 0.552 0.806 0 0 0 0 0 0 0.321 0.194 0.448
SL000695 Lipocalin 2 P80188 3934 LCN2 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL000836 Hemoglobin P69905  P688713039  3043 HBA1 HBB RFU No No CE 0 0 0 0 0 0 0 0 0 0.397 0.225 0.569 0.603 0.431 0.775
SL001691 FGF7 P21781 2252 FGF7 RFU No No CE 0 0 0 0 0 0 0 0 0 0.602 0.470 0.733 0.398 0.267 0.530
SL001713 IL-17 Q16552 3605 IL17A RFU No No CE 0 0 0 0 0 0 0 0 0 0.241 0.044 0.437 0.759 0.563 0.956
SL001716 IL-12 P29459   P294603592 3593 IL12A IL12B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001717 IL-10 P22301 3586 IL10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001718 IL-13 P35225 3596 IL13 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001720 VCAM-1 P19320 7412 VCAM1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.388 0.212 0.564 0.612 0.436 0.788
SL001721 PECAM-1 P16284 5175 PECAM1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001726 GM-CSF P04141 1437 CSF2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001729 G-CSF P09919 1440 CSF3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.223 0.029 0.416 0.777 0.584 0.971
SL001737 STRATIFIN P31947 2810 SFN RFU No No CE 0 0 0 0 0 0 0 0 0 0.475 0.317 0.634 0.525 0.366 0.683
SL001753 Sialoadhesin Q9BZZ2 6614 SIGLEC1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001766 HCG P01215 P012331081 1082 CGA CGB RFU No No DE 0.502 0.504 0.502 0 0 0 0.502 0.311 0.694 0 0 0 0.498 0.306 0.689
SL001774 FABP P05413 2170 FABP3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.422 0.253 0.591 0.578 0.409 0.747
SL001777 Cystatin C P01034 1471 CST3 RFU No No DE 0.593 0.635 0.571 0 0 0 0.593 0.439 0.747 0 0 0 0.407 0.253 0.561
SL001795 IL-1b P01584 3553 IL1B RFU No No CE 0 0 0 0 0 0 0 0 0 0.169 -0.029 0.367 0.831 0.633 1.029
SL001796 Myeloperoxidase P05164 4353 MPO RFU No No AE 0.600 0.644 0.576 0.600 0.447 0.753 0 0 0 0 0 0 0.400 0.247 0.553
SL001797 Kallikrein 6 Q92876 5653 KLK6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.202 0.002 0.402 0.798 0.598 0.998
SL001800 TNF sR-II P20333 7133 TNFRSF1B RFU No No CE 0 0 0 0 0 0 0 0 0 0.493 0.337 0.650 0.507 0.350 0.663
SL001802 IFN-g P01579 3458 IFNG RFU No No CE 0 0 0 0 0 0 0 0 0 0.697 0.592 0.802 0.303 0.198 0.408
SL001815 Mn SOD P04179 6648 SOD2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.488 0.330 0.646 0.512 0.354 0.670
SL001868 CASA P47710 1446 CSN1S1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001888 SLPI P03973 6590 SLPI RFU No No AE 0.529 0.543 0.521 0.529 0.362 0.695 0 0 0 0 0 0 0.471 0.305 0.638
SL001890 GA733-1 protein P09758 4070 TACSTD2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001896 Clusterin P10909 1191 CLU RFU No No CE 0 0 0 0 0 0 0 0 0 0.363 0.184 0.542 0.637 0.458 0.816
SL001897 SPINT2 O43291 10653 SPINT2 RFU No No AE 0.685 0.751 0.646 0.685 0.553 0.816 0 0 0 0 0 0 0.315 0.184 0.447
SL001902 BCAM P50895 4059 BCAM RFU No No AE 0.523 0.543 0.516 0.523 0.290 0.757 0 0 0 0 0 0 0.477 0.243 0.710
SL001905 Mesothelin Q13421 10232 MSLN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001938 Activin A P08476 3624 INHBA RFU No No CE 0 0 0 0 0 0 0 0 0 0.318 0.134 0.501 0.682 0.499 0.866
SL001943 IL-6 sRa P08887 3570 IL6R RFU No No AE 0.845 0.899 0.804 0.845 0.777 0.913 0 0 0 0 0 0 0.155 0.087 0.223
SL001945 sE-Selectin P16581 6401 SELE RFU No No AE 0.723 0.792 0.680 0.723 0.605 0.841 0 0 0 0 0 0 0.277 0.159 0.395
SL001947 MIA Q16674 8190 MIA RFU No No DE 0.669 0.730 0.634 0 0 0 0.669 0.538 0.801 0 0 0 0.331 0.199 0.462
SL001973 Mammaglobin 2 O75556 4246 SCGB2A1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL001992 TNF sR-I P19438 7132 TNFRSF1A RFU No No AE 0.502 0.504 0.502 0.502 0.313 0.692 0 0 0 0 0 0 0.498 0.308 0.687
SL001995 Angiopoietin-1 Q15389 284 ANGPT1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.293 0.107 0.480 0.707 0.520 0.893
SL001996 Angiopoietin-2 O15123 285 ANGPT2 RFU No No AE 0.666 0.726 0.632 0.666 0.535 0.798 0 0 0 0 0 0 0.334 0.202 0.465
SL001997 IL-1 sRI P14778 3554 IL1R1 RFU No No AE 0.539 0.560 0.529 0.539 0.362 0.715 0 0 0 0 0 0 0.461 0.285 0.638
SL001998 TFPI P10646 7035 TFPI RFU No No CE 0 0 0 0 0 0 0 0 0 0.540 0.392 0.687 0.460 0.313 0.608
SL001999 MDM2 Q00987 4193 MDM2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.220 0.026 0.415 0.780 0.585 0.974
SL002036 FGFR4 P22455 2264 FGFR4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002075 IFN-aA P01563 3440 IF2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.836 0.774 0.898 0.164 0.102 0.226
SL002077 Alkaline phosphatase  boneP05186 249 ALPL RFU No No AE 0.592 0.635 0.570 0.592 0.435 0.749 0 0 0 0 0 0 0.408 0.251 0.565
SL002078 TGF-b R II P37173 7048 TGFBR2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.149 -0.050 0.348 0.851 0.652 1.050
SL002081 Cadherin-5 P33151 1003 CDH5 RFU No No DE 0.645 0.706 0.611 0 0 0 0.645 0.495 0.794 0 0 0 0.355 0.206 0.505
SL002086 Ficolin-3 O75636 8547 FCN3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.655 0.538 0.772 0.345 0.228 0.462
SL002093 Histone H2A.z P0C0S5 3015 H2AFZ RFU No No DE 0.695 0.781 0.649 0 0 0 0.695 0.542 0.848 0 0 0 0.305 0.152 0.458
SL002506 suPAR Q03405 5329 PLAUR RFU No No AE 0.538 0.560 0.528 0.538 0.357 0.719 0 0 0 0 0 0 0.462 0.281 0.643
SL002508 IL-18 BPa O95998 10068 IL18BP RFU No No DE 0.296 0.135 0.358 0 0 0 0.296 0.075 0.516 0 0 0 0.704 0.484 0.925
SL002517 TNF-a P01375 7124 TNF RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002519 ERBB3 P21860 2065 ERBB3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.612 0.482 0.742 0.388 0.258 0.518
SL002522 Rb P06400 5925 RB1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002524 sCD4 P01730 920 CD4 RFU No No DE 0.844 0.908 0.798 0 0 0 0.844 0.766 0.923 0 0 0 0.156 0.077 0.234
SL002525 C2 P06681 717 C2 RFU No No AE 0.508 0.513 0.506 0.508 0.312 0.704 0 0 0 0 0 0 0.492 0.296 0.688
SL002528 NPS-PLA2 P14555 5320 PLA2G2A RFU No No CE 0 0 0 0 0 0 0 0 0 0.650 0.531 0.768 0.350 0.232 0.469
SL002539 OPG O00300 4982 TNFRSF11B RFU No No CE 0 0 0 0 0 0 0 0 0 0.356 0.176 0.537 0.644 0.463 0.824
SL002541 sRANKL O14788 8600 TNFSF11 RFU No No CE 0 0 0 0 0 0 0 0 0 0.269 0.075 0.462 0.731 0.538 0.925
SL002542 K-ras P01116 3845 KRAS RFU No No DE 0.652 0.718 0.617 0 0 0 0.652 0.501 0.803 0 0 0 0.348 0.197 0.499
SL002561 PTHrP P12272 5744 PTHLH RFU No No CE 0 0 0 0 0 0 0 0 0 0.327 0.144 0.510 0.673 0.490 0.856
SL002621 Midkine P21741 4192 MDK RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL002640 PlGF P49763 5228 PGF RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002646 MMP-14 P50281 4323 MMP14 RFU No No DE 0.372 0.077 0.425 0 0 0 0.372 0.023 0.721 0 0 0 0.628 0.279 0.977
SL002650 M2-PK P14618 5315 PKM2 RFU No No AE 0.731 0.798 0.689 0.731 0.620 0.843 0 0 0 0 0 0 0.269 0.157 0.380
SL002654 Epithelial cell kise P29317 1969 EPHA2 RFU No No DE 0.443 0.404 0.460 0 0 0 0.443 0.239 0.648 0 0 0 0.557 0.352 0.761
SL002655 CTGF P29279 1490 CTGF RFU No No AE 0.509 0.514 0.506 0.509 0.319 0.699 0 0 0 0 0 0 0.491 0.301 0.681
SL002662 Coagulation Factor XI P03951 2160 F11 RFU No No AE 0.514 0.523 0.511 0.514 0.334 0.695 0 0 0 0 0 0 0.486 0.305 0.666
SL002684 CSF-1 P09603 1435 CSF1 RFU No No DE 0.434 0.335 0.459 0 0 0 0.434 0.133 0.736 0 0 0 0.566 0.264 0.867
SL002695 Glutamate carboxypeptidaseQ96KP4 55748 CNDP2 RFU No No DE 0.534 0.566 0.523 0 0 0 0.534 0.291 0.777 0 0 0 0.466 0.223 0.709
SL002702 PIM1 P11309 5292 PIM1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002704 PTN P21246 5764 PTN RFU No No DE 0.336 0.185 0.389 0 0 0 0.336 0.096 0.576 0 0 0 0.664 0.424 0.904
SL002705 Thrombospondin-1 P07996 7057 THBS1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.369 0.193 0.545 0.631 0.455 0.807
SL002706 CD23 P06734 2208 FCER2 RFU No No AE 0.521 0.533 0.516 0.521 0.346 0.696 0 0 0 0 0 0 0.479 0.304 0.654
SL002755 PAPP-A Q13219 5069 PAPPA RFU No No DE 0.724 0.792 0.681 0 0 0 0.724 0.607 0.841 0 0 0 0.276 0.159 0.393
SL002756 hnRNP K P61978 3190 HNRNPK RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL002763 Kallikrein 11 Q9UBX7 11012 KLK11 RFU No No CE 0 0 0 0 0 0 0 0 0 0.595 0.462 0.728 0.405 0.272 0.538
SL002783 Cardiotrophin-1 Q16619 1489 CTF1 RFU No No DE 0.366 0.194 0.414 0 0 0 0.366 0.085 0.647 0 0 0 0.634 0.353 0.915
SL002792 BARK1 P25098 156 ADRBK1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.595 0.463 0.727 0.405 0.273 0.537
SL002803 PGP9.5 P09936 7345 UCHL1 RFU No No AE 0.742 0.818 0.695 0.742 0.623 0.861 0 0 0 0 0 0 0.258 0.139 0.377
SL002823 sL-Selectin P14151 6402 SELL RFU No No DE 0.301 0.136 0.363 0 0 0 0.301 0.074 0.528 0 0 0 0.699 0.472 0.926
SL002922 sICAM-1 P05362 3383 ICAM1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.573 0.435 0.710 0.427 0.290 0.565
SL003041 PF-4 P02776 5196 PF4 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL003043 TIMP-3 P35625 7078 TIMP3 RFU No No AE 0.569 0.603 0.552 0.569 0.407 0.732 0 0 0 0 0 0 0.431 0.268 0.593
SL003060 bFGF-R P11362 2260 FGFR1 RFU No No DE 0.524 0.538 0.518 0 0 0 0.524 0.342 0.707 0 0 0 0.476 0.293 0.658
SL003080 MIF P14174 4282 MIF RFU No No AE 0.621 0.678 0.591 0.621 0.460 0.782 0 0 0 0 0 0 0.379 0.218 0.540
SL003104 Eotaxin-2 O00175 6369 CCL24 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003166 ALCAM Q13740 214 ALCAM RFU No No CE 0 0 0 0 0 0 0 0 0 0.446 0.274 0.618 0.554 0.382 0.726
SL003167 BLC O43927 10563 CXCL13 RFU No No AE 0.380 0.291 0.416 0.380 0.166 0.595 0 0 0 0 0 0 0.620 0.405 0.834
SL003168 CTACK Q9Y4X3 10850 CCL27 RFU No No CE 0 0 0 0 0 0 0 0 0 0.170 -0.035 0.376 0.830 0.624 1.035
SL003169 E-78 P42830 6374 CXCL5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.266 0.071 0.461 0.734 0.539 0.929
SL003171 FGF-4 P08620 2249 FGF4 RFU No No DE 0.540 0.579 0.527 0 0 0 0.540 0.295 0.785 0 0 0 0.460 0.215 0.705
SL003172 GCP-2 P80162 6372 CXCL6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.417 0.249 0.586 0.583 0.414 0.751
SL003173 Gro-a P09341 2919 CXCL1 RFU No No AE 0.568 0.606 0.550 0.568 0.388 0.748 0 0 0 0 0 0 0.432 0.252 0.612
SL003176 I-309 P22362 6346 CCL1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.279 0.087 0.472 0.721 0.528 0.913
SL003177 sICAM-2 P13598 3384 ICAM2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.162 -0.045 0.368 0.838 0.632 1.045
SL003178 sICAM-3 P32942 3385 ICAM3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003179 Integrin a1b1 P56199  P055563672 3688 ITGA1 ITGB1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.529 0.383 0.676 0.471 0.324 0.617
SL003182 Integrin aVb5 P06756  P180843685 3693 ITGAV ITGB5 RFU No No DE 0.510 0.517 0.507 0 0 0 0.510 0.300 0.719 0 0 0 0.490 0.281 0.700
SL003183 IP-10 P02778 3627 CXCL10 RFU No No AE 0.528 0.541 0.521 0.528 0.366 0.690 0 0 0 0 0 0 0.472 0.310 0.634
SL003184 sLeptin R P48357 3953 LEPR RFU No No AE 0.958 0.976 0.941 0.958 0.939 0.977 0 0 0 0 0 0 0.042 0.023 0.061
SL003186 Lymphotactin P47992 6375 XCL1 RFU No No DE 0.607 0.692 0.574 0 0 0 0.607 0.387 0.828 0 0 0 0.393 0.172 0.613
SL003187 MDC O00626 6367 CCL22 RFU No No DE 0.661 0.725 0.625 0 0 0 0.661 0.519 0.803 0 0 0 0.339 0.197 0.481
SL003189 MIP-3b Q99731 6363 CCL19 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003190 MIP-5 Q16663 6359 CCL15 RFU No No DE 0.636 0.692 0.605 0 0 0 0.636 0.490 0.782 0 0 0 0.364 0.218 0.510
SL003191 P-2 P02775 5473 PPBP RFU No No CE 0 0 0 0 0 0 0 0 0 0.345 0.165 0.524 0.655 0.476 0.835
SL003192 Properdin P27918 5199 CFP RFU No No CE 0 0 0 0 0 0 0 0 0 0.420 0.249 0.590 0.580 0.410 0.751
SL003193 6Ckine O00585 6366 CCL21 RFU No No AE 0.701 0.771 0.660 0.701 0.573 0.829 0 0 0 0 0 0 0.299 0.171 0.427
SL003196 TARC Q92583 6361 CCL17 RFU No No CE 0 0 0 0 0 0 0 0 0 0.412 0.242 0.582 0.588 0.418 0.758
SL003197 TECK O15444 6370 CCL25 RFU No No CE 0 0 0 0 0 0 0 0 0 0.632 0.510 0.755 0.368 0.245 0.490
SL003198 Tescin P24821 3371 TNC RFU No No AE 0.806 0.869 0.762 0.806 0.721 0.891 0 0 0 0 0 0 0.194 0.109 0.279
SL003199 sTie-1 P35590 7075 TIE1 RFU No No DE 0.764 0.843 0.715 0 0 0 0.764 0.650 0.879 0 0 0 0.236 0.121 0.350
SL003200 sTie-2 Q02763 7010 TEK RFU No No AE 0.538 0.558 0.528 0.538 0.361 0.714 0 0 0 0 0 0 0.462 0.286 0.639
SL003201 VEGF sR2 P35968 3791 KDR RFU No No CE 0 0 0 0 0 0 0 0 0 0.560 0.415 0.704 0.440 0.296 0.585
SL003220 C3adesArg P01024 718 C3 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL003280 HMG-1 P09429 3146 HMGB1 RFU No No DE 0.750 0.833 0.700 0 0 0 0.750 0.624 0.875 0 0 0 0.250 0.125 0.376
SL003300 HCC-4 O15467 6360 CCL16 RFU No No DCE 0.165 -0.077 0.249 0 0 0 0.165 -0.040 0.370 0.646 0.451 0.841 0.189 0.104 0.273
SL003301 Ck-b-8-1 P55773 6368 CCL23 RFU No No CE 0 0 0 0 0 0 0 0 0 0.303 0.116 0.490 0.697 0.510 0.884
SL003302 MPIF-1 P55773 6368 CCL23 RFU No No AE 0.749 0.822 0.703 0.749 0.636 0.862 0 0 0 0 0 0 0.251 0.138 0.364
SL003303 CCL28 Q9NRJ3 56477 CCL28 RFU No No CE 0 0 0 0 0 0 0 0 0 0.360 0.182 0.538 0.640 0.462 0.818
SL003304 IGF-I sR P08069 3480 IGF1R RFU No No DE 0.529 0.546 0.521 0 0 0 0.529 0.342 0.716 0 0 0 0.471 0.284 0.658
SL003305 IL-2 sRa P01589 3559 IL2RA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003307 IL-2 sRg P31785 3561 IL2RG RFU No No ACE 0.423 0.209 0.438 0.423 0.028 0.819 0 0 0 0.371 -0.011 0.752 0.206 0.116 0.297
SL003308 IL-4 sR P24394 3566 IL4R RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003309 LBP P18428 3929 LBP RFU No No AE 0.603 0.647 0.579 0.603 0.451 0.755 0 0 0 0 0 0 0.397 0.245 0.549
SL003310 VEGF121 P15692 7422 VEGFA RFU No No CE 0 0 0 0 0 0 0 0 0 0.156 -0.044 0.355 0.844 0.645 1.044
SL003322 VEGF sR3 P35916 2324 FLT4 RFU No No DE 0.849 0.905 0.807 0 0 0 0.849 0.780 0.918 0 0 0 0.151 0.082 0.220
SL003323 PARC P55774 6362 CCL18 RFU No No CE 0 0 0 0 0 0 0 0 0 0.641 0.521 0.762 0.359 0.238 0.479
SL003324 Coagulation Factor Xa P00742 2159 F10 RFU No No DE 0.623 0.685 0.592 0 0 0 0.623 0.455 0.791 0 0 0 0.377 0.209 0.545
SL003326 I-TAC O14625 6373 CXCL11 RFU No No DE 0.525 0.537 0.519 0 0 0 0.525 0.358 0.691 0 0 0 0.475 0.309 0.642
SL003327 Factor D P00746 1675 CFD RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003328 Factor I P05156 3426 CFI RFU No No AE 0.461 0.437 0.472 0.461 0.272 0.650 0 0 0 0 0 0 0.539 0.350 0.728
SL003329 HCC-1 Q16627 6358 CCL14 RFU No No AE 0.733 0.803 0.690 0.733 0.619 0.848 0 0 0 0 0 0 0.267 0.152 0.381
SL003331 MMP-16 P51512 4325 MMP16 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003332 MMP-17 Q9ULZ9 4326 MMP17 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003334 EMAP-2 Q12904 9255 AIMP1 RFU No No DE 0.868 0.924 0.824 0 0 0 0.868 0.801 0.934 0 0 0 0.132 0.066 0.199
SL003341 Fibrinogen g-chain dimerP02679 2266 FGG RFU No No AE 0.364 0.244 0.408 0.364 0.129 0.599 0 0 0 0 0 0 0.636 0.401 0.871
SL003362 C3d P01024 718 C3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003440 PAFAH Q13093 7941 PLA2G7 RFU No No DE 0.518 0.530 0.513 0 0 0 0.518 0.316 0.720 0 0 0 0.482 0.280 0.684
SL003461 ACTH P01189 5443 POMC RFU No No DE 0.416 0.113 0.453 0 0 0 0.416 0.025 0.807 0 0 0 0.584 0.193 0.975
SL003520 calreticulin P27797 811 CALR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003522 ERP29 P30040 10961 ERP29 RFU No No CE 0 0 0 0 0 0 0 0 0 0.436 0.269 0.604 0.564 0.396 0.731
SL003524 Protein disulfide isomerase A3P30101 2923 PDIA3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.527 0.379 0.674 0.473 0.326 0.621
SL003542 NG36 Q96KQ7 10919 EHMT2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.421 0.249 0.594 0.579 0.406 0.751
SL003643 Glutathione S-transferase PiP09211 2950 GSTP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.491 0.335 0.647 0.509 0.353 0.665
SL003647 annexin VI P08133 309 ANXA6 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL003648 Rab GDP dissociation inhibitor betaP50395 2665 GDI2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.605 0.475 0.735 0.395 0.265 0.525
SL003653 phosphoglycerate kise 1P00558 5230 PGK1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.390 0.216 0.564 0.610 0.436 0.784
SL003655 Transketolase P29401 7086 TKT RFU No No CE 0 0 0 0 0 0 0 0 0 0.626 0.502 0.750 0.374 0.250 0.498
SL003657 Calcineurin Q08209  P630985530 5534 PPP3CA PPP3R1RFU No No AE 0.718 0.784 0.677 0.718 0.602 0.834 0 0 0 0 0 0 0.282 0.166 0.398
SL003658 Aflatoxin B1 aldehyde reductaseO43488 8574 AKR7A2 RFU No No DCE 0.240 0.003 0.307 0 0 0 0.240 0.001 0.478 0.548 0.325 0.771 0.212 0.117 0.308
SL003674 BCL2-like 1 protein Q07817 598 BCL2L1 RFU No No DE 0.452 0.396 0.469 0 0 0 0.452 0.182 0.723 0 0 0 0.548 0.277 0.818
SL003679 IGF-II receptor P11717 3482 IGF2R RFU No No DE 0.671 0.735 0.635 0 0 0 0.671 0.536 0.807 0 0 0 0.329 0.193 0.464
SL003680 sRAGE Q15109 177 AGER RFU No No AE 0.810 0.868 0.767 0.810 0.730 0.889 0 0 0 0 0 0 0.190 0.111 0.270
SL003685 PBEF P43490 10135 MPT RFU No No CE 0 0 0 0 0 0 0 0 0 0.396 0.224 0.569 0.604 0.431 0.776
SL003687 Nucleoside diphosphate kise AP15531 4830 NME1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003690 RANK Q9Y6Q6 8792 TNFRSF11A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003703 BFL1 Q16548 597 BCL2A1 RFU No No DE 0.752 0.834 0.702 0 0 0 0.752 0.629 0.875 0 0 0 0.248 0.125 0.371
SL003711 Caspase-3 P42574 836 CASP3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.546 0.403 0.689 0.454 0.311 0.597
SL003717 Caspase-10 Q92851 843 CASP10 RFU No No CE 0 0 0 0 0 0 0 0 0 0.385 0.200 0.570 0.615 0.430 0.800
SL003726 Chk2 O96017 11200 CHEK2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003728 cIAP-2 Q13489 330 BIRC3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003733 SMAC Q9NR28 56616 DIABLO RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003735 4-1BB ligand P41273 8744 TNFSF9 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003738 B7 P33681 941 CD80 RFU No No CE 0 0 0 0 0 0 0 0 0 0.475 0.318 0.633 0.525 0.367 0.682
SL003739 DcR3 O95407 8771 TNFRSF6B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003744 Galectin-3 P17931 3958 LGALS3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.615 0.485 0.744 0.385 0.256 0.515
SL003753 DLC8 P63167 8655 DYNLL1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003761 pTEN P60484 5728 PTEN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003764 NCAM-120 P13591 4684 NCAM1 RFU No No AE 0.700 0.768 0.660 0.700 0.573 0.827 0 0 0 0 0 0 0.300 0.173 0.427
SL003770 SARP-2 Q8N474 6422 SFRP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.490 0.334 0.645 0.510 0.355 0.666
SL003785 GAPDH  liver P04406 2597 GAPDH RFU No No AE 0.713 0.779 0.673 0.713 0.596 0.831 0 0 0 0 0 0 0.287 0.169 0.404
SL003793 MEK1 Q02750 5604 MAP2K1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.172 -0.027 0.372 0.828 0.628 1.027
SL003800 Kallikrein 4 Q9Y5K2 9622 KLK4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003803 ERBB4 Q15303 2066 ERBB4 RFU No No DE 0.736 0.846 0.679 0 0 0 0.736 0.577 0.895 0 0 0 0.264 0.105 0.423
SL003849 FGF9 P31371 2254 FGF9 RFU No No DE 0.488 0.445 0.493 0 0 0 0.488 0.100 0.875 0 0 0 0.512 0.125 0.900
SL003862 CD40 ligand  soluble P29965 959 CD40LG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003863 kallikrein 5 Q9Y337 25818 KLK5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.314 0.126 0.502 0.686 0.498 0.874
SL003872 gp130  soluble P40189 3572 IL6ST RFU No No CE 0 0 0 0 0 0 0 0 0 0.525 0.372 0.678 0.475 0.322 0.628
SL003915 kallikrein 8 O60259 11202 KLK8 RFU No No CE 0 0 0 0 0 0 0 0 0 0.528 0.379 0.677 0.472 0.323 0.621
SL003916 kallikrein 12 Q9UKR0 43849 KLK12 RFU No No DE 0.399 0.333 0.428 0 0 0 0.399 0.201 0.597 0 0 0 0.601 0.403 0.799
SL003918 kallikrein 13 Q9UKR3 26085 KLK13 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003919 kallikrein 14 Q9P0G3 43847 KLK14 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003930 HPG- P15428 3248 HPGD RFU No No DE 0.777 0.868 0.722 0 0 0 0.777 0.653 0.901 0 0 0 0.223 0.099 0.347
SL003951 BDNF P23560 627 BDNF RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL003970 PTH P01270 5741 PTH RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003974 Activated Protein C P04070 5624 PROC RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003990 FGFR-2 P21802 2263 FGFR2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003993 BMP-6 P22004 654 BMP6 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL003994 BMP-1 P13497 649 BMP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.505 0.350 0.660 0.495 0.340 0.650
SL004008 Proteise-3 P24158 5657 PRTN3 RFU No No DE 0.534 0.552 0.525 0 0 0 0.534 0.360 0.708 0 0 0 0.466 0.292 0.640
SL004009 RAC1 P63000 5879 RAC1 RFU No No DCE 0.242 -0.072 0.314 0 0 0 0.242 -0.027 0.512 0.508 0.258 0.758 0.250 0.140 0.359
SL004010 SCF sR P10721 3815 KIT RFU No No DE 0.593 0.636 0.571 0 0 0 0.593 0.436 0.751 0 0 0 0.407 0.249 0.564
SL004015 TAFI Q96IY4 1361 CPB2 RFU No No AE 0.631 0.688 0.601 0.631 0.480 0.783 0 0 0 0 0 0 0.369 0.217 0.520
SL004016 CXCL16  soluble Q9H2A7 58191 CXCL16 RFU No No CE 0 0 0 0 0 0 0 0 0 0.500 0.343 0.657 0.500 0.343 0.657
SL004060 Endothelin-converting enzyme 1P42892 1889 ECE1 RFU No No AE 0.676 0.738 0.640 0.676 0.546 0.806 0 0 0 0 0 0 0.324 0.194 0.454
SL004063 FGFR-3 P22607 2261 FGFR3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004064 GIB P04054 5319 PLA2G1B RFU No No AE 0.353 0.232 0.398 0.353 0.127 0.578 0 0 0 0 0 0 0.647 0.422 0.873
SL004066 GIIE Q9NZK7 30814 PLA2G2E RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004067 GX O15496 8399 PLA2G10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004068 Granzyme B P10144 3002 GZMB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004070 Ubiquitin P62979 6233 RPS27A RFU No No DE 0.233 -0.096 0.328 0 0 0 0.233 -0.043 0.509 0 0 0 0.767 0.491 1.043
SL004078 BMP-7 P18075 655 BMP7 RFU No No AE 0.620 0.673 0.592 0.620 0.467 0.773 0 0 0 0 0 0 0.380 0.227 0.533
SL004080 BMPR1A P36894 657 BMPR1A RFU No No DE 0.395 0.289 0.430 0 0 0 0.395 0.144 0.646 0 0 0 0.605 0.354 0.856
SL004081 Bone proteoglycan II P07585 1634 DCN RFU No No CE 0 0 0 0 0 0 0 0 0 0.449 0.280 0.618 0.551 0.382 0.720
SL004118 TrATPase P13686 54 ACP5 RFU No No AE 0.698 0.771 0.655 0.698 0.561 0.834 0 0 0 0 0 0 0.302 0.166 0.439
SL004119 discoidin domain receptor 1Q08345 780 DDR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004120 Discoidin domain receptor 2Q16832 4921 DDR2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.146 -0.056 0.348 0.854 0.652 1.056
SL004125 IR P06213 3643 INSR RFU No No CE 0 0 0 0 0 0 0 0 0 0.346 0.165 0.527 0.654 0.473 0.835
SL004126 4-1BB Q07011 3604 TNFRSF9 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004128 Activin RIB P36896 91 ACVR1B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004131 B7-2 P42081 942 CD86 RFU No No DE 0.190 -0.119 0.294 0 0 0 0.190 -0.060 0.440 0 0 0 0.810 0.560 1.060
SL004133 BMP RII Q13873 659 BMPR2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004134 CD27 P26842 939 CD27 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL004136 Dtk Q06418 7301 TYRO3 RFU No No DE 0.586 0.649 0.561 0 0 0 0.586 0.377 0.796 0 0 0 0.414 0.204 0.623
SL004137 EphA1 P21709 2041 EPHA1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.351 0.173 0.530 0.649 0.470 0.827
SL004140 Ephrin-A4 P52798 1945 EF4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.438 0.269 0.607 0.562 0.393 0.731
SL004141 Ephrin-A5 P52803 1946 EF5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.347 0.166 0.529 0.653 0.471 0.834
SL004142 Ephrin-B3 Q15768 1949 EFNB3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004143 GFRa-2 O00451 2675 GFRA2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.633 0.510 0.757 0.367 0.243 0.490
SL004144 GFRa-3 O60609 2676 GFRA3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004145 HVEM Q92956 8764 TNFRSF14 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004146 IL-1 R4 Q01638 9173 IL1RL1 RFU No No AE 0.763 0.836 0.715 0.763 0.653 0.872 0 0 0 0 0 0 0.237 0.128 0.347
SL004147 IL-10 Rb Q08334 3588 IL10RB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004148 IL-12 Rb1 P42701 3594 IL12RB1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004149 IL-13 Ra1 P78552 3597 IL13RA1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.198 0.001 0.395 0.802 0.605 0.999
SL004151 IL-15 Ra Q13261 3601 IL15RA RFU No No DE 0.746 0.847 0.691 0 0 0 0.746 0.601 0.891 0 0 0 0.254 0.109 0.399
SL004152 IL-18 Ra Q13478 8809 IL18R1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.598 0.466 0.730 0.402 0.270 0.534
SL004153 M-CSF R P07333 1436 CSF1R RFU No No AE 0.577 0.612 0.558 0.577 0.418 0.736 0 0 0 0 0 0 0.423 0.264 0.582
SL004154 NCAM-L1 P32004 3897 L1CAM RFU No No AE 0.578 0.615 0.560 0.578 0.420 0.737 0 0 0 0 0 0 0.422 0.263 0.580
SL004155 PDGF Rb P09619 5159 PDGFRB RFU No No AE 0.725 0.791 0.683 0.725 0.610 0.839 0 0 0 0 0 0 0.275 0.161 0.390
SL004156 TRAIL R1 O00220 8797 TNFRSF10A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004159 TRAIL R4 Q9UBN6 8793 TNFRSF10D RFU No No CE 0 0 0 0 0 0 0 0 0 0.494 0.336 0.652 0.506 0.348 0.664
SL004160 TrkB Q16620 4915 NTRK2 RFU No No AE 0.466 0.445 0.476 0.466 0.273 0.660 0 0 0 0 0 0 0.534 0.340 0.727
SL004180 CD30 P28908 943 TNFRSF8 RFU No No DE 0.637 0.732 0.597 0 0 0 0.637 0.433 0.842 0 0 0 0.363 0.158 0.567
SL004182 GV P39877 5322 PLA2G5 RFU No No DE 0.779 0.873 0.723 0 0 0 0.779 0.654 0.905 0 0 0 0.221 0.095 0.346
SL004183 P-Cadherin P22223 1001 CDH3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004208 annexin I P04083 301 ANXA1 RFU No No AE 0.263 -0.064 0.350 0.263 -0.027 0.554 0 0 0 0 0 0 0.737 0.446 1.027
SL004209 annexin II P07355 302 ANXA2 RFU No No AE 0.425 0.377 0.446 0.425 0.229 0.622 0 0 0 0 0 0 0.575 0.378 0.771
SL004230 tau P10636 4137 MAPT RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004253 17-beta-HSD 1 P14061 3292 HSD17B1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004258 Adiponectin Q15848 9370 ADIPOQ RFU No No AE 0.720 0.793 0.676 0.720 0.595 0.845 0 0 0 0 0 0 0.280 0.155 0.405
SL004260 resistin Q9HD89 56729 RETN RFU No No AE 0.561 0.594 0.545 0.561 0.388 0.734 0 0 0 0 0 0 0.439 0.266 0.612
SL004271 GFAP P14136 2670 GFAP RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004296 Myokise  human P00568 203 AK1 RFU No No AE 0.552 0.579 0.539 0.552 0.380 0.724 0 0 0 0 0 0 0.448 0.276 0.620
SL004297 NEUREGULIN-1 Q02297 3084 NRG1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.372 0.193 0.551 0.628 0.449 0.807
SL004298 granzyme A P12544 3001 GZMA RFU No No CE 0 0 0 0 0 0 0 0 0 0.161 -0.040 0.361 0.839 0.639 1.040
SL004299 Livin B Q96CA5 79444 BIRC7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004301 Ku70 P12956 2547 XRCC6 RFU No No DE 0.353 0.192 0.404 0 0 0 0.353 0.092 0.615 0 0 0 0.647 0.385 0.908
SL004304 STX1a Q16623 6804 STX1A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004305 Topoisomerase I P11387 7150 TOP1 RFU No No DE 0.716 0.804 0.668 0 0 0 0.716 0.571 0.861 0 0 0 0.284 0.139 0.429
SL004306 UBC9 P63279 7329 UBE2I RFU No No AE 0.698 0.765 0.658 0.698 0.572 0.825 0 0 0 0 0 0 0.302 0.175 0.428
SL004326 TNFSF18 Q9UNG2 8995 TNFSF18 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004327 BAFF Q9Y275 10673 TNFSF13B RFU No No CE 0 0 0 0 0 0 0 0 0 0.299 0.110 0.487 0.701 0.513 0.890
SL004329 BMP-14 P43026 8200 GDF5 RFU No No DE 0.445 0.370 0.465 0 0 0 0.445 0.158 0.731 0 0 0 0.555 0.269 0.842
SL004330 CD22 P20273 933 CD22 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004331 CNTF P26441 1270 CNTF RFU No No DE 0.499 0.498 0.500 0 0 0 0.499 0.182 0.816 0 0 0 0.501 0.184 0.818
SL004332 EG-VEGF P58294 84432 PROK1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004333 FGF-10 O15520 2255 FGF10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004334 FGF-16 O43320 8823 FGF16 RFU No No CE 0 0 0 0 0 0 0 0 0 0.585 0.450 0.719 0.415 0.281 0.550
SL004335 FGF-17 O60258 8822 FGF17 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004336 FGF-18 O76093 8817 FGF18 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004337 FGF-19 O95750 9965 FGF19 RFU No No AE 0.554 0.583 0.540 0.554 0.381 0.727 0 0 0 0 0 0 0.446 0.273 0.619
SL004338 FGF-20 Q9NP95 26281 FGF20 RFU No No AE 0.707 0.789 0.661 0.707 0.565 0.849 0 0 0 0 0 0 0.293 0.151 0.435
SL004339 FGF-5 P12034 2250 FGF5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004340 FGF-6 P10767 2251 FGF6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.401 0.228 0.573 0.599 0.427 0.772
SL004342 FGF-8B P55075 2253 FGF8 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004343 Flt3 ligand P49771 2323 FLT3LG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004345 GDF-11 O95390 10220 GDF11 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004346 IL-20 Q9NYY1 50604 IL20 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004347 IL-22 Q9GZX6 50616 IL22 RFU No No DE 0.474 0.451 0.482 0 0 0 0.474 0.239 0.708 0 0 0 0.526 0.292 0.761
SL004348 IFN-lambda 1 Q8IU54 282618 IL29 RFU No No CE 0 0 0 0 0 0 0 0 0 0.529 0.381 0.677 0.471 0.323 0.619
SL004349 IFN-lambda 2 Q8IZJ0 282616 IL28A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004350 IL-17B Q9UHF5 27190 IL17B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004351 IL-17E Q9H293 64806 IL25 RFU No No DE 0.434 0.348 0.458 0 0 0 0.434 0.150 0.719 0 0 0 0.566 0.281 0.850
SL004352 IL-17F Q96PD4 112744 IL17F RFU No No DE 0.628 0.726 0.589 0 0 0 0.628 0.410 0.845 0 0 0 0.372 0.155 0.590
SL004353 IL-17D Q8TAD2 53342 IL17D RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004354 IL-19 Q9UHD0 29949 IL19 RFU No No CE 0 0 0 0 0 0 0 0 0 0.543 0.396 0.690 0.457 0.310 0.604
SL004355 LD78-beta P16619 414062 CCL3L1 RFU No No DE 0.595 0.679 0.565 0 0 0 0.595 0.360 0.830 0 0 0 0.405 0.170 0.640
SL004356 LAG-1 Q8NHW4 388372 CCL4L1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.188 -0.009 0.384 0.812 0.616 1.009
SL004359 Neurotrophin-3 P20783 4908 NTF3 RFU No No DE 0.640 0.725 0.602 0 0 0 0.640 0.451 0.829 0 0 0 0.360 0.171 0.549
SL004360 Neurotrophin-5 P34130 4909 NTF4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004362 SCGF-beta Q9Y240 6320 CLEC11A RFU No No AE 0.613 0.661 0.587 0.613 0.464 0.763 0 0 0 0 0 0 0.387 0.237 0.536
SL004363 SCGF-alpha Q9Y240 6320 CLEC11A RFU No No AE 0.737 0.805 0.693 0.737 0.625 0.849 0 0 0 0 0 0 0.263 0.151 0.375
SL004364 TACI O14836 23495 TNFRSF13B RFU No No CE 0 0 0 0 0 0 0 0 0 0.246 0.047 0.445 0.754 0.555 0.953
SL004365 TWEAK O43508 8742 TNFSF12 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004366 TWEAKR Q9NP84 51330 TNFRSF12A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004367 DKK1 O94907 22943 DKK1 RFU No No AE 0.547 0.577 0.534 0.547 0.355 0.739 0 0 0 0 0 0 0.453 0.261 0.645
SL004400 Coagulation Factor IXabP00740 2158 F9 RFU No No CE 0 0 0 0 0 0 0 0 0 0.438 0.267 0.609 0.562 0.391 0.733
SL004415 ACE2 Q9BYF1 59272 ACE2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004438 Cystatin M Q15828 1474 CST6 RFU No No AE 0.755 0.825 0.710 0.755 0.647 0.862 0 0 0 0 0 0 0.245 0.138 0.353
SL004457 Protease nexin I P07093 5270 SERPINE2 RFU No No DE 0.325 0.171 0.381 0 0 0 0.325 0.091 0.559 0 0 0 0.675 0.441 0.909
SL004458 Elafin P19957 5266 PI3 RFU No No AE 0.476 0.460 0.482 0.476 0.280 0.671 0 0 0 0 0 0 0.524 0.329 0.720
SL004466 Heparin cofactor II P05546 3053 SERPIND1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.458 0.293 0.623 0.542 0.377 0.707
SL004469 amyloid precursor proteinP05067 351 APP RFU No No CE 0 0 0 0 0 0 0 0 0 0.388 0.214 0.561 0.612 0.439 0.786
SL004477 calgranulin B P06702 6280 S100A9 RFU No No DE 0.463 0.440 0.474 0 0 0 0.463 0.267 0.660 0 0 0 0.537 0.340 0.733
SL004482 Endoglin P17813 2022 ENG RFU No No AE 0.485 0.476 0.489 0.485 0.294 0.676 0 0 0 0 0 0 0.515 0.324 0.706
SL004484 SP-D P35247 6441 SFTPD RFU No No DE 0.597 0.669 0.568 0 0 0 0.597 0.384 0.810 0 0 0 0.403 0.190 0.616
SL004486 VEGF-C P49767 7424 VEGFC RFU No No CE 0 0 0 0 0 0 0 0 0 0.229 0.032 0.425 0.771 0.575 0.968
SL004492 TLR2 O60603 7097 TLR2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.332 0.147 0.516 0.668 0.484 0.853
SL004511 BPI P17213 671 BPI RFU No No DE 0.612 0.663 0.585 0 0 0 0.612 0.456 0.768 0 0 0 0.388 0.232 0.544
SL004515 PGRP-S O75594 8993 PGLYRP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.313 0.130 0.497 0.687 0.503 0.870
SL004516 MBL P11226 4153 MBL2 RFU No No AE 0.813 0.873 0.770 0.813 0.733 0.893 0 0 0 0 0 0 0.187 0.107 0.267
SL004536 LEAP-1 P81172 57817 HAMP RFU No No DE 0.224 -0.004 0.310 0 0 0 0.224 -0.002 0.450 0 0 0 0.776 0.550 1.002
SL004556 DAF P08174 1604 CD55 RFU No No AE 0.590 0.628 0.569 0.590 0.441 0.739 0 0 0 0 0 0 0.410 0.261 0.559
SL004579 Macrophage mannose receptorP22897 4360 MRC1 RFU No No AE 0.784 0.852 0.738 0.784 0.687 0.881 0 0 0 0 0 0 0.216 0.119 0.313
SL004580 Macrophage scavenger receptorP21757 4481 MSR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004588 IL-1 R AcP Q9NPH3 3556 IL1RAP RFU No No AE 0.806 0.866 0.762 0.806 0.723 0.888 0 0 0 0 0 0 0.194 0.112 0.277
SL004589 Azurocidin P20160 566 AZU1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.542 0.397 0.687 0.458 0.313 0.603
SL004591 G-CSF-R Q99062 1441 CSF3R RFU No No CE 0 0 0 0 0 0 0 0 0 0.171 -0.027 0.369 0.829 0.631 1.027
SL004605 40S ribosomal protein SAP08865 3921 RPSA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004610 LRP8 Q14114 7804 LRP8 RFU No No CE 0 0 0 0 0 0 0 0 0 0.414 0.243 0.586 0.586 0.414 0.757
SL004625 ADAMTS-4 O75173 9507 ADAMTS4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.351 0.166 0.535 0.649 0.465 0.834
SL004626 ADAMTS-5 Q9U0 11096 ADAMTS5 RFU No No DE 0.832 0.901 0.783 0 0 0 0.832 0.746 0.918 0 0 0 0.168 0.082 0.254
SL004635 CD30 Ligand P32971 944 TNFSF8 RFU No No AE 0.690 0.760 0.649 0.690 0.555 0.825 0 0 0 0 0 0 0.310 0.175 0.445
SL004636 Flt-3 P36888 2322 FLT3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.625 0.500 0.750 0.375 0.250 0.500
SL004637 MSP R Q04912 4486 MST1R RFU No No DE 0.482 0.443 0.490 0 0 0 0.482 0.138 0.827 0 0 0 0.518 0.173 0.862
SL004639 TrkC Q16288 4916 NTRK3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.498 0.343 0.653 0.502 0.347 0.657
SL004642 ADAM 9 Q13443 8754 ADAM9 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004643 Angiopoietin-4 Q9Y264 51378 ANGPT4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.361 0.182 0.540 0.639 0.460 0.818
SL004644 EDA Q92838 1896 EDA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004645 HAI-1 O43278 6692 SPINT1 RFU No No DE 0.539 0.564 0.529 0 0 0 0.539 0.350 0.729 0 0 0 0.461 0.271 0.650
SL004646 Layilin Q6UX15 143903 LAYN RFU No No AE 0.337 0.168 0.392 0.337 0.083 0.591 0 0 0 0 0 0 0.663 0.409 0.917
SL004648 LIGHT O43557 8740 TNFSF14 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004649 OX40 Ligand P23510 7292 TNFSF4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004650 sFRP-3 Q92765 2487 FRZB RFU No No DE 0.326 0.141 0.385 0 0 0 0.326 0.069 0.583 0 0 0 0.674 0.417 0.931
SL004652 WIF-1 Q9Y5W5 11197 WIF1 RFU No No DE 0.231 0.019 0.313 0 0 0 0.231 0.011 0.451 0 0 0 0.769 0.549 0.989
SL004654 Granzyme H P20718 2999 GZMH RFU No No DE 0.251 -0.009 0.335 0 0 0 0.251 -0.005 0.506 0 0 0 0.749 0.494 1.005
SL004660 BSP P21815 3381 IBSP RFU No No CE 0 0 0 0 0 0 0 0 0 0.387 0.214 0.561 0.613 0.439 0.786
SL004661 Aggrecan P16112 176 ACAN RFU No No AE 0.384 0.278 0.421 0.384 0.146 0.621 0 0 0 0 0 0 0.616 0.379 0.854
SL004668 Apo E3 P02649 348 APOE RFU No No CE 0 0 0 0 0 0 0 0 0 0.640 0.520 0.761 0.360 0.239 0.480
SL004669 Apo E4 P02649 348 APOE RFU No No CE 0 0 0 0 0 0 0 0 0 0.710 0.609 0.811 0.290 0.189 0.391
SL004670 Artemin Q5T4W7 9048 ARTN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004671 BAFF Receptor Q96RJ3 115650 TNFRSF13C RFU No No CE 0 0 0 0 0 0 0 0 0 0.400 0.228 0.573 0.600 0.427 0.772
SL004672 BCMA Q02223 608 TNFRSF17 RFU No No AE 0.706 0.767 0.668 0.706 0.594 0.819 0 0 0 0 0 0 0.294 0.181 0.406
SL004673 Cathepsin S P25774 1520 CTSS RFU No No DE 0.521 0.534 0.515 0 0 0 0.521 0.331 0.712 0 0 0 0.479 0.288 0.669
SL004676 IGFBP-5 P24593 3488 IGFBP5 RFU No No AE 0.239 0.019 0.321 0.239 0.010 0.467 0 0 0 0 0 0 0.761 0.533 0.990
SL004683 Noggin Q13253 9241 NOG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004685 Persephin O60542 5623 PSPN RFU No No CE 0 0 0 0 0 0 0 0 0 0.152 -0.051 0.354 0.848 0.646 1.051
SL004686 TNFSF15 O95150 9966 TNFSF15 RFU No No AE 0.544 0.570 0.532 0.544 0.353 0.734 0 0 0 0 0 0 0.456 0.266 0.647
SL004687 TSLP Q969D9 85480 TSLP RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004689 WISP-1 O95388 8840 WISP1 RFU No No DE 0.275 0.057 0.350 0 0 0 0.275 0.029 0.522 0 0 0 0.725 0.478 0.971
SL004692 CLF-1/CLC Complex O75462 Q9UBD99244 23529CRLF1 CLCF1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004697 HPV E7 Type 16 P03129 1489079 Human-virus RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004698 HPV E7 Type18 P06788 1489089 Human-virus RFU No No AE 0.511 0.517 0.508 0.511 0.328 0.695 0 0 0 0 0 0 0.489 0.305 0.672
SL004704 COMMD7 Q86VX2 149951 COMMD7 RFU No No CE 0 0 0 0 0 0 0 0 0 0.269 0.077 0.460 0.731 0.540 0.923
SL004708 CTAP-III P02775 5473 PPBP RFU No No CE 0 0 0 0 0 0 0 0 0 0.367 0.191 0.543 0.633 0.457 0.809
SL004712 SDF-1 P48061 6387 CXCL12 RFU No No CE 0 0 0 0 0 0 0 0 0 0.409 0.233 0.584 0.591 0.416 0.767
SL004714 LIF sR P42702 3977 LIFR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004716 JNK2 P45984 5601 MAPK9 RFU No No DE 0.696 0.784 0.650 0 0 0 0.696 0.541 0.851 0 0 0 0.304 0.149 0.459
SL004718 Karyopherin-a2 P52292 3838 KP2 RFU No No AE 0.251 -0.009 0.335 0.251 -0.005 0.506 0 0 0 0 0 0 0.749 0.494 1.005
SL004720 Calcineurin B a P63098 5534 PPP3R1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004723 HDAC8 Q9BY41 55869 HDAC8 RFU No No AE 0.518 0.530 0.513 0.518 0.323 0.713 0 0 0 0 0 0 0.482 0.287 0.677
SL004724 MOZ Q92794 7994 KAT6A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004725 Hat1 O14929 8520 HAT1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004726 CD97 P48960 976 CD97 RFU No No DE 0.245 -0.121 0.340 0 0 0 0.245 -0.050 0.540 0 0 0 0.755 0.460 1.050
SL004737 Tropomyosin 1 alpha chainP09493 7168 TPM1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004739 ITI heavy chain H4 Q14624 3700 ITIH4 RFU No No AE 0.779 0.844 0.735 0.779 0.685 0.873 0 0 0 0 0 0 0.221 0.127 0.315
SL004742 Afamin P43652 173 AFM RFU No No AE 0.463 0.437 0.474 0.463 0.259 0.667 0 0 0 0 0 0 0.537 0.333 0.741
SL004750 DEAD-box protein 19BQ9UMR2 11269 DDX19B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004751 HO-2 P30519 3163 HMOX2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004752 DRR1 O95990 11170 FAM107A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004757 DRG-1 Q9NP79 51534 VTA1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.569 0.431 0.707 0.431 0.293 0.569
SL004759 eIF-5 P55010 1983 EIF5 RFU No No DE 0.822 0.894 0.773 0 0 0 0.822 0.731 0.913 0 0 0 0.178 0.087 0.269
SL004760 PAFAH beta subunit P68402 5049 PAFAH1B2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.642 0.521 0.763 0.358 0.237 0.479
SL004765 MAPKAPK3 Q16644 7867 MAPKAPK3 RFU No No AE 0.734 0.806 0.690 0.734 0.618 0.851 0 0 0 0 0 0 0.266 0.149 0.382
SL004768 AIF1 P55008 199 AIF1 RFU No No AE 0.387 0.301 0.421 0.387 0.172 0.602 0 0 0 0 0 0 0.613 0.398 0.828
SL004771 Aurora kise A O14965 6790 AURKA RFU No No DE 0.500 0.500 0.500 0 0 0 0.500 0.260 0.739 0 0 0 0.500 0.261 0.740
SL004781 CSK P41240 1445 CSK RFU No No AE 0.753 0.817 0.710 0.753 0.651 0.855 0 0 0 0 0 0 0.247 0.145 0.349
SL004782 TSG-6 P98066 7130 TNFAIP6 RFU No No AE 0.656 0.714 0.623 0.656 0.522 0.791 0 0 0 0 0 0 0.344 0.209 0.478
SL004791 DR3 Q93038 8718 TNFRSF25 RFU No No DE 0.880 0.927 0.843 0 0 0 0.880 0.826 0.935 0 0 0 0.120 0.065 0.174
SL004795 ERAB Q99714 3028 HSD17B10 RFU No No DCE 0.230 -0.053 0.303 0 0 0 0.230 -0.022 0.481 0.539 0.305 0.772 0.232 0.129 0.335
SL004804 Nectin-like protein 1 Q8N126 57863 CADM3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004805 Nectin-like protein 2 Q9BY67 23705 CADM1 RFU No No DE 0.383 0.278 0.421 0 0 0 0.383 0.146 0.620 0 0 0 0.617 0.380 0.854
SL004812 Triosephosphate isomeraseP60174 7167 TPI1 RFU No No ACE 0.374 -0.437 0.412 0.374 -0.039 0.787 0 0 0 0.371 -0.014 0.756 0.256 0.144 0.368
SL004814 Coactosin-like protein Q14019 23406 COTL1 RFU No No DE 0.545 0.587 0.530 0 0 0 0.545 0.304 0.787 0 0 0 0.455 0.213 0.696
SL004820 Phosphoglycerate mutase 1P18669 5223 PGAM1 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL004823 Cyclophilin A P62937 5478 PPIA RFU No No CE 0 0 0 0 0 0 0 0 0 0.601 0.470 0.732 0.399 0.268 0.530
SL004837 Activin AB P08476 P095293624 3625 INHBA INHBB RFU No No CE 0 0 0 0 0 0 0 0 0 0.389 0.215 0.563 0.611 0.437 0.785
SL004844 EphA5 P54756 2044 EPHA5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004845 EphB4 P54760 2050 EPHB4 RFU No No DE 0.289 0.146 0.350 0 0 0 0.289 0.087 0.492 0 0 0 0.711 0.508 0.913
SL004849 IL-1 sR9 Q9NP60 26280 IL1RAPL2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004850 IL-17 sR Q96F46 23765 IL17RA RFU No No DE 0.936 0.962 0.912 0 0 0 0.936 0.907 0.965 0 0 0 0.064 0.035 0.093
SL004851 ALK-1 P37023 94 ACVRL1 RFU No No DE 0.563 0.668 0.539 0 0 0 0.563 0.252 0.875 0 0 0 0.437 0.125 0.748
SL004852 B7-H1 Q9NZQ7 29126 CD274 RFU No No CE 0 0 0 0 0 0 0 0 0 0.152 -0.047 0.351 0.848 0.649 1.047
SL004853 B7-H2 O75144 23308 ICOSLG RFU No No AE 0.472 0.455 0.480 0.472 0.279 0.665 0 0 0 0 0 0 0.528 0.335 0.721
SL004855 contactin-1 Q12860 1272 CNTN1 RFU No No AE 0.464 0.439 0.475 0.464 0.256 0.672 0 0 0 0 0 0 0.536 0.328 0.744
SL004856 Desmoglein-1 Q02413 1828 DSG1 RFU No No AE 0.262 -0.182 0.356 0.262 -0.064 0.587 0 0 0 0 0 0 0.738 0.413 1.064
SL004857 Desmoglein-2 Q14126 1829 DSG2 RFU No No DE 0.618 0.673 0.590 0 0 0 0.618 0.461 0.776 0 0 0 0.382 0.224 0.539
SL004858 GFRa-1 P56159 2674 GFRA1 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL004859 GITR Q9Y5U5 8784 TNFRSF18 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004860 HTRA2 O43464 27429 HTRA2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.371 0.194 0.548 0.629 0.452 0.806
SL004861 IL-18 Rb O95256 8807 IL18RAP RFU No No DE 0.794 0.880 0.740 0 0 0 0.794 0.680 0.908 0 0 0 0.206 0.092 0.320
SL004862 PD-L2 Q9BQ51 80380 PDCD1LG2 RFU No No DE 0.584 0.639 0.560 0 0 0 0.584 0.385 0.783 0 0 0 0.416 0.217 0.615
SL004863 TAJ Q9NS68 55504 TNFRSF19 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004864 Cadherin-12 P55289 1010 CDH12 RFU No No DE 0.300 -0.176 0.383 0 0 0 0.300 -0.052 0.653 0 0 0 0.700 0.347 1.052
SL004865 Cadherin-6 P55285 1004 CDH6 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004866 Carbonic anhydrase I P00915 759 CA1 RFU No No AE 0.551 0.578 0.538 0.551 0.379 0.723 0 0 0 0 0 0 0.449 0.277 0.621
SL004867 Carbonic anhydrase IIIP07451 761 CA3 RFU No No AE 0.591 0.633 0.569 0.591 0.433 0.748 0 0 0 0 0 0 0.409 0.252 0.567
SL004868 Carbonic anhydrase VIIP43166 766 CA7 RFU No No DE 0.389 0.111 0.435 0 0 0 0.389 0.032 0.746 0 0 0 0.611 0.254 0.968
SL004869 Carbonic anhydrase XIIIQ8N1Q1 377677 CA13 RFU No No CE 0 0 0 0 0 0 0 0 0 0.498 0.344 0.651 0.502 0.349 0.656
SL004871 DR6 O75509 27242 TNFRSF21 RFU No No CE 0 0 0 0 0 0 0 0 0 0.538 0.390 0.686 0.462 0.314 0.610
SL004872 EDAR Q9UNE0 10913 EDAR RFU No No AE 0.765 0.829 0.722 0.765 0.668 0.862 0 0 0 0 0 0 0.235 0.138 0.332
SL004875 IL-1Rrp2 Q9HB29 8808 IL1RL2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.286 0.094 0.478 0.714 0.522 0.906
SL004876 Kallistatin P29622 5267 SERPI4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.487 0.325 0.650 0.513 0.350 0.675
SL004891 hnRNP A2/B1 P22626 3181 HNRNPA2B1 RFU No No DE 0.723 0.809 0.674 0 0 0 0.723 0.583 0.862 0 0 0 0.277 0.138 0.417
SL004899 HSP70 protein 8 P11142 3312 HSPA8 RFU No No DE 0.548 0.613 0.530 0 0 0 0.548 0.261 0.835 0 0 0 0.452 0.165 0.739
SL004901 Protein disulfide-isomeraseP07237 5034 P4HB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004908 Tropomyosin 2 P07951 7169 TPM2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004914 PPase Q15181 5464 PPA1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004915 NCC27 O00299 1192 CLIC1 RFU No No AE 0.745 0.809 0.702 0.745 0.640 0.849 0 0 0 0 0 0 0.255 0.151 0.360
SL004919 Peroxiredoxin-1 Q06830 5052 PRDX1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.517 0.367 0.667 0.483 0.333 0.633
SL004920 Cofilin-1 P23528 1072 CFL1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.624 0.499 0.750 0.376 0.250 0.501
SL004921 NDP kise B P22392 4831 NME2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.560 0.420 0.700 0.440 0.300 0.580
SL004925 AGR2 O95994 10551 AGR2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004932 Peroxiredoxin-5 P30044 25824 PRDX5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004938 CaMKK alpha Q8N5S9 84254 CAMKK1 RFU No No DE 0.383 0.293 0.418 0 0 0 0.383 0.165 0.601 0 0 0 0.617 0.399 0.835
SL004939 PTP-1B P18031 5770 PTPN1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL004940 PTP-1C P29350 5777 PTPN6 RFU No No ACE 0.275 -0.378 0.353 0.275 -0.080 0.631 0 0 0 0.498 0.166 0.830 0.227 0.127 0.327
SL005034 RAN P62826 5901 RAN RFU No No AE 0.616 0.667 0.589 0.616 0.463 0.769 0 0 0 0 0 0 0.384 0.231 0.537
SL005059 TGF-b R III Q03167 7049 TGFBR3 RFU No No AE 0.544 0.568 0.533 0.544 0.372 0.717 0 0 0 0 0 0 0.456 0.283 0.628
SL005084 Periostin Q15063 10631 POSTN RFU No No DE 0.396 0.313 0.428 0 0 0 0.396 0.174 0.617 0 0 0 0.604 0.383 0.826
SL005087 IGFBP-7 Q16270 3490 IGFBP7 RFU No No AE 0.446 0.405 0.463 0.446 0.229 0.664 0 0 0 0 0 0 0.554 0.336 0.771
SL005102 SHBG P04278 6462 SHBG RFU No No CE 0 0 0 0 0 0 0 0 0 0.370 0.194 0.547 0.630 0.453 0.806
SL005115 Spondin-1 Q9HCB6 10418 SPON1 RFU No No DE 0.514 0.522 0.510 0 0 0 0.514 0.334 0.695 0 0 0 0.486 0.305 0.666
SL005152 TIG2 Q99969 5919 RARRES2 RFU No No DE 0.615 0.681 0.584 0 0 0 0.615 0.431 0.799 0 0 0 0.385 0.201 0.569
SL005153 CNTFR alpha P26992 1271 CNTFR RFU No No AE 0.551 0.580 0.538 0.551 0.374 0.729 0 0 0 0 0 0 0.449 0.271 0.626
SL005155 Cripto P13385 6997 TDGF1 RFU No No DE 0.538 0.588 0.524 0 0 0 0.538 0.252 0.823 0 0 0 0.462 0.177 0.748
SL005156 DAN P41271 4681 NBL1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.539 0.393 0.685 0.461 0.315 0.607
SL005157 DC-SIGN Q9NNX6 30835 CD209 RFU No No AE 0.559 0.589 0.544 0.559 0.388 0.729 0 0 0 0 0 0 0.441 0.271 0.612
SL005158 DC-SIGNR Q9H2X3 10332 CLEC4M RFU No No CE 0 0 0 0 0 0 0 0 0 0.348 0.161 0.535 0.652 0.465 0.839
SL005159 EPO-R P19235 2057 EPOR RFU No No DE 0.843 0.909 0.795 0 0 0 0.843 0.762 0.923 0 0 0 0.157 0.077 0.238
SL005160 ESAM Q96AP7 90952 ESAM RFU No No AE 0.692 0.759 0.653 0.692 0.563 0.821 0 0 0 0 0 0 0.308 0.179 0.437
SL005161 FGF-12 P61328 2257 FGF12 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005164 Galectin-2 P05162 3957 LGALS2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005165 Galectin-4 P56470 3960 LGALS4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.147 -0.056 0.349 0.853 0.651 1.056
SL005167 Galectin-8 O00214 3964 LGALS8 RFU No No DE 0.695 0.809 0.643 0 0 0 0.695 0.511 0.879 0 0 0 0.305 0.121 0.489
SL005168 Growth hormone receptorP10912 2690 GHR RFU No No CE 0 0 0 0 0 0 0 0 0 0.609 0.479 0.738 0.391 0.262 0.521
SL005169 sICAM-5 Q9UMF0 7087 ICAM5 RFU No No AE 0.766 0.830 0.722 0.766 0.668 0.864 0 0 0 0 0 0 0.234 0.136 0.332
SL005170 ICOS Q9Y6W8 29851 ICOS RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005171 IGFBP-4 P22692 3487 IGFBP4 RFU No No AE 0.615 0.666 0.588 0.615 0.462 0.769 0 0 0 0 0 0 0.385 0.231 0.538
SL005172 IGFBP-6 P24592 3489 IGFBP6 RFU No No AE 0.393 0.318 0.424 0.393 0.186 0.600 0 0 0 0 0 0 0.607 0.400 0.814
SL005174 IL-17B R Q9NRM6 55540 IL17RB RFU No No AE 0.356 0.244 0.399 0.356 0.138 0.574 0 0 0 0 0 0 0.644 0.426 0.862
SL005178 IL-1F7 Q9NZH6 27178 IL1F7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005181 IL-20 Ra Q9UHF4 53832 IL20RA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005183 IL-22BP Q969J5 116379 IL22RA2 RFU No No AE 0.531 0.550 0.523 0.531 0.347 0.716 0 0 0 0 0 0 0.469 0.284 0.653
SL005184 IL-23 P29460  Q9NPF73593 51561IL12B IL23A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005185 IL-23 R Q5VWK5 149233 IL23R RFU No No AE 0.660 0.739 0.620 0.660 0.495 0.826 0 0 0 0 0 0 0.340 0.174 0.505
SL005187 IL-3 Ra P26951 3563 IL3RA RFU No No CE 0 0 0 0 0 0 0 0 0 0.424 0.255 0.592 0.576 0.408 0.745
SL005188 IL-5 Ra Q01344 3568 IL5RA RFU No No CE 0 0 0 0 0 0 0 0 0 0.519 0.369 0.669 0.481 0.331 0.631
SL005189 IL-7 Ra P16871 3575 IL7R RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005190 ILT-2 Q8NHL6 10859 LILRB1 RFU No No AE 0.830 0.887 0.788 0.830 0.756 0.904 0 0 0 0 0 0 0.170 0.096 0.244
SL005191 ILT-4 Q8N423 10288 LILRB2 RFU No No AE 0.797 0.862 0.752 0.797 0.707 0.887 0 0 0 0 0 0 0.203 0.113 0.293
SL005193 JAM-B P57087 58494 JAM2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005194 JAM-C Q9BX67 83700 JAM3 RFU No No DCE 0.232 -0.034 0.304 0 0 0 0.232 -0.014 0.478 0.556 0.321 0.790 0.212 0.119 0.306
SL005195 LAG-3 P18627 3902 LAG3 RFU No No AE 0.637 0.696 0.605 0.637 0.485 0.789 0 0 0 0 0 0 0.363 0.211 0.515
SL005196 LSAMP Q13449 4045 LSAMP RFU No No AE 0.594 0.638 0.572 0.594 0.437 0.752 0 0 0 0 0 0 0.406 0.248 0.563
SL005197 LIMP II Q14108 950 SCARB2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005199 MICA Q29983 4276 MICA RFU No No CE 0 0 0 0 0 0 0 0 0 0.504 0.352 0.657 0.496 0.343 0.648
SL005200 MICB Q29980 4277 MICB RFU No No CE 0 0 0 0 0 0 0 0 0 0.366 0.188 0.543 0.634 0.457 0.812
SL005201 MIS P03971 268 AMH RFU No No CE 0 0 0 0 0 0 0 0 0 0.313 0.120 0.506 0.687 0.494 0.880
SL005202 MSP P26927 4485 MST1 RFU No No AE 0.938 0.964 0.914 0.938 0.909 0.966 0 0 0 0 0 0 0.062 0.034 0.091
SL005204 NKG2D P26718 22914 KLRK1 RFU No No AE 0.579 0.637 0.555 0.579 0.365 0.792 0 0 0 0 0 0 0.421 0.208 0.635
SL005205 NKp30 O14931 259197 NCR3 RFU No No DE 0.865 0.924 0.821 0 0 0 0.865 0.797 0.934 0 0 0 0.135 0.066 0.203
SL005206 NKp44 O95944 9436 NCR2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005207 NKp46 O76036 9437 NCR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005208 Nogo Receptor Q9BZR6 65078 RTN4R RFU No No CE 0 0 0 0 0 0 0 0 0 0.517 0.366 0.668 0.483 0.332 0.634
SL005209 Notch-3 Q9UM47 4854 NOTCH3 RFU No No AE 0.374 0.275 0.412 0.374 0.154 0.593 0 0 0 0 0 0 0.626 0.407 0.846
SL005210 Nr-CAM Q92823 4897 NRCAM RFU No No AE 0.502 0.504 0.502 0.502 0.308 0.696 0 0 0 0 0 0 0.498 0.304 0.692
SL005212 Prolactin Receptor P16471 5618 PRLR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005213 RELT Q969Z4 84957 RELT RFU No No AE 0.679 0.761 0.636 0.679 0.521 0.837 0 0 0 0 0 0 0.321 0.163 0.479
SL005214 Semaphorin-6A Q9H2E6 57556 SEMA6A RFU No No CE 0 0 0 0 0 0 0 0 0 0.452 0.288 0.615 0.548 0.385 0.712
SL005215 Siglec-3 P20138 945 CD33 RFU No No DE 0.902 0.941 0.870 0 0 0 0.902 0.858 0.946 0 0 0 0.098 0.054 0.142
SL005217 Siglec-6 O43699 946 SIGLEC6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.287 0.100 0.475 0.713 0.525 0.900
SL005218 Siglec-7 Q9Y286 27036 SIGLEC7 RFU No No AE 0.570 0.605 0.552 0.570 0.401 0.739 0 0 0 0 0 0 0.430 0.261 0.599
SL005219 Siglec-9 Q9Y336 27180 SIGLEC9 RFU No No AE 0.996 0.998 0.994 0.996 0.994 0.998 0 0 0 0 0 0 0.004 0.002 0.006
SL005220 Sonic Hedgehog Q15465 6469 SHH RFU No No CE 0 0 0 0 0 0 0 0 0 0.422 0.253 0.592 0.578 0.408 0.747
SL005221 SREC-I Q14162 8578 SCARF1 RFU No No AE 0.559 0.591 0.544 0.559 0.384 0.734 0 0 0 0 0 0 0.441 0.266 0.616
SL005222 SREC-II Q96GP6 91179 SCARF2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005223 TCCR Q6UWB1 9466 IL27RA RFU No No CE 0 0 0 0 0 0 0 0 0 0.148 -0.054 0.350 0.852 0.650 1.054
SL005224 Thrombopoietin ReceptorP40238 4352 MPL RFU No No DE 0.630 0.720 0.592 0 0 0 0.630 0.426 0.835 0 0 0 0.370 0.165 0.574
SL005225 TrkA P04629 4914 NTRK1 RFU No No AE 0.186 -0.095 0.286 0.186 -0.050 0.422 0 0 0 0 0 0 0.814 0.578 1.050
SL005226 TSLP R Q9HC73 64109 CRLF2 RFU No No DE 0.299 -0.028 0.376 0 0 0 0.299 -0.011 0.609 0 0 0 0.701 0.391 1.011
SL005227 ULBP-1 Q9BZM6 80329 ULBP1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005228 ULBP-2 Q9BZM5 80328 ULBP2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005229 ULBP-3 Q9BZM4 79465 ULBP3 RFU No No AE 0.763 0.828 0.719 0.763 0.664 0.862 0 0 0 0 0 0 0.237 0.138 0.336
SL005230 UNC5H3 O95185 8633 UNC5C RFU No No AE 0.473 0.458 0.480 0.473 0.294 0.651 0 0 0 0 0 0 0.527 0.349 0.706
SL005231 UNC5H4 Q6UXZ4 137970 UNC5D RFU No No DE 0.493 0.488 0.495 0 0 0 0.493 0.301 0.685 0 0 0 0.507 0.315 0.699
SL005233 XEDAR Q9HAV5 60401 EDA2R RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005234 GDF-9 O60383 2661 GDF9 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005235 NOG Q9H9S0 79923 NOG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005236 NovH P48745 4856 NOV RFU No No DE 0.235 -0.014 0.321 0 0 0 0.235 -0.007 0.477 0 0 0 0.765 0.523 1.007
SL005250 Chymase P23946 1215 CMA1 RFU No No DE 0.502 0.504 0.501 0 0 0 0.502 0.194 0.809 0 0 0 0.498 0.191 0.806
SL005256 Histone H1.2 P16403 3006 HIST1H1C RFU No No DE 0.663 0.735 0.624 0 0 0 0.663 0.509 0.817 0 0 0 0.337 0.183 0.491
SL005258 PLK-1 P53350 5347 PLK1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005261 TCPTP P17706 5771 PTPN2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005263 RAP P30533 4043 LRPAP1 RFU No No DE 0.848 0.900 0.809 0 0 0 0.848 0.785 0.912 0 0 0 0.152 0.088 0.215
SL005308 PSME3 P61289 10197 PSME3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005352 FABPE Q01469 2171 FABP5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005358 prostatic binding proteinP30086 5037 PEBP1 RFU No No AE 0.727 0.794 0.685 0.727 0.614 0.840 0 0 0 0 0 0 0.273 0.160 0.386
SL005361 Apo D P05090 347 APOD RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005372 Sorting nexin 4 O95219 8723 SNX4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.653 0.537 0.770 0.347 0.230 0.463
SL005392 Arylsulfatase A P15289 410 ARSA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005437 MEPE Q9NQ76 56955 MEPE RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005488 SPARCL1 Q14515 8404 SPARCL1 RFU No No AE 0.761 0.829 0.716 0.761 0.657 0.865 0 0 0 0 0 0 0.239 0.135 0.343
SL005491 OBCAM Q14982 4978 OPCML RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005493 paraoxose 1 P27169 5444 PON1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005508 Carbonic anhydrase 9 Q16790 768 CA9 RFU No No CE 0 0 0 0 0 0 0 0 0 0.297 0.111 0.483 0.703 0.517 0.889
SL005572 Gelsolin P06396 2934 GSN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005574 Aminoacylase-1 Q03154 95 ACY1 RFU No No DE 0.333 0.159 0.390 0 0 0 0.333 0.078 0.589 0 0 0 0.667 0.411 0.922
SL005575 Fucosyltransferase 3 P21217 2525 FUT3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005588 FER P16591 2241 FER RFU No No CE 0 0 0 0 0 0 0 0 0 0.610 0.482 0.738 0.390 0.262 0.518
SL005629 GK Q9UJ70 55577 GK RFU No No AE 0.625 0.678 0.596 0.625 0.477 0.773 0 0 0 0 0 0 0.375 0.227 0.523
SL005630 PSA6 P60900 5687 PSMA6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.530 0.382 0.677 0.470 0.323 0.618
SL005675 ATP synthase beta chainP06576 506 ATP5B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005679 TCTP P13693 7178 TPT1 RFU No No AE 0.785 0.847 0.741 0.785 0.695 0.874 0 0 0 0 0 0 0.215 0.126 0.305
SL005685 EF-1-beta P24534 1933 EEF1B2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.435 0.269 0.600 0.565 0.400 0.731
SL005687 eIF-5A-1 P63241 1984 EIF5A RFU No No CE 0 0 0 0 0 0 0 0 0 0.596 0.464 0.728 0.404 0.272 0.536
SL005694 Peroxiredoxin-6 P30041 9588 PRDX6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.670 0.557 0.782 0.330 0.218 0.443
SL005703 Notch 1 P46531 4851 NOTCH1 RFU No No AE 0.513 0.521 0.510 0.513 0.327 0.700 0 0 0 0 0 0 0.487 0.300 0.673
SL005725 GRB2-related adapter protein 2O75791 9402 GRAP2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL005730 cGMP-stimulated PDE O00408 5138 PDE2A RFU No No DE 0.265 -0.014 0.348 0 0 0 0.265 -0.007 0.536 0 0 0 0.735 0.464 1.007
SL005764 sCD163 Q86VB7 9332 CD163 RFU No No AE 0.723 0.786 0.683 0.723 0.613 0.833 0 0 0 0 0 0 0.277 0.167 0.387
SL005789 Stanniocalcin-1 P52823 6781 STC1 RFU No No AE 0.688 0.753 0.650 0.688 0.560 0.817 0 0 0 0 0 0 0.312 0.183 0.440
SL005793 Cyclophilin F P30405 10105 PPIF RFU No No CE 0 0 0 0 0 0 0 0 0 0.584 0.450 0.718 0.416 0.282 0.550
SL005797 PIGR P01833 5284 PIGR RFU No No AE 0.608 0.655 0.583 0.608 0.457 0.759 0 0 0 0 0 0 0.392 0.241 0.543
SL005846 Moesin P26038 4478 MSN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006029 Chitotriosidase-1 Q13231 1118 CHIT1 RFU No No ACE 0.557 0.904 0.518 0.557 0.182 0.931 0 0 0 0.339 -0.038 0.716 0.104 0.057 0.151
SL006088 Sphingosine kise 1 Q9NYA1 8877 SPHK1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.699 0.594 0.803 0.301 0.197 0.406
SL006091 NCK1 P16333 4690 NCK1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006108 CD5L O43866 922 CD5L RFU No No CE 0 0 0 0 0 0 0 0 0 0.424 0.257 0.592 0.576 0.408 0.743
SL006114 ROR1 Q01973 4919 ROR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006119 TFF3 Q07654 7033 TFF3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.184 -0.015 0.383 0.816 0.617 1.015
SL006132 Lamin-B1 P20700 4001 LMNB1 RFU No No DE 0.546 0.599 0.530 0 0 0 0.546 0.278 0.814 0 0 0 0.454 0.186 0.722
SL006189 KIF23 Q02241 9493 KIF23 RFU No No DE 0.362 0.171 0.413 0 0 0 0.362 0.071 0.654 0 0 0 0.638 0.346 0.929
SL006197 DJ homolog Q96DA6 131118 DJC19 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006268 NSF1C Q9UNZ2 55968 NSFL1C RFU No No CE 0 0 0 0 0 0 0 0 0 0.479 0.321 0.636 0.521 0.364 0.679
SL006372 YES P07947 7525 YES1 RFU No No AE 0.704 0.770 0.664 0.704 0.581 0.826 0 0 0 0 0 0 0.296 0.174 0.419
SL006374 BMX P51813 660 BMX RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006378 Esterase D P10768 2098 ESD RFU No No CE 0 0 0 0 0 0 0 0 0 0.337 0.155 0.519 0.663 0.481 0.845
SL006397 NRP1 O14786 8829 NRP1 RFU No No AE 0.335 0.217 0.383 0.335 0.127 0.543 0 0 0 0 0 0 0.665 0.457 0.873
SL006406 PLXC1 O60486 10154 PLXNC1 RFU No No AE 0.692 0.759 0.653 0.692 0.564 0.821 0 0 0 0 0 0 0.308 0.179 0.436
SL006448 HRG P04196 3273 HRG RFU No No CE 0 0 0 0 0 0 0 0 0 0.467 0.306 0.627 0.533 0.373 0.694
SL006460 GP1BA P07359 2811 GP1BA RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006476 NMT1 P30419 4836 NMT1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.540 0.396 0.685 0.460 0.315 0.604
SL006480 TRY3 P35030 5646 PRSS3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006512 HGFA Q04756 3083 HGFAC RFU No No AE 0.826 0.881 0.785 0.826 0.755 0.898 0 0 0 0 0 0 0.174 0.102 0.245
SL006522 LG3BP Q08380 3959 LGALS3BP RFU No No CE 0 0 0 0 0 0 0 0 0 0.739 0.646 0.832 0.261 0.168 0.354
SL006523 MFGM Q08431 4240 MFGE8 RFU No No CE 0 0 0 0 0 0 0 0 0 0.494 0.340 0.649 0.506 0.351 0.660
SL006528 SEPR Q12884 2191 FAP RFU No No CE 0 0 0 0 0 0 0 0 0 0.255 0.061 0.450 0.745 0.550 0.939
SL006542 FCN2 Q15485 2220 FCN2 RFU No No DE 0.707 0.788 0.662 0 0 0 0.707 0.567 0.848 0 0 0 0.293 0.152 0.433
SL006544 BGH3 Q15582 7045 TGFBI RFU No No CE 0 0 0 0 0 0 0 0 0 0.385 0.208 0.563 0.615 0.437 0.792
SL006550 ECM1 Q16610 1893 ECM1 RFU No No AE 0.493 0.487 0.495 0.493 0.285 0.700 0 0 0 0 0 0 0.507 0.300 0.715
SL006610 ATS13 Q76LX8 11093 ADAMTS13 RFU No No CE 0 0 0 0 0 0 0 0 0 0.600 0.468 0.732 0.400 0.268 0.532
SL006629 SIRT2 Q8IXJ6 22933 SIRT2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.431 0.265 0.598 0.569 0.402 0.735
SL006675 CKAP2 Q8WWK9 26586 CKAP2 RFU No No AE 0.286 0.110 0.353 0.286 0.060 0.512 0 0 0 0 0 0 0.714 0.488 0.940
SL006694 CNDP1 Q96KN2 84735 CNDP1 RFU No No AE 0.670 0.730 0.635 0.670 0.540 0.801 0 0 0 0 0 0 0.330 0.199 0.460
SL006698 transcription factor MLR1  isoform CRA_bQ8N3X6 254251 LCORL RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006705 PFD5 Q99471 5204 PFDN5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.341 0.154 0.528 0.659 0.472 0.846
SL006713 Collectin Kidney 1 Q9BWP8 78989 COLEC11 RFU No No AE 0.621 0.670 0.594 0.621 0.476 0.765 0 0 0 0 0 0 0.379 0.235 0.524
SL006777 FETUB Q9UGM5 26998 FETUB RFU No No AE 0.638 0.690 0.609 0.638 0.502 0.775 0 0 0 0 0 0 0.362 0.225 0.498
SL006803 ANGL3 Q9Y5C1 27329 ANGPTL3 RFU No No DE 0.919 0.955 0.887 0 0 0 0.919 0.878 0.959 0 0 0 0.081 0.041 0.122
SL006805 MRCKB Q9Y5S2 9578 CDC42BPB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006830 complement factor H-related 5Q9BXR6 81494 CFHR5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.385 0.210 0.560 0.615 0.440 0.790
SL006892 ABL1 P00519 25 ABL1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006910 Cathepsin V O60911 1515 CTSL2 RFU No No AE 0.361 0.269 0.400 0.361 0.162 0.559 0 0 0 0 0 0 0.639 0.441 0.838
SL006911 CHK1 O14757 1111 CHEK1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006912 FGR P09769 2268 FGR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006913 FYN P06241 2534 FYN RFU No No AE 0.672 0.729 0.638 0.672 0.548 0.797 0 0 0 0 0 0 0.328 0.203 0.452
SL006914 Glucocorticoid receptorP04150 2908 NR3C1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.363 0.185 0.540 0.637 0.460 0.815
SL006915 IL-27 Q8NEV9 Q14213246778 10148IL27 EBI3 RFU No No AE 0.264 -0.018 0.347 0.264 -0.008 0.536 0 0 0 0 0 0 0.736 0.464 1.008
SL006916 LCK P06239 3932 LCK RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006917 LYN P07948 4067 LYN RFU No No CE 0 0 0 0 0 0 0 0 0 0.587 0.454 0.720 0.413 0.280 0.546
SL006918 MK01 P28482 5594 MAPK1 RFU No No ACE 0.426 0.230 0.440 0.426 0.030 0.821 0 0 0 0.364 -0.016 0.744 0.210 0.118 0.302
SL006919 RSK-like protein kise O75582 9252 RPS6KA5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.543 0.398 0.687 0.457 0.313 0.602
SL006920 MAPK14 Q16539 1432 MAPK14 RFU No No CE 0 0 0 0 0 0 0 0 0 0.569 0.431 0.707 0.431 0.293 0.569
SL006921 PDK1 Q15118 5163 PDK1 RFU No No DE 0.264 -0.014 0.347 0 0 0 0.264 -0.007 0.534 0 0 0 0.736 0.466 1.007
SL006922 RAD51 Q06609 5888 RAD51 RFU No No AE 0.438 0.403 0.455 0.438 0.255 0.621 0 0 0 0 0 0 0.562 0.379 0.745
SL006923 TBP P20226 6908 TBP RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006924 ART O00253 181 AGRP RFU No No DE 0.505 0.509 0.504 0 0 0 0.505 0.308 0.702 0 0 0 0.495 0.298 0.692
SL006970 DLL1 O00548 28514 DLL1 RFU No No AE 0.257 0.054 0.333 0.257 0.030 0.485 0 0 0 0 0 0 0.743 0.515 0.970
SL006992 MATN3 O15232 4148 MATN3 RFU No No DE 0.553 0.613 0.535 0 0 0 0.553 0.287 0.819 0 0 0 0.447 0.181 0.713
SL006993 MK13 O15264 5603 MAPK13 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL006998 PDPK1 O15530 5170 PDPK1 RFU No No AE 0.730 0.794 0.689 0.730 0.622 0.838 0 0 0 0 0 0 0.270 0.162 0.378
SL007003 DHH O43323 50846 DHH RFU No No AE 0.604 0.649 0.579 0.604 0.452 0.756 0 0 0 0 0 0 0.396 0.244 0.548
SL007022 HNRPQ O60506 10492 SYNCRIP RFU No No CE 0 0 0 0 0 0 0 0 0 0.259 0.063 0.456 0.741 0.544 0.937
SL007024 GREM1 O60565 26585 GREM1 RFU No No AE 0.628 0.700 0.594 0.628 0.448 0.808 0 0 0 0 0 0 0.372 0.192 0.552
SL007025 JAK2 O60674 3717 JAK2 RFU No No AE 0.779 0.841 0.736 0.779 0.687 0.870 0 0 0 0 0 0 0.221 0.130 0.313
SL007049 CYTF O76096 8530 CST7 RFU No No DE 0.721 0.784 0.681 0 0 0 0.721 0.610 0.832 0 0 0 0.279 0.168 0.390
SL007056 BMP10 O95393 27302 BMP10 RFU No No CE 0 0 0 0 0 0 0 0 0 0.240 0.046 0.434 0.760 0.566 0.954
SL007059 LY86 O95711 9450 LY86 RFU No No CE 0 0 0 0 0 0 0 0 0 0.211 0.010 0.411 0.789 0.589 0.990
SL007100 LKHA4 P09960 4048 LTA4H RFU No No CE 0 0 0 0 0 0 0 0 0 0.506 0.354 0.658 0.494 0.342 0.646
SL007121 CATE P14091 1510 CTSE RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007122 IDE P14735 3416 IDE RFU No No CE 0 0 0 0 0 0 0 0 0 0.182 -0.016 0.379 0.818 0.621 1.016
SL007145 NR1D1 P20393 9572 NR1D1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007153 PERL P22079 4025 LPO RFU No No AE 0.550 0.579 0.537 0.550 0.366 0.734 0 0 0 0 0 0 0.450 0.266 0.634
SL007173 GRN P28799 2896 GRN RFU No No DE 0.707 0.772 0.667 0 0 0 0.707 0.588 0.826 0 0 0 0.293 0.174 0.412
SL007179 EPHB2 P29323 2048 EPHB2 RFU No No AE 0.533 0.549 0.525 0.533 0.371 0.695 0 0 0 0 0 0 0.467 0.305 0.629
SL007181 TYK2 P29597 7297 TYK2 RFU No No AE 0.246 0.021 0.327 0.246 0.011 0.481 0 0 0 0 0 0 0.754 0.519 0.989
SL007195 CD70 P32970 970 CD70 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007206 TSP2 P35442 7058 THBS2 RFU No No AE 0.496 0.493 0.497 0.496 0.306 0.686 0 0 0 0 0 0 0.504 0.314 0.694
SL007207 TSP4 P35443 7060 THBS4 RFU No No AE 0.350 0.239 0.395 0.350 0.137 0.564 0 0 0 0 0 0 0.650 0.436 0.863
SL007228 KPCI P41743 5584 PRKCI RFU No No AE 0.756 0.821 0.713 0.756 0.655 0.857 0 0 0 0 0 0 0.244 0.143 0.345
SL007237 MP2K4 P45985 6416 MAP2K4 RFU No No ACE 0.365 -0.420 0.407 0.365 -0.042 0.772 0 0 0 0.375 -0.001 0.750 0.261 0.145 0.376
SL007250 PK3CG P48736 5294 PIK3CG RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007261 AMPM2 P50579 10988 METAP2 RFU No No AE 0.795 0.858 0.750 0.795 0.706 0.883 0 0 0 0 0 0 0.205 0.117 0.294
SL007266 PSD7 P51665 5713 PSMD7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007280 CATC P53634 1075 CTSC RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007281 MK12 P53778 6300 MAPK12 RFU No No DE 0.678 0.759 0.635 0 0 0 0.678 0.521 0.834 0 0 0 0.322 0.166 0.479
SL007284 CRIS3 P54108 10321 CRISP3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007295 CAD15 P55291 1013 CDH15 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007324 CSK21 P68400 1457 CSNK2A1 RFU No No DE 0.479 0.452 0.487 0 0 0 0.479 0.193 0.766 0 0 0 0.521 0.234 0.807
SL007327 OLR1 P78380 4973 OLR1 RFU No No AE 0.403 0.329 0.432 0.403 0.187 0.618 0 0 0 0 0 0 0.597 0.382 0.813
SL007328 JAG1 P78504 182 JAG1 RFU No No DE 0.651 0.714 0.617 0 0 0 0.651 0.505 0.798 0 0 0 0.349 0.202 0.495
SL007336 SET Q01105 6418 SET RFU No No CE 0 0 0 0 0 0 0 0 0 0.169 -0.040 0.378 0.831 0.622 1.040
SL007356 NOTC2 Q04721 4853 NOTCH2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007358 KPCT Q04759 5588 PRKCQ RFU No No DE 0.243 -0.193 0.342 0 0 0 0.243 -0.072 0.557 0 0 0 0.757 0.443 1.072
SL007373 PPID Q08752 5481 PPID RFU No No AE 0.747 0.812 0.704 0.747 0.643 0.852 0 0 0 0 0 0 0.253 0.148 0.357
SL007385 IL24 Q13007 11009 IL24 RFU No No DE 0.200 -0.093 0.299 0 0 0 0.200 -0.047 0.448 0 0 0 0.800 0.552 1.047
SL007403 DMP1 Q13316 1758 DMP1 RFU No No DE 0.236 -0.017 0.323 0 0 0 0.236 -0.009 0.480 0 0 0 0.764 0.520 1.009
SL007423 IL-11 RA Q14626 3590 IL11RA RFU No No AE 0.211 -0.008 0.298 0.211 -0.005 0.427 0 0 0 0 0 0 0.789 0.573 1.005
SL007429 GPNMB Q14956 10457 GPNMB RFU No No AE 0.678 0.737 0.642 0.678 0.552 0.803 0 0 0 0 0 0 0.322 0.197 0.448
SL007453 MK11 Q15759 5600 MAPK11 RFU No No AE 0.187 -0.086 0.287 0.187 -0.046 0.420 0 0 0 0 0 0 0.813 0.580 1.046
SL007464 AMHR2 Q16671 269 AMHR2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.366 0.184 0.547 0.634 0.453 0.816
SL007471 COLEC12 Q5KU26 81035 COLEC12 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007502 ST4S6 Q7LFX5 51363 CHST15 RFU No No AE 0.617 0.674 0.588 0.617 0.452 0.782 0 0 0 0 0 0 0.383 0.218 0.548
SL007531 BMPER Q8N8U9 168667 BMPER RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007547 TIMD3 Q8TDQ0 84868 HAVCR2 RFU No No AE 0.422 0.371 0.444 0.422 0.226 0.618 0 0 0 0 0 0 0.578 0.382 0.774
SL007560 STAB2 Q8WWQ8 55576 STAB2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007620 IL-12 RB2 Q99665 3595 IL12RB2 RFU No No DE 0.315 0.136 0.376 0 0 0 0.315 0.069 0.560 0 0 0 0.685 0.440 0.931
SL007640 CLC7A Q9BXN2 64581 CLEC7A RFU No No AE 0.707 0.786 0.663 0.707 0.570 0.845 0 0 0 0 0 0 0.293 0.155 0.430
SL007642 ANGL4 Q9BY76 51129 ANGPTL4 RFU No No DE 0.335 0.098 0.396 0 0 0 0.335 0.040 0.629 0 0 0 0.665 0.371 0.960
SL007651 FGF23 Q9GZV9 8074 FGF23 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007673 NET4 Q9HB63 59277 NTN4 RFU No No DE 0.440 0.390 0.459 0 0 0 0.440 0.213 0.667 0 0 0 0.560 0.333 0.787
SL007674 LY9 Q9HBG7 4063 LY9 RFU No No CE 0 0 0 0 0 0 0 0 0 0.541 0.397 0.686 0.459 0.314 0.603
SL007680 ROBO2 Q9HCK4 6092 ROBO2 RFU No No AE 0.505 0.508 0.504 0.505 0.314 0.696 0 0 0 0 0 0 0.495 0.304 0.686
SL007729 ARTS1 Q9NZ08 51752 ERAP1 RFU No No AE 0.724 0.796 0.681 0.724 0.603 0.846 0 0 0 0 0 0 0.276 0.154 0.397
SL007747 TBK1 Q9UHD2 29110 TBK1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.294 0.106 0.482 0.706 0.518 0.894
SL007752 DAPK2 Q9UIK4 23604 DAPK2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007756 GDF2 Q9UK05 2658 GDF2 RFU No No DE 0.675 0.740 0.638 0 0 0 0.675 0.539 0.811 0 0 0 0.325 0.189 0.461
SL007774 JAG2 Q9Y219 3714 JAG2 RFU No No DE 0.718 0.825 0.664 0 0 0 0.718 0.553 0.883 0 0 0 0.282 0.117 0.447
SL007804 BGN P21810 633 BGN RFU No No CE 0 0 0 0 0 0 0 0 0 0.500 0.347 0.654 0.500 0.346 0.653
SL007806 IL22RA1 Q8N6P7 58985 IL22RA1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007869 PPIB P23284 5479 PPIB RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL007871 Cytidylate kise P30085 51727 CMPK1 RFU No No AE 0.503 0.505 0.502 0.503 0.325 0.681 0 0 0 0 0 0 0.497 0.319 0.675
SL007888 Cystatin-S P01036 1472 CST4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008008 ARGI1 P05089 383 ARG1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008023 HPLN1 P10915 1404 HAPLN1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008039 AK1A1 P14550 10327 AKR1A1 RFU No No AE 0.829 0.884 0.787 0.829 0.756 0.901 0 0 0 0 0 0 0.171 0.099 0.244
SL008059 RS3 P23396 6188 RPS3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008063 PPAC P24666 52 ACP1 RFU No No AE 0.824 0.882 0.781 0.824 0.748 0.900 0 0 0 0 0 0 0.176 0.100 0.252
SL008072 CO8A1 P27658 1295 COL8A1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008085 3HIDH P31937 11112 HIBADH RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008099 CAPG P40121 822 CAPG RFU No No AE 0.759 0.820 0.718 0.759 0.665 0.854 0 0 0 0 0 0 0.241 0.146 0.335
SL008102 MDHC P40925 4190 MDH1 RFU No No DE 0.784 0.856 0.736 0 0 0 0.784 0.682 0.886 0 0 0 0.216 0.114 0.318
SL008122 DUS3 P51452 1845 DUSP3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.551 0.409 0.693 0.449 0.307 0.591
SL008143 UBE2N P61088 7334 UBE2N RFU No No CE 0 0 0 0 0 0 0 0 0 0.622 0.497 0.747 0.378 0.253 0.503
SL008157 UB2L3 P68036 7332 UBE2L3 RFU No No AE 0.756 0.823 0.712 0.756 0.653 0.859 0 0 0 0 0 0 0.244 0.141 0.347
SL008176 PSME1 Q06323 5720 PSME1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.467 0.307 0.628 0.533 0.372 0.693
SL008177 C1QBP Q07021 708 C1QBP RFU No No DE 0.360 0.251 0.403 0 0 0 0.360 0.141 0.579 0 0 0 0.640 0.421 0.859
SL008178 DERM Q07507 1805 DPT RFU No No CE 0 0 0 0 0 0 0 0 0 0.437 0.269 0.604 0.563 0.396 0.731
SL008190 SPTA2 Q13813 6709 SPTAN1 RFU No No DE 0.479 0.434 0.488 0 0 0 0.479 0.137 0.822 0 0 0 0.521 0.178 0.863
SL008193 NID2 Q14112 22795 NID2 RFU No No AE 0.249 0.016 0.331 0.249 0.008 0.490 0 0 0 0 0 0 0.751 0.510 0.992
SL008309 RTN4 Q9NQC3 57142 RTN4 RFU No No DE 0.572 0.607 0.555 0 0 0 0.572 0.410 0.735 0 0 0 0.428 0.265 0.590
SL008331 PA2G4 Q9UQ80 5036 PA2G4 RFU No No AE 0.719 0.783 0.678 0.719 0.605 0.832 0 0 0 0 0 0 0.281 0.168 0.395
SL008378 4EBP2 Q13542 1979 EIF4EBP2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008380 CATZ Q9UBR2 1522 CTSZ RFU No No AE 0.797 0.863 0.752 0.797 0.707 0.888 0 0 0 0 0 0 0.203 0.112 0.293
SL008382 CYTD P28325 1473 CST5 RFU No No AE 0.605 0.649 0.581 0.605 0.458 0.753 0 0 0 0 0 0 0.395 0.247 0.542
SL008414 EphB6 O15197 2051 EPHB6 RFU No No CE 0 0 0 0 0 0 0 0 0 0.205 0.003 0.406 0.795 0.594 0.997
SL008416 MRC2 Q9UBG0 9902 MRC2 RFU No No DE 0.516 0.523 0.512 0 0 0 0.516 0.349 0.682 0 0 0 0.484 0.318 0.651
SL008421 ATS1 Q9UHI8 9510 ADAMTS1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008504 GNS P15586 2799 GNS RFU No No CE 0 0 0 0 0 0 0 0 0 0.163 -0.036 0.362 0.837 0.638 1.036
SL008516 CYTT P09228 1470 CST2 RFU No No AE 0.639 0.698 0.607 0.639 0.491 0.787 0 0 0 0 0 0 0.361 0.213 0.509
SL008574 OMD Q99983 4958 OMD RFU No No DE 0.594 0.638 0.572 0 0 0 0.594 0.437 0.752 0 0 0 0.406 0.248 0.563
SL008588 SLAF5 Q9UIB8 8832 CD84 RFU No No CE 0 0 0 0 0 0 0 0 0 0.409 0.235 0.583 0.591 0.417 0.765
SL008590 Olfactomedin-4 Q6UX06 10562 OLFM4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008611 ASAHL Q02083 27163 AA RFU No No DE 0.654 0.719 0.619 0 0 0 0.654 0.506 0.802 0 0 0 0.346 0.198 0.494
SL008623 CNTN2 Q02246 6900 CNTN2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.520 0.371 0.670 0.480 0.330 0.629
SL008639 IDS P22304 3423 IDS RFU No No CE 0 0 0 0 0 0 0 0 0 0.440 0.275 0.605 0.560 0.395 0.725
SL008644 BST1 Q10588 683 BST1 RFU No No AE 0.887 0.931 0.852 0.887 0.837 0.938 0 0 0 0 0 0 0.113 0.062 0.163
SL008703 CBPE P16870 1363 CPE RFU No No CE 0 0 0 0 0 0 0 0 0 0.340 0.158 0.522 0.660 0.478 0.842
SL008709 DSC3 Q14574 1825 DSC3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008728 NRX3B Q9HDB5 9369 NRXN3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.543 0.397 0.689 0.457 0.311 0.603
SL008759 GPVI Q9HCN6 51206 GP6 RFU No No DCE 0.271 -0.030 0.334 0 0 0 0.271 -0.010 0.552 0.467 0.209 0.725 0.262 0.146 0.377
SL008773 CD109 Q6YHK3 135228 CD109 RFU No No AE 0.441 0.401 0.458 0.441 0.240 0.642 0 0 0 0 0 0 0.559 0.358 0.760
SL008808 SKP1 P63208 6500 SKP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.624 0.499 0.749 0.376 0.251 0.501
SL008822 EMR2 Q9UHX3 30817 EMR2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.385 0.211 0.559 0.615 0.441 0.789
SL008835 ASGR1 P07306 432 ASGR1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008865 PSA2 P25787 5683 PSMA2 RFU No No DE 0.493 0.488 0.495 0 0 0 0.493 0.291 0.695 0 0 0 0.507 0.305 0.709
SL008904 LYVE1 Q9Y5Y7 10894 LYVE1 RFU No No DE 0.547 0.575 0.534 0 0 0 0.547 0.360 0.733 0 0 0 0.453 0.267 0.640
SL008909 LGMN Q99538 5641 LGMN RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008916 DPP2 Q9UHL4 29952 DPP7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008933 PARK7 Q99497 11315 PARK7 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL008936 CHL1 O00533 10752 CHL1 RFU No No AE 0.556 0.584 0.542 0.556 0.387 0.725 0 0 0 0 0 0 0.444 0.275 0.613
SL008945 TGM3 Q08188 7053 TGM3 RFU No No DE 0.498 0.496 0.498 0 0 0 0.498 0.319 0.676 0 0 0 0.502 0.324 0.681
SL008956 ARSB P15848 411 ARSB RFU No No DE 0.717 0.810 0.667 0 0 0 0.717 0.568 0.867 0 0 0 0.283 0.133 0.432
SL009045 ENPP7 Q6UWV6 339221 ENPP7 RFU No No DE 0.737 0.806 0.694 0 0 0 0.737 0.625 0.850 0 0 0 0.263 0.150 0.375
SL009054 NRX1B P58400 9378 NRXN1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009089 PGCB Q96GW7 63827 BCAN RFU No No DE 0.652 0.713 0.618 0 0 0 0.652 0.508 0.796 0 0 0 0.348 0.204 0.492
SL009202 JAML1 Q86YT9 120425 AMICA1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009207 Dyctin subunit 2 Q13561 10540 DCTN2 RFU No No AE 0.272 0.076 0.344 0.272 0.041 0.504 0 0 0 0 0 0 0.728 0.496 0.959
SL009213 Cathepsin A P10619 5476 CTSA RFU No No DE 0.460 0.430 0.472 0 0 0 0.460 0.245 0.675 0 0 0 0.540 0.325 0.755
SL009216 dopa decarboxylase P20711 1644 DDC RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009324 FSTL3 O95633 10272 FSTL3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.603 0.471 0.735 0.397 0.265 0.529
SL009341 BASI P35613 682 BSG RFU No No DE 0.293 0.000 0.370 0 0 0 0.293 0.000 0.586 0 0 0 0.707 0.414 1.000
SL009400 CRDL1 Q9BU40 91851 CHRDL1 RFU No No AE 0.367 0.270 0.406 0.367 0.156 0.578 0 0 0 0 0 0 0.633 0.422 0.844
SL009412 DKK3 Q9UBP4 27122 DKK3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.280 0.087 0.474 0.720 0.526 0.913
SL009431 HINT1 P49773 3094 HINT1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009628 ING1 Q9UK53 3621 ING1 RFU No No ACE 0.374 0.085 0.409 0.374 0.019 0.729 0 0 0 0.438 0.095 0.781 0.188 0.105 0.272
SL009629 MBD4 O95243 8930 MBD4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009768 CBX5 P45973 23468 CBX5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009790 RUXF P62306 6636 SNRPF RFU No No AE 0.542 0.568 0.530 0.542 0.350 0.734 0 0 0 0 0 0 0.458 0.266 0.650
SL009791 hnRNP A/B Q99729 3182 HNRNPAB RFU No No DE 0.665 0.737 0.626 0 0 0 0.665 0.513 0.817 0 0 0 0.335 0.183 0.487
SL009792 PUR8 P30566 158 ADSL RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL009868 SSRP1 Q08945 6749 SSRP1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009951 WNT7A O00755 7476 WNT7A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL009988 ADAM12 O43184 8038 ADAM12 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010250 Stress-induced-phosphoprotein 1P31948 10963 STIP1 RFU No No AE 0.684 0.750 0.646 0.684 0.553 0.816 0 0 0 0 0 0 0.316 0.184 0.447
SL010288 Carbonic anhydrase 6 P23280 765 CA6 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL010328 MED-1 Q15648 5469 MED1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010348 FN1.4 P02751 2335 FN1 RFU No No DE 0.557 0.586 0.542 0 0 0 0.557 0.385 0.728 0 0 0 0.443 0.272 0.615
SL010349 FN1.3 P02751 2335 FN1 RFU No No DE 0.734 0.804 0.691 0 0 0 0.734 0.619 0.849 0 0 0 0.266 0.151 0.381
SL010368 IDUA P35475 3425 IDUA RFU No No DE 0.722 0.793 0.678 0 0 0 0.722 0.599 0.844 0 0 0 0.278 0.156 0.401
SL010369 Carbonic Anhydrase IVP22748 762 CA4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.189 -0.010 0.387 0.811 0.613 1.010
SL010371 CD39 P49961 953 ENTPD1 RFU No No DE 0.536 0.582 0.523 0 0 0 0.536 0.256 0.816 0 0 0 0.464 0.184 0.744
SL010372 Enterokise P98073 5651 PRSS7 RFU No No DE 0.714 0.836 0.657 0 0 0 0.714 0.532 0.896 0 0 0 0.286 0.104 0.468
SL010373 FCAR P24071 2204 FCAR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010374 METAP1 P53582 23173 METAP1 RFU No No AE 0.742 0.816 0.696 0.742 0.625 0.860 0 0 0 0 0 0 0.258 0.140 0.375
SL010375 ASAH2 Q9NR71 56624 ASAH2 RFU No No DE 0.697 0.763 0.658 0 0 0 0.697 0.572 0.822 0 0 0 0.303 0.178 0.428
SL010376 MMEL2 Q495T6 79258 MMEL1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010378 RET P07949 5979 RET RFU No No AE 0.571 0.606 0.553 0.571 0.407 0.735 0 0 0 0 0 0 0.429 0.265 0.593
SL010379 Semaphorin 3A Q14563 10371 SEMA3A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010381 Soggy-1 Q9UK85 27120 DKKL1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.407 0.235 0.579 0.593 0.421 0.765
SL010384 Testican-1 Q08629 6695 SPOCK1 RFU No No AE 0.709 0.780 0.667 0.709 0.584 0.835 0 0 0 0 0 0 0.291 0.165 0.416
SL010388 Trypsin 2 P07478 5645 PRSS2 RFU No No AE 0.562 0.598 0.546 0.562 0.379 0.746 0 0 0 0 0 0 0.438 0.254 0.621
SL010390 URB Q76M96 151887 CCDC80 RFU No No DE 0.505 0.508 0.504 0 0 0 0.505 0.327 0.683 0 0 0 0.495 0.317 0.673
SL010391 WFKN2 Q8TEU8 124857 WFIKKN2 RFU No No AE 0.595 0.638 0.573 0.595 0.441 0.749 0 0 0 0 0 0 0.405 0.251 0.559
SL010392 GASP-2 Q96D09 114928 GPRASP2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.222 0.028 0.417 0.778 0.583 0.972
SL010393 KREM2 Q8NCW0 79412 KREMEN2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010449 Carbonic Anhydrase XQ9NS85 56934 CA10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010450 CD48 P09326 962 CD48 RFU No No CE 0 0 0 0 0 0 0 0 0 0.296 0.105 0.486 0.704 0.514 0.895
SL010451 CFC1 P0CG37 55997 CFC1 RFU No No DE 0.342 0.221 0.390 0 0 0 0.342 0.125 0.560 0 0 0 0.658 0.440 0.875
SL010454 Contactin-4 Q8IWV2 152330 CNTN4 RFU No No CE 0 0 0 0 0 0 0 0 0 0.544 0.396 0.693 0.456 0.307 0.604
SL010455 Contactin-5 O94779 53942 CNTN5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010456 CYTN P01037 1469 CST1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.283 0.096 0.471 0.717 0.529 0.904
SL010457 DLL4 Q9NR61 54567 DLL4 RFU No No DE 0.338 -0.031 0.405 0 0 0 0.338 -0.010 0.686 0 0 0 0.662 0.314 1.010
SL010458 Endocan Q9NQ30 11082 ESM1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010461 FCGR1 P12314 2209 FCGR1A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010462 FCN1 O00602 2219 FCN1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010463 GPC2 Q8N158 221914 GPC2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.261 0.070 0.451 0.739 0.549 0.930
SL010464 LRIG3 Q6UXM1 121227 LRIG3 RFU No No AE 0.514 0.522 0.510 0.514 0.330 0.698 0 0 0 0 0 0 0.486 0.302 0.670
SL010465 MATN2 O00339 4147 MATN2 RFU No No AE 0.470 0.452 0.479 0.470 0.278 0.663 0 0 0 0 0 0 0.530 0.337 0.722
SL010466 MFRP Q9BY79 83552 MFRP RFU No No CE 0 0 0 0 0 0 0 0 0 0.255 0.064 0.446 0.745 0.554 0.936
SL010467 RGMA Q96B86 56963 RGMA RFU No No AE 0.440 0.396 0.458 0.440 0.227 0.653 0 0 0 0 0 0 0.560 0.347 0.773
SL010468 RGMB Q6NW40 285704 RGMB RFU No No CE 0 0 0 0 0 0 0 0 0 0.275 0.076 0.474 0.725 0.526 0.924
SL010469 RGM-C Q6ZVN8 148738 HFE2 RFU No No AE 0.455 0.424 0.468 0.455 0.249 0.662 0 0 0 0 0 0 0.545 0.338 0.751
SL010470 Semaphorin 3E O15041 9723 SEMA3E RFU No No AE 0.630 0.683 0.601 0.630 0.485 0.775 0 0 0 0 0 0 0.370 0.225 0.515
SL010471 Testican-2 Q92563 9806 SPOCK2 RFU No No AE 0.699 0.761 0.661 0.699 0.581 0.817 0 0 0 0 0 0 0.301 0.183 0.419
SL010488 ABL2 P42684 27 ABL2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010489 CAMK1 Q14012 8536 CAMK1 RFU Calibration Scale Factors in the tail of the DistributionNo No NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
SL010490 CAMK1D Q8IU85 57118 CAMK1D RFU No No CE 0 0 0 0 0 0 0 0 0 0.214 0.016 0.412 0.786 0.588 0.984
SL010491 CAMK2A Q9UQM7 815 CAMK2A RFU No No AE 0.699 0.763 0.660 0.699 0.577 0.821 0 0 0 0 0 0 0.301 0.179 0.423
SL010492 CAMK2B Q13554 816 CAMK2B RFU No No DE 0.368 0.242 0.411 0 0 0 0.368 0.124 0.612 0 0 0 0.632 0.388 0.876
SL010493 CAMK2D Q13557 817 CAMK2D RFU No No AE 0.769 0.835 0.725 0.769 0.671 0.867 0 0 0 0 0 0 0.231 0.133 0.329
SL010494 CDK1/cyclin B P06493 P14635983 891 CDC2 CCNB1 RFU No No DE 0.870 0.926 0.827 0 0 0 0.870 0.805 0.936 0 0 0 0.130 0.064 0.195
SL010495 CDK2/cyclin A P24941 P202481017 890 CDK2 CC2 RFU No No DE 0.267 0.000 0.348 0 0 0 0.267 0.000 0.534 0 0 0 0.733 0.466 1.000
SL010496 CDK5/p35 Q00535 Q150781020 8851 CDK5 CDK5R1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010498 EPHA3 P29320 2042 EPHA3 RFU No No AE 0.604 0.667 0.575 0.604 0.414 0.794 0 0 0 0 0 0 0.396 0.206 0.586
SL010499 HCK P08631 3055 HCK RFU No No CE 0 0 0 0 0 0 0 0 0 0.216 0.019 0.414 0.784 0.586 0.981
SL010500 LYNB P07948 4067 LYN RFU No No CE 0 0 0 0 0 0 0 0 0 0.515 0.366 0.665 0.485 0.335 0.634
SL010501 MP2K2 P36507 5605 MAP2K2 RFU No No DE 0.786 0.850 0.742 0 0 0 0.786 0.695 0.878 0 0 0 0.214 0.122 0.305
SL010502 MK08 P45983 5599 MAPK8 RFU No No DE 0.621 0.689 0.589 0 0 0 0.621 0.443 0.800 0 0 0 0.379 0.200 0.557
SL010503 MAPK2 P49137 9261 MAPKAPK2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.471 0.313 0.630 0.529 0.370 0.687
SL010504 MAPK5 Q8IW41 8550 MAPKAPK5 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010505 MATK P42679 4145 MATK RFU No No DE 0.283 -0.133 0.369 0 0 0 0.283 -0.045 0.612 0 0 0 0.717 0.388 1.045
SL010508 PAK3 O75914 5063 PAK3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.168 -0.033 0.369 0.832 0.631 1.033
SL010509 PAK6 Q9NQU5 56924 PAK6 RFU No No AE 0.760 0.824 0.717 0.760 0.661 0.859 0 0 0 0 0 0 0.240 0.141 0.339
SL010510 PAK7 Q9P286 57144 PAK7 RFU No No AE 0.449 0.418 0.463 0.449 0.263 0.634 0 0 0 0 0 0 0.551 0.366 0.737
SL010512 PIK3CA/PIK3R1 P42336 P279865290 5295 PIK3CA PIK3R1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010513 PRKACA P17612 5566 PRKACA RFU No No CE 0 0 0 0 0 0 0 0 0 0.553 0.412 0.695 0.447 0.305 0.588
SL010514 PTK6 Q13882 5753 PTK6 RFU No No DE 0.381 0.241 0.422 0 0 0 0.381 0.111 0.650 0 0 0 0.619 0.350 0.889
SL010515 RPS6KA3 P51812 6197 RPS6KA3 RFU No No DE 0.670 0.745 0.630 0 0 0 0.670 0.517 0.823 0 0 0 0.330 0.177 0.483
SL010516 SRCN1 P12931 6714 SRC RFU No No AE 0.718 0.782 0.677 0.718 0.604 0.832 0 0 0 0 0 0 0.282 0.168 0.396
SL010517 STK16 O75716 8576 STK16 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010518 TEC P42680 7006 TEC RFU No No DE 0.546 0.573 0.533 0 0 0 0.546 0.356 0.735 0 0 0 0.454 0.265 0.644
SL010519 ZAP70 P43403 7535 ZAP70 RFU No No CE 0 0 0 0 0 0 0 0 0 0.426 0.256 0.595 0.574 0.405 0.744
SL010520 AURKB Q96GD4 9212 AURKB RFU No No CE 0 0 0 0 0 0 0 0 0 0.180 -0.023 0.383 0.820 0.617 1.023
SL010521 BTK Q06187 695 BTK RFU No No ACE 0.394 -0.508 0.424 0.394 -0.032 0.820 0 0 0 0.349 -0.051 0.748 0.257 0.146 0.369
SL010522 CDK8/cyclin C P49336 P248631024 892 CDK8 CCNC RFU No No CE 0 0 0 0 0 0 0 0 0 0.396 0.220 0.571 0.604 0.429 0.780
SL010523 HIPK3 Q9H422 10114 HIPK3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.206 0.010 0.401 0.794 0.599 0.990
SL010528 UFM1 P61960 51569 UFM1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.445 0.281 0.609 0.555 0.391 0.719
SL010529 UFC1 Q9Y3C8 51506 UFC1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.490 0.334 0.645 0.510 0.355 0.666
SL010530 OCAD1 Q9NX40 54940 OCIAD1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010610 CLC4K Q9UJ71 50489 CD207 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010612 Dkk-4 Q9UBT3 27121 DKK4 RFU No No AE 0.540 0.564 0.530 0.540 0.357 0.724 0 0 0 0 0 0 0.460 0.276 0.643
SL010613 IL-17 RD Q8NFM7 54756 IL17RD RFU No No DE 0.364 0.249 0.407 0 0 0 0.364 0.135 0.593 0 0 0 0.636 0.407 0.865
SL010616 SHP-2 Q06124 5781 PTPN11 RFU No No CE 0 0 0 0 0 0 0 0 0 0.527 0.379 0.675 0.473 0.325 0.621
SL010617 TPSB2 P20231 64499 TPSB2 RFU No No ACE 0.635 1.021 0.569 0.635 0.294 0.975 0 0 0 0.304 -0.039 0.647 0.062 0.033 0.090
SL010619 TPSG1 Q9NRR2 25823 TPSG1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL010830 41 P11171 2035 EPB41 RFU No No CE 0 0 0 0 0 0 0 0 0 0.479 0.321 0.636 0.521 0.364 0.679
SL010927 IMB1 Q14974 3837 KPNB1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.496 0.342 0.650 0.504 0.350 0.658
SL010928 IMDH2 P12268 3615 IMPDH2 RFU No No DE 0.622 0.683 0.592 0 0 0 0.622 0.456 0.789 0 0 0 0.378 0.211 0.544
SL010973 PSA1 P25786 5682 PSMA1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.278 0.085 0.471 0.722 0.529 0.915
SL011049 MASP3 P48740 5648 MASP1 RFU No No DE 0.564 0.597 0.548 0 0 0 0.564 0.397 0.732 0 0 0 0.436 0.268 0.603
SL011068 IL-17 RC Q8C3 84818 IL17RC RFU No No CE 0 0 0 0 0 0 0 0 0 0.193 -0.004 0.389 0.807 0.611 1.004
SL011069 Marapsin Q9BQR3 83886 PRSS27 RFU No No CE 0 0 0 0 0 0 0 0 0 0.413 0.242 0.585 0.587 0.415 0.758
SL011071 PDGF-CC Q9NRA1 56034 PDGFC RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011073 XPNPEP1 Q9NQW7 7511 XPNPEP1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.479 0.322 0.636 0.521 0.364 0.678
SL011100 CD226 Q15762 10666 CD226 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011202 SA P54920 8775 PA RFU No No ACE 0.362 -0.133 0.404 0.362 -0.021 0.746 0 0 0 0.409 0.048 0.769 0.229 0.128 0.330
SL011211 IF4G2 P78344 1982 EIF4G2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.572 0.435 0.709 0.428 0.291 0.565
SL011232 CDC37 Q16543 11140 CDC37 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011404 PDE4D Q08499 5144 PDE4D RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011405 PDE5A O76074 8654 PDE5A RFU No No CE 0 0 0 0 0 0 0 0 0 0.578 0.442 0.714 0.422 0.286 0.558
SL011406 PDE7A Q13946 5150 PDE7A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011448 TNR4 P43489 7293 TNFRSF4 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011498 PACAP-38 P18509 116 ADCYAP1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011499 PH P01298 5539 PPY RFU No No CE 0 0 0 0 0 0 0 0 0 0.398 0.227 0.570 0.602 0.430 0.773
SL011508 PACAP-27 P18509 116 ADCYAP1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011509 PYY P10082 5697 PYY RFU No No AE 0.639 0.700 0.606 0.639 0.486 0.792 0 0 0 0 0 0 0.361 0.208 0.514
SL011510 Somatostatin-28 P61278 6750 SST RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011528 RS7 P62081 6201 RPS7 RFU No No DE 0.522 0.537 0.516 0 0 0 0.522 0.320 0.725 0 0 0 0.478 0.275 0.680
SL011529 SBDS Q9Y3A5 51119 SBDS RFU No No AE 0.730 0.792 0.689 0.730 0.623 0.837 0 0 0 0 0 0 0.270 0.163 0.377
SL011530 DLRB1 Q9NP97 83658 DYNLRB1 RFU No No AE 0.722 0.784 0.683 0.722 0.613 0.831 0 0 0 0 0 0 0.278 0.169 0.387
SL011532 ETHE1 O95571 23474 ETHE1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.389 0.216 0.563 0.611 0.437 0.784
SL011533 SGTA O43765 6449 SGTA RFU No No CE 0 0 0 0 0 0 0 0 0 0.423 0.255 0.591 0.577 0.409 0.745
SL011535 RBM39 Q14498 9584 RBM39 RFU No No DE 0.592 0.676 0.562 0 0 0 0.592 0.352 0.831 0 0 0 0.408 0.169 0.648
SL011549 ARI3A Q99856 1820 ARID3A RFU No No CE 0 0 0 0 0 0 0 0 0 0.261 0.070 0.451 0.739 0.549 0.930
SL011616 IF4A3 P38919 9775 EIF4A3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011628 DBNL Q9UJU6 28988 DBNL RFU No No CE 0 0 0 0 0 0 0 0 0 0.159 -0.040 0.359 0.841 0.641 1.040
SL011629 AIP O00170 9049 AIP RFU No No CE 0 0 0 0 0 0 0 0 0 0.609 0.480 0.738 0.391 0.262 0.520
SL011630 SE6L2 Q6UXD5 26470 SEZ6L2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.409 0.238 0.579 0.591 0.421 0.762
SL011631 CA Q13765 4666 CA RFU No No CE 0 0 0 0 0 0 0 0 0 0.451 0.289 0.614 0.549 0.386 0.711
SL011708 ARP19 P56211 10776 ARPP19 RFU No No CE 0 0 0 0 0 0 0 0 0 0.502 0.350 0.655 0.498 0.345 0.650
SL011709 PLPP Q96GD0 57026 PDXP RFU No No AE 0.756 0.820 0.713 0.756 0.655 0.856 0 0 0 0 0 0 0.244 0.144 0.345
SL011768 NUDC3 Q8IVD9 23386 NUDCD3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.374 0.197 0.552 0.626 0.448 0.803
SL011769 AN32B Q92688 10541 ANP32B RFU No No CE 0 0 0 0 0 0 0 0 0 0.433 0.268 0.599 0.567 0.401 0.732
SL011770 LCMT1 Q9UIC8 51451 LCMT1 RFU No No AE 0.484 0.470 0.489 0.484 0.261 0.707 0 0 0 0 0 0 0.516 0.293 0.739
SL011772 PESC O00541 23481 PES1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL011808 CPNE1 Q99829 8904 CPNE1 RFU No No AE 0.826 0.885 0.782 0.826 0.749 0.903 0 0 0 0 0 0 0.174 0.097 0.251
SL011809 XTP3A Q9H773 79077 DCTPP1 RFU No No AE 0.366 0.271 0.406 0.366 0.158 0.575 0 0 0 0 0 0 0.634 0.425 0.842
SL012108 PLCG1 P19174 5335 PLCG1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL012168 LIN7B Q9HAP6 64130 LIN7B RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL012188 EP15R Q9UBC2 58513 EPS15L1 RFU No No AE 0.397 0.315 0.429 0.397 0.176 0.618 0 0 0 0 0 0 0.603 0.382 0.824
SL012248 FAK1 Q05397 5747 PTK2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL012457 NXPH1 P58417 30010 NXPH1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.732 0.637 0.827 0.268 0.173 0.363
SL012469 GPC5 P78333 2262 GPC5 RFU No No AE 0.472 0.453 0.480 0.472 0.276 0.667 0 0 0 0 0 0 0.528 0.333 0.724
SL012538 ARMEL Q49AH0 441549 CDNF RFU No No AE 0.319 0.178 0.374 0.319 0.100 0.538 0 0 0 0 0 0 0.681 0.462 0.900
SL012698 KI2L4 Q99706 3805 KIR2DL4 RFU No No DE 0.218 -0.045 0.310 0 0 0 0.218 -0.023 0.459 0 0 0 0.782 0.541 1.023
SL012707 PCSK9 Q8NBP7 255738 PCSK9 RFU No No DE 0.558 0.594 0.542 0 0 0 0.558 0.369 0.748 0 0 0 0.442 0.252 0.631
SL012740 ATS15 Q8TE58 170689 ADAMTS15 RFU No No DE 0.480 0.451 0.488 0 0 0 0.480 0.184 0.777 0 0 0 0.520 0.223 0.816
SL012754 ASM3A Q92484 10924 SMPDL3A RFU No No CE 0 0 0 0 0 0 0 0 0 0.209 0.013 0.406 0.791 0.594 0.987
SL012822 BSSP4 Q9GZN4 64063 PRSS22 RFU No No CE 0 0 0 0 0 0 0 0 0 0.539 0.392 0.686 0.461 0.314 0.608
SL013240 CRK P46108 1398 CRK RFU No No CE 0 0 0 0 0 0 0 0 0 0.508 0.356 0.659 0.492 0.341 0.644
SL013488 CLC1B Q9P126 51266 CLEC1B RFU No No AE 0.726 0.794 0.684 0.726 0.611 0.842 0 0 0 0 0 0 0.274 0.158 0.389
SL013489 AMNLS Q9BXJ7 81693 AMN RFU No No CE 0 0 0 0 0 0 0 0 0 0.277 0.087 0.467 0.723 0.533 0.913
SL013490 BOC Q9BWV1 91653 BOC RFU No No CE 0 0 0 0 0 0 0 0 0 0.171 -0.028 0.370 0.829 0.630 1.028
SL013548 IL-34 Q6ZMJ4 146433 IL34 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL013570 DYRK3 O43781 8444 DYRK3 RFU No No DE 0.298 -0.061 0.377 0 0 0 0.298 -0.022 0.618 0 0 0 0.702 0.382 1.022
SL013754 RASA1 P20936 5921 RASA1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.149 -0.055 0.353 0.851 0.647 1.055
SL013928 PPIE Q9UNP9 10450 PPIE RFU No No CE 0 0 0 0 0 0 0 0 0 0.563 0.423 0.703 0.437 0.297 0.577
SL013969 KYNU Q16719 8942 KYNU RFU No No DE 0.525 0.540 0.518 0 0 0 0.525 0.331 0.718 0 0 0 0.475 0.282 0.669
SL013988 CHST2 Q9Y4C5 9435 CHST2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.380 0.205 0.555 0.620 0.445 0.795
SL013989 RSPO2 Q6UXX9 340419 RSPO2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014008 FUT5 Q11128 2527 FUT5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.542 0.398 0.687 0.458 0.313 0.602
SL014009 HDGR2 Q7Z4V5 84717 HDGFRP2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014028 ENTP5 O75356 957 ENTPD5 RFU No No AE 0.663 0.721 0.629 0.663 0.532 0.795 0 0 0 0 0 0 0.337 0.205 0.468
SL014029 SPHK2 Q9NRA0 56848 SPHK2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014048 CO1 Q86Y22 91522 COL23A1 RFU No No DCE 0.274 0.041 0.333 0 0 0 0.274 0.017 0.532 0.512 0.266 0.757 0.214 0.120 0.309
SL014069 PCSK7 Q16549 9159 PCSK7 RFU No No CE 0 0 0 0 0 0 0 0 0 0.620 0.493 0.746 0.380 0.254 0.507
SL014070 SLIK5 O94991 26050 SLITRK5 RFU No No CE 0 0 0 0 0 0 0 0 0 0.374 0.198 0.550 0.626 0.450 0.802
SL014071 FLRT1 Q9NZU1 23769 FLRT1 RFU No No CE 0 0 0 0 0 0 0 0 0 0.392 0.218 0.566 0.608 0.434 0.782
SL014088 FCRL3 Q96P31 115352 FCRL3 RFU No No CE 0 0 0 0 0 0 0 0 0 0.228 0.033 0.422 0.772 0.578 0.967
SL014091 SORC2 Q96PQ0 57537 SORCS2 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014092 CDON Q4KMG0 50937 CDON RFU No No CE 0 0 0 0 0 0 0 0 0 0.468 0.306 0.630 0.532 0.370 0.694
SL014093 ENTP3 O75355 956 ENTPD3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014094 GP114 Q8IZF4 221188 GPR114 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014096 LRRT1 Q86UE6 347730 LRRTM1 RFU No No DE 0.158 -0.104 0.262 0 0 0 0.158 -0.059 0.375 0 0 0 0.842 0.625 1.059
SL014108 LRRT3 Q86VH5 347731 LRRTM3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014111 KIRR3 Q8IZU9 84623 KIRREL3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014113 NLGNX Q8N0W4 57502 NLGN4X RFU No No CE 0 0 0 0 0 0 0 0 0 0.215 0.019 0.411 0.785 0.589 0.981
SL014129 H6ST1 O60243 9394 HS6ST1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014130 CHST6 Q9GZX3 4166 CHST6 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014148 ROBO3 Q96MS0 64221 ROBO3 RFU No No DE 0.699 0.809 0.647 0 0 0 0.699 0.521 0.877 0 0 0 0.301 0.123 0.479
SL014208 CRTAM O95727 56253 CRTAM RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014209 KLRF1 Q9NZS2 51348 KLRF1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014228 SLAF6 Q96DU3 114836 SLAMF6 RFU No No DE 0.332 0.185 0.386 0 0 0 0.332 0.098 0.566 0 0 0 0.668 0.434 0.902
SL014268 OX2G P41217 4345 CD200 RFU No No CE 0 0 0 0 0 0 0 0 0 0.308 0.122 0.494 0.692 0.506 0.878
SL014269 KI3L2 P43630 3812 KIR3DL2 RFU No No DE 0.270 0.045 0.346 0 0 0 0.270 0.023 0.516 0 0 0 0.730 0.484 0.977
SL014270 CLM6 Q08708 10871 CD300C RFU No No AE 0.345 0.230 0.391 0.345 0.133 0.556 0 0 0 0 0 0 0.655 0.444 0.867
SL014288 MO2R1 Q8TD46 131450 CD200R1 RFU No No DE 0.367 0.257 0.408 0 0 0 0.367 0.141 0.593 0 0 0 0.633 0.407 0.859
SL014289 KI3S1 Q14943 3813 KIR3DS1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014292 SIG14 Q08ET2 1E+08 SIGLEC14 RFU No No DE 0.974 0.986 0.963 0 0 0 0.974 0.962 0.986 0 0 0 0.026 0.014 0.038
SL014294 EPHAA Q5JZY3 284656 EPHA10 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014308 FGF-8A P55075 2253 FGF8 RFU No No CE 0 0 0 0 0 0 0 0 0 0.167 -0.032 0.366 0.833 0.634 1.032
SL014468 SH21A O60880 4068 SH2D1A RFU No No CE 0 0 0 0 0 0 0 0 0 0.165 -0.034 0.364 0.835 0.636 1.034
SL014469 SHC1 P29353 6464 SHC1 RFU No No AE 0.684 0.746 0.647 0.684 0.557 0.811 0 0 0 0 0 0 0.316 0.189 0.443
SL014470 BCAR3 O75815 8412 BCAR3 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL014735 IMDH1 P20839 3614 IMPDH1 RFU No No AE 0.657 0.724 0.621 0.657 0.507 0.807 0 0 0 0 0 0 0.343 0.193 0.493
SL015728 GCKR Q14397 2646 GCKR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016128 TXD12 O95881 51060 TXNDC12 RFU No No AE 0.869 0.918 0.830 0.869 0.810 0.928 0 0 0 0 0 0 0.131 0.072 0.190
SL016129 FAM107B Q9H098 83641 FAM107B RFU No No CE 0 0 0 0 0 0 0 0 0 0.186 -0.012 0.384 0.814 0.616 1.012
SL016130 BRF-1 Q92994 2972 BRF1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016148 C34 gp41 HIV FragmentQ70626 None Human-virus RFU No No DE 0.331 0.122 0.391 0 0 0 0.331 0.054 0.608 0 0 0 0.669 0.392 0.946
SL016548 AMPK a1b1g1 Q13131 Q9Y478 P546195562 5564 5571PRKAA1 PRKAB1  PRKAG1RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016549 AMPK a2b2g1 P54646 O43741 P546195563 5 5 5571PRKAA2 PRKAB2 PRKAG1RFU No No CE 0 0 0 0 0 0 0 0 0 0.181 -0.017 0.378 0.819 0.622 1.017
SL016550 CK2-A1:B P68400 P678701457 1460 CSNK2A1 CSNK2BRFU No No CE 0 0 0 0 0 0 0 0 0 0.680 0.571 0.790 0.320 0.210 0.429
SL016551 CK2-A2:B P19784 P678701459 1460 CSNK2A2 CSNK2BRFU No No AE 0.208 -0.114 0.308 0.208 -0.054 0.470 0 0 0 0 0 0 0.792 0.530 1.054
SL016553 PDE3A Q14432 5139 PDE3A RFU No No DE 0.501 0.502 0.501 0 0 0 0.501 0.289 0.713 0 0 0 0.499 0.287 0.711
SL016554 PDE9A O76083 5152 PDE9A RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016555 PDE11 Q9HCR9 50940 PDE11A RFU No No DE 0.655 0.727 0.618 0 0 0 0.655 0.497 0.813 0 0 0 0.345 0.187 0.503
SL016557 HMGR P04035 3156 HMGCR RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016563 GHC2 Q9H1K4 83733 SLC25A18 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016566 DRAK2 O94768 9262 STK17B RFU No No DE 0.710 0.788 0.665 0 0 0 0.710 0.575 0.845 0 0 0 0.290 0.155 0.425
SL016567 TAK1-TAB1 O43318 Q157506885 10454MAP3K7 TAB1 RFU No No E 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
SL016928 SLAF7 Q9NQ25 57823 SLAMF7 RFU No No AE 0.902 0.939 0.871 0.902 0.860 0.944 0 0 0 0 0 0 0.098 0.056 0.140
SL017188 GSK-3 alpha/beta P49840 P498412931 2932 GSK3A GSK3B RFU No No CE 0 0 0 0 0 0 0 0 0 0.649 0.531 0.767 0.351 0.233 0.469
SL017189 Kininogen  HMW P01042 3827 KNG1 RFU No No AE 0.596 0.644 0.572 0.596 0.429 0.763 0 0 0 0 0 0 0.404 0.237 0.571
SL017610 Gro-b/g P19876 P19875None CXCL3 CXCL2 RFU No No CE 0 0 0 0 0 0 0 0 0 0.432 0.267 0.598 0.568 0.402 0.733
SL017611 14/03/2003 P31946  P62258  P61981  Q04917  P27348  P63104  P319477 29 7531 7532 7533 109 1 7534 2810YWHAB YWHAE YWHAG YWHAH WHAQ YWHAZ SFNRFU No No CE 0 0 0 0 0 0 0 0 0 0.626 0.502 0.750 0.374 0.250 0.498
SL017612 HSP 90a/b P07900 P08238None HSP90AA1 HSP90AB1RFU No No DCE 0.253 -0.049 0.321 0 0 0 0.253 -0.018 0.524 0.496 0.246 0.747 0.250 0.140 0.361
SL017613 FCG2A/B P12318 P31994None FCGR2A FCGR2BRFU No No DE 0.940 0.965 0.917 0 0 0 0.940 0.913 0.967 0 0 0 0.060 0.033 0.087
SL017614 PKB a/b/g Family None None RFU No No CE 0 0 0 0 0 0 0 0 0 0.639 0.519 0.760 0.361 0.240 0.481
SL018625 TLR4:MD-2 complex O00206  Q9Y6Y9709  23643TLR4 LY96 RFU No No CE 0 0 0 0 0 0 0 0 0 0.593 0.459 0.727 0.407 0.273 0.541
